≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Pediculosis, acariasis and other infestations

DOID EFO Endpoint Browser PheWeb

AB1_PEDICULOSIS_ACARIASIS_OTHERINFEST

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — B85-B89
  • Hospital discharge: ICD-9 — 13[2-4]
  • Hospital discharge: ICD-8 — 13[2-4]
  • Cause of death: ICD-10 — B85-B89
  • Cause of death: ICD-9 — 13[2-4]
  • Cause of death: ICD-8 — 13[2-4]

2 out of 7 registries used, show all original rules.

2336

4. Check minimum number of events

None

2336

5. Include endpoints

2622

6. Filter based on genotype QC (FinnGen only)

2529

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
2
First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 25111 8819 16113
Only index persons 21263 7492 13771
Unadjusted period prevalence (%)
Whole population 0.38 0.25 0.45
Only index persons 0.44 0.28 0.53
Median age at first event (years)
Whole population 21.80 23.25 20.75
Only index persons 21.54 23.12 20.67

-FinnGen-

Key figures

All Female Male
Number of individuals 2529 1150 1379
Unadjusted period prevalence (%) 0.53 0.41 0.63
Median age at first event (years) 28.41 33.58 24.10

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
2622
Matched controls
26219
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
13300, ,
ICD-8 Finland
+∞
307.7
508
*
B86
ICD-10 Finland
Scabies
95.0
307.7
1403
314
L29.9
ICD-10 Finland
Pruritus, unspecified
7.5
146.3
218
312
1330A
ICD-9 Finland
Acariasis, Scabies
+∞
146.2
139
*
P02CF01
ATC
ivermectin; oral
21.4
126.4
95
46
13609
ICD-8 Finland
Other and unspecified infective and parasitic diseases, Morbus infectiosus sive parasitarius NUD
+∞
107.0
102
*
B88.0
ICD-10 Finland
Other acariasis
28.7
104.2
70
25
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.6
96.0
758
3571
13603
ICD-8 Finland
Other and unspecified infective and parasitic diseases, Morbus Reiter, syndroma urethro-oculo-articularis
+∞
92.2
88
*
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
2.8
87.6
513
2069
D07AC01
ATC
betamethasone; topical
2.2
83.0
1107
6480
S72
ICPC
Scabies/other acariasis
7.5
79.5
116
161
S02
ICPC
Pruritus
4.3
69.4
186
454
13410
ICD-8 Finland
Other infestation, Phthirus infestation
+∞
69.1
66
*
L29
ICD-10 Finland
Pruritus
7.2
62.8
95
137
L29.8
ICD-10 Finland
Other pruritus
8.0
60.5
83
107
E0000UV, ,
ATC
1.9
54.9
1174
7824
D07BA04
ATC
hydrocortisone and antiseptics; topical
2.6
54.6
365
1550
1369X
ICD-9 Finland
Other and unspecified infectious and parasitic diseases, Unspecified infectious and parasitic diseases
+∞
51.2
49
*
D07AB08
ATC
desonide; topical
2.4
42.4
334
1520
D07AB02
ATC
hydrocortisone butyrate; topical
1.8
42.1
807
5093
R06AE07
ATC
cetirizine; oral
1.7
39.4
1178
8420
B85.3
ICD-10 Finland
Phthiriasis
187.6
35.8
37
*
S29
ICPC
Skin symptom/complaint other
1.9
34.3
551
3259
H02AB06
ATC
prednisolone; systemic
1.7
33.7
1183
8705
TQW80
NOMESCO Finland
Local dermatologic skincare
3.9
33.3
101
269
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
5.3
32.7
66
127
13608
ICD-8 Finland
Other and unspecified infective and parasitic diseases
+∞
32.4
31
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.6
30.8
1138
8420
N02AX02
ATC
tramadol; systemic, rectal
1.6
30.6
1073
7836
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.3
29.5
241
1108
J01DB01
ATC
cefalexin; oral
1.8
29.1
2165
18943
D07AD01
ATC
clobetasol; topical
1.8
27.0
426
2489
D07AC13
ATC
mometasone; topical
1.7
26.9
735
5007
M79.6
ICD-10 Finland
Pain in limb
1.6
26.2
1101
8301
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
2.2
25.5
228
1087
L50.3
ICD-10 Finland
Dermatographic urticaria
4.0
25.2
72
184
N05AH04
ATC
quetiapine; oral
1.7
24.2
500
3153
XQ845
NOMESCO Finland
Dermatoscopy
4.1
24.0
66
164
L30.3
ICD-10 Finland
Infective dermatitis
2.9
24.0
114
403
T36
ICD-10 Finland
Poisoning by systemic antibiotics
2.5
24.0
152
623
N06AX11
ATC
mirtazapine; oral
1.6
23.9
845
6091
A02BC02
ATC
pantoprazole; systemic
1.5
23.8
1640
13655
N03AX16
ATC
[U] pregabalin
1.7
23.3
539
3501
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.5
23.1
1083
8295
J01FF01
ATC
clindamycin; systemic
1.6
22.6
661
4548
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.6
21.7
652
4508
R06AX27
ATC
desloratadine; oral
1.6
21.7
768
5515
AA1AD
NOMESCO Finland
CT of head and brain
1.6
21.7
628
4306
S21
ICPC
Skin texture symptom/complaint
1.8
21.5
377
2264
SPAT1249
SPAT
Treatment-related counselling outside office
1.5
21.3
927
6954
N02AJ06
ATC
codeine and paracetamol; systemic
1.5
21.3
1106
8608
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.6
21.2
575
3878
N05CF01
ATC
zopiclone; oral
1.6
21.2
708
5015
69100
ICD-8 Finland
Infantile eczema and related conditions, Eczema atopicum. Prurigo Besnier. Eczema pruriginosum allergicum
4.0
21.0
59
149
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
1.9
20.9
292
1633
1322A
ICD-9 Finland
Pediculosis and phthirus infestation, Phthirus pubis [pubic louse]
+∞
20.9
20
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
1.8
20.6
345
2041
N05BA04
ATC
oxazepam; oral
1.6
20.5
609
4191
N07BA03
ATC
varenicline; oral
2.3
20.5
157
701
N06AB04
ATC
citalopram; systemic
1.7
20.5
480
3118
N05BA01
ATC
diazepam; systemic, rectal
1.8
20.0
310
1792
F32.9
ICD-10 Finland
Depressive episode, unspecified
1.7
19.9
368
2240
N02BE01
ATC
paracetamol; systemic, rectal
1.7
19.8
2230
20223
XQ843
NOMESCO Finland
Examination of infestation with microscope
201.5
19.6
20
*
N06AX16
ATC
venlafaxine; oral
1.7
19.3
377
2328
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.5
19.3
712
5137
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.5
19.0
894
6780
13299
ICD-8 Finland
Pediculosis
+∞
18.8
18
*
EB1AA
NOMESCO Finland
Intraoral radiographic dental examination
1.4
18.6
1395
11542
WYA05
NOMESCO Finland
Emergency visit or other similar visit involving procedures
1.4
17.7
1167
9395
B85.0
ICD-10 Finland
Pediculosis due to Pediculus humanus capitis
37.0
17.6
22
6
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
2.5
17.4
111
457
L02.4
ICD-10 Finland
Cutaneous abscess, furuncle and carbuncle of limb
2.5
17.3
107
434
SAA01
NOMESCO Finland
Simple examination of mouth
1.5
17.2
1879
16558
M54.5
ICD-10 Finland
Low back pain
1.5
17.2
904
6973
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
1.8
16.8
257
1476
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
1.4
16.7
1042
8279
SPAT1254
SPAT
Administration of medicine
1.7
16.4
348
2192
K02.1
ICD-10 Finland
Caries of dentine
1.4
16.4
1555
13289
D11
ICPC
Diarrhoea
1.7
16.2
317
1954
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
1.6
16.2
482
3300
R07.4
ICD-10 Finland
Chest pain, unspecified
1.5
16.1
636
4626
R51.80
ICD-10 Finland
Headache
1.6
16.0
398
2610
D07AA02
ATC
hydrocortisone; topical
1.6
15.5
353
2263
SPAT1240
SPAT
Therapeutic discussion
1.7
15.5
284
1720
I50.9
ICD-10 Finland
Heart failure, unspecified
1.8
15.4
233
1333
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
1.9
15.3
191
1029
N05AX08
ATC
risperidone; systemic
1.9
15.2
195
1060
SPAT1263
SPAT
Sampling
1.4
15.1
953
7550
SPAT1310
SPAT
Counselling related to known health issue
1.4
14.9
723
5459
J01MA12
ATC
levofloxacin; systemic
1.6
14.8
395
2631
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
1.6
14.8
373
2453
P15
ICPC
Chronic alcohol abuse
2.3
14.7
108
474
UJF32
NOMESCO Finland
Coloscopy
1.5
14.7
543
3887
L20.9
ICD-10 Finland
Atopic dermatitis, unspecified
2.3
14.7
114
513
N03AX12
ATC
[U] gabapentin; oral
1.6
14.5
357
2334
SPAT1148
SPAT
Treatment of chronic ulcer or burn
1.7
14.3
261
1577
D07BC01
ATC
betamethasone and antiseptics; topical
1.7
14.3
275
1686
C03CA01
ATC
furosemide; systemic
1.5
14.3
503
3562
P01AB01
ATC
metronidazole; oral, rectal
1.4
14.3
880
6928
SPAT1260
SPAT
Consultation of another employee
1.6
14.3
381
2538
R52.9
ICD-10 Finland
Pain, unspecified
1.7
14.2
249
1487
S18
ICPC
Laceration/cut
1.4
14.2
1089
8893
L17
ICPC
Foot/toe symptom/complaint
1.4
14.0
706
5359
A46
ICD-10 Finland
Erysipelas
1.6
14.0
330
2132
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
1.8
14.0
217
1251
F60.30
ICD-10 Finland
Emotionally unstable personality disorder, impulsive
2.9
14.0
63
217
SPAT1283
SPAT
Restricted health certificate
1.5
14.0
469
3287
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
1.6
13.9
331
2143
N02BF02
ATC
pregabalin; oral
1.9
13.9
170
909
J01MA02
ATC
ciprofloxacin; systemic
1.4
13.7
846
6653
K04.5
ICD-10 Finland
Chronic apical periodontitis
1.4
13.6
658
4955
R06.0
ICD-10 Finland
Dyspnoea
1.5
13.5
583
4298
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
1.8
13.3
202
1158
L03
ICPC
Low back symptom/complaint
1.4
13.1
691
5277
X59
ICD-10 Finland
Exposure to unspecified factor
1.5
13.1
480
3422
SPAT1149
SPAT
Suture or treatment of traumatic wound
1.7
13.1
262
1623
SAA02
NOMESCO Finland
Basic examination of mouth
1.4
13.0
1734
15374
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
1.5
12.9
420
2920
J01DA01
ATC
[U] cefalexin
1.4
12.9
1429
12298
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
1.8
12.8
209
1224
A49.9
ICD-10 Finland
Bacterial infection, unspecified
1.7
12.8
225
1346
SPAT1301
SPAT
No procedures
1.4
12.8
662
5039
N05AH03
ATC
olanzapine; systemic
1.9
12.7
177
987
WX110
NOMESCO Finland
Infiltration anesthesia
1.4
12.7
1816
16246
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
1.7
12.7
245
1504
M54.4
ICD-10 Finland
Lumbago with sciatica
1.5
12.6
428
3000
R03AC02
ATC
salbutamol; inhalant
1.4
12.6
1305
11096
W19
ICD-10 Finland
Unspecified fall
1.7
12.6
233
1412
N05CD07
ATC
temazepam; oral
1.7
12.6
214
1268
F10.00
ICD-10 Finland
Alcohol-related acute intoxication uncomplicated
2.8
12.5
63
231
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
1.7
12.5
231
1400
UJF30
NOMESCO Finland
Ileoscopy through colon
1.7
12.5
240
1470
EBA05
NOMESCO Finland
Complicated extraction of tooth
1.4
12.5
566
4201
J02AC01
ATC
fluconazole; systemic
1.4
12.5
799
6300
WX290
NOMESCO Finland
Other blockage of nerve
1.3
12.4
1267
10744
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
1.4
12.4
544
4015
JN3AD
NOMESCO Finland
Abdominal CT examination
1.6
12.3
296
1921
J01AA02
ATC
doxycycline; systemic
1.4
12.2
1806
16180
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.4
12.2
591
4437
SPAT1211
SPAT
Application of soft bandage
1.8
12.1
202
1189
F10.29
ICD-10 Finland
Addiction caused by alcohol UNS
2.4
12.0
82
349
L40.0
ICD-10 Finland
Psoriasis vulgaris
2.1
12.0
116
570
N02AA05
ATC
oxycodone; systemic
1.6
12.0
344
2324
L85.3
ICD-10 Finland
Xerosis cutis
3.8
11.9
35
92
M02.3
ICD-10 Finland
Reiter disease
11.8
11.8
21
18
F10.30
ICD-10 Finland
Withdrawal symptoms caused by alcohol uncomplicated
3.3
11.8
44
136
L20.0
ICD-10 Finland
Besnier prurigo
1.7
11.8
209
1253
Z01.2
ICD-10 Finland
Dental examination
1.3
11.8
1166
9815
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
1.6
11.7
258
1637
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
1.7
11.7
239
1487
SFC01
NOMESCO Finland
Additional procedure necessary for restorative treatment
1.4
11.7
639
4897
F60.31
ICD-10 Finland
Emotionally unstable personality disorder, borderline condition
3.0
11.7
50
168
H02AB04
ATC
methylprednisolone; systemic
1.6
11.6
301
1988
M01AE03
ATC
ketoprofen; systemic, rectal
1.4
11.6
758
5985
SFA30
NOMESCO Finland
Three-surface restoration
1.3
11.5
1014
8380
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
1.8
11.5
180
1041
EBA00
NOMESCO Finland
Extraction of tooth
1.4
11.5
921
7505
R60.0
ICD-10 Finland
Localized oedema
1.6
11.5
253
1607
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
1.6
11.4
262
1680
S97
ICPC
Chronic ulcer skin
2.0
11.4
132
693
L28.2
ICD-10 Finland
Other prurigo
8.3
11.3
24
29
F19.29
ICD-10 Finland
Addiction caused by several drugs in combination and by other psychoactive substances UNS
5.1
11.3
23
45
M03BX02
ATC
tizanidine; oral
1.3
11.2
1486
13009
P01
ICPC
Feeling anxious/nervous/tense
1.5
11.2
358
2476
L28.1
ICD-10 Finland
Prurigo nodularis
4.5
11.2
27
61
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
1.3
11.2
1310
11265
F41.9
ICD-10 Finland
Anxiety disorder, unspecified
1.6
11.2
289
1907
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
2.0
11.2
125
649
JN3BD
NOMESCO Finland
Extensive abdominal CT
1.7
11.2
204
1233
L04AX03
ATC
methotrexate; systemic
1.7
11.1
219
1352
M01AE02
ATC
naproxen; oral, rectal
1.3
11.0
1373
11902
D01
ICPC
Abdominal pain/cramps general
1.6
11.0
310
2086
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
1.7
11.0
213
1309
SPAT1144
SPAT
Treatment of reopened or infected surgical wound
1.9
10.9
143
782
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
1.8
10.9
176
1027
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
1.4
10.9
713
5620
SPAT1222
SPAT
Counselling/guidance promoting independent living
1.6
10.8
277
1822
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
1.6
10.8
233
1470
WX408
NOMESCO Finland
General anesthesy, balanced
1.4
10.8
560
4244
L04AA01
ATC
[U] ciclosporin
3.6
10.7
35
99
P99
ICPC
Psychological disorders other
2.2
10.6
92
434
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
1.5
10.6
311
2112
N06AB10
ATC
escitalopram; oral
1.4
10.5
496
3695
N06AX21
ATC
duloxetine; oral
1.6
10.5
273
1802
D07XC01
ATC
betamethasone; topical
1.6
10.5
265
1738
SPAT1238
SPAT
Brief therapy
2.8
10.5
51
184
L28
ICPC
Limited function/disability (L)
1.5
10.5
341
2365
Z02.7
ICD-10 Finland
Issue of medical certificate
1.7
10.5
183
1092
IHZ05, ,
SPAT
1.9
10.5
134
728
N06AB06
ATC
sertraline; oral
1.6
10.4
283
1889
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
1.7
10.4
184
1103
R02
ICPC
Shortness of breath/dyspnoea
1.6
10.3
288
1932
P03
ICPC
Feeling depressed
1.6
10.3
276
1835
R42
ICD-10 Finland
Dizziness and giddiness
1.4
10.3
448
3289
M01AB05
ATC
diclofenac; systemic, rectal
1.3
10.3
1546
13692
M75.1
ICD-10 Finland
Rotator cuff syndrome
1.4
10.3
564
4314
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
1.4
10.2
492
3678
A02BC01
ATC
omeprazole; systemic
1.4
10.2
546
4160
A28
ICPC
Limited function/disability NOS
1.5
10.1
291
1968
T74.1
ICD-10 Finland
Physical abuse
2.5
10.0
60
241
L04AX01
ATC
azathioprine; systemic
2.0
10.0
103
520
L04AD01
ATC
ciclosporin; systemic
2.7
10.0
52
195
P76
ICPC
Depressive disorder
1.7
10.0
182
1100
L30.8
ICD-10 Finland
Other specified dermatitis
2.3
9.9
73
322
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
1.6
9.9
233
1502
ZXD05
NOMESCO Finland
Urgent procedure
1.4
9.9
655
5160
N05AA02
ATC
levomepromazine; systemic
2.0
9.9
99
495
F12.1
ICD-10 Finland
Mental and behavioural disorders due to use of cannabinoids, harmful use
5.2
9.8
20
39
SFA10
NOMESCO Finland
One-surface restoration
1.3
9.8
1372
11999
SFA20
NOMESCO Finland
Two-surface restoration
1.3
9.8
1453
12809
K04.0
ICD-10 Finland
Pulpitis
1.6
9.8
240
1564
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
2.0
9.7
102
518
A29
ICPC
General symptom/complaint other
1.5
9.7
278
1876
D02AE01
ATC
carbamide; topical
1.8
9.7
140
791
WZC30
NOMESCO Finland
Teaching
1.5
9.7
362
2582
B18.2
ICD-10 Finland
Chronic viral hepatitis C
3.1
9.7
40
132
J20
ICD-10 Finland
Acute bronchitis
1.6
9.6
232
1507
R06AE09
ATC
levocetirizine; oral
1.5
9.6
333
2341
F10.09
ICD-10 Finland
Alcohol intoxication UNS
2.3
9.5
67
290
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
1.8
9.5
138
780
L50.9
ICD-10 Finland
Urticaria, unspecified
2.0
9.5
97
488
R05
ICD-10 Finland
Cough
1.4
9.5
470
3529
B88.9
ICD-10 Finland
Infestation, unspecified
100.4
9.4
10
*
A04
ICPC
Weakness/tiredness general
1.5
9.4
357
2553
B87.0
ICD-10 Finland
Cutaneous myiasis
+∞
9.4
9
*
N06AX12
ATC
bupropion; oral
1.6
9.4
195
1220
Z71.8
ICD-10 Finland
Other specified counselling
1.3
9.4
799
6526
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
1.8
9.4
145
837
R53
ICD-10 Finland
Malaise and fatigue
1.4
9.3
553
4275
R05
ICPC
Cough
1.4
9.3
563
4366
N07BB01
ATC
disulfiram; oral
1.9
9.3
122
669
EB1VA, ,
NOMESCO Finland
1.4
9.2
426
3158
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
1.5
9.2
302
2097
M25.5
ICD-10 Finland
Pain in joint
1.3
9.2
767
6241
L12
ICPC
Hand/finger symptom/complaint
1.4
9.2
404
2969
R21
ICPC
Throat symptom/complaint
1.4
9.1
541
4180
A06AC01
ATC
ispaghula (psylla seeds); oral
1.4
9.1
501
3827
M10.9
ICD-10 Finland
Gout, unspecified
1.8
9.0
145
846
R56.8
ICD-10 Finland
Other and unspecified convulsions
1.8
9.0
123
684
R74
ICPC
Upper respiratory infection acute
1.3
9.0
832
6867
NH1AD
NOMESCO Finland
Ankle and foot CT
2.4
8.9
61
261
A06AD11
ATC
lactulose; oral
1.5
8.9
253
1703
SFA40
NOMESCO Finland
Restoration involving the entire crown of the tooth
1.4
8.9
483
3678
M79.2
ICD-10 Finland
Neuralgia and neuritis, unspecified
2.5
8.9
55
225
R10.1
ICD-10 Finland
Pain localized to upper abdomen
1.4
8.9
386
2829
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.4
8.9
552
4296
R41.0
ICD-10 Finland
Disorientation, unspecified
2.4
8.8
58
244
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
1.9
8.8
115
631
E000001, ,
ATC
1.4
8.7
433
3247
R50.9
ICD-10 Finland
Fever, unspecified
1.4
8.7
346
2493
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.3
8.7
1277
11166
Y25
ICPC
Fear sexually transm disease male
2.2
8.7
71
328
SPAT1104
SPAT
Monitoring of emergency patient
1.8
8.7
132
758
N05AX12
ATC
aripiprazole; systemic
1.8
8.7
116
641
F10.20
ICD-10 Finland
Alcohol dependence currently independent
2.3
8.7
61
265
J45.9
ICD-10 Finland
Asthma, unspecified
1.4
8.6
397
2938
SPAT1229
SPAT
Assessment of need for aid
1.8
8.6
127
723
J01FA10
ATC
azithromycin; systemic
1.3
8.6
1396
12357
H01
ICPC
Ear pain/earache
1.5
8.5
281
1953
Z11.3
ICD-10 Finland
Special screening examination for infections with a predominantly sexual mode of transmission
1.7
8.5
157
953
N05AD01
ATC
haloperidol; systemic
2.3
8.4
64
287
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
1.5
8.4
323
2312
S88
ICPC
Dermatitis contact/allergic
2.5
8.4
51
207
F32.1
ICD-10 Finland
Moderate depressive episode
1.7
8.4
158
964
Z76.0
ICD-10 Finland
Issue of repeat prescription
1.3
8.4
644
5168
WZA90
NOMESCO Finland
Other medical or dental certificate
1.4
8.4
541
4232
F43.1
ICD-10 Finland
Post-traumatic stress disorder
2.1
8.4
76
367
A03
ICPC
Fever
1.4
8.4
441
3341
N03AE01
ATC
clonazepam; systemic
1.8
8.3
120
678
WZC30, ,
SPAT
1.6
8.3
188
1202
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
1.7
8.3
166
1029
S06.0
ICD-10 Finland
Concussion
1.5
8.3
252
1722
F10.40
ICD-10 Finland
Withdrawal symptoms and delirium caused by alcohol without seizures
3.1
8.2
33
107
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
1.4
8.2
415
3119
L02.1
ICD-10 Finland
Cutaneous abscess, furuncle and carbuncle of neck
3.4
8.2
29
87
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
1.6
8.2
169
1056
Z00.0
ICD-10 Finland
General medical examination
1.4
8.2
427
3228
S10
ICPC
Boil/carbuncle
1.7
8.1
138
818
QX2XE
NOMESCO Finland
Ultrsound examination of soft tissue not elsewhere classified
2.1
8.1
70
331
F43.22
ICD-10 Finland
Adaptation disorder with mixed anxiety and depression
1.8
8.1
118
669
XQ848
NOMESCO Finland
Dermatological photography
2.2
8.1
66
305
T82
ICPC
Obesity
1.9
8.1
104
567
P19
ICPC
Drug abuse
3.1
8.1
32
103
M75.9
ICD-10 Finland
Shoulder lesion, unspecified
1.8
8.1
118
670
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
1.5
8.1
219
1460
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
1.3
8.0
637
5130
F41.2
ICD-10 Finland
Mixed anxiety and depressive disorder
1.5
8.0
259
1792
F10.25
ICD-10 Finland
Alcohol dependence continuous use
2.4
8.0
53
224
85000
ICD-8 Finland
Concussion, Current or unspecified
2.3
8.0
57
249
M13.9
ICD-10 Finland
Arthritis, unspecified
1.6
8.0
161
1000
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.3
8.0
839
7018
D02AX
ATC
Other emollients and protectives
2.1
8.0
73
354
K52.9
ICD-10 Finland
Noninfective gastroenteritis and colitis, unspecified
2.0
7.9
89
464
J01DA09
ATC
[U] cefadroxil
1.3
7.9
563
4464
F10.39
ICD-10 Finland
Withdrawal symptoms caused by alcohol UNS
2.8
7.9
38
137
F17.29
ICD-10 Finland
Addiction caused by tobacco UNS
2.3
7.9
55
238
P29
ICPC
Psychological sympt/compl other
1.6
7.9
199
1305
SPAT1227
SPAT
Substance abuse rehabilitation
3.7
7.9
24
65
N03AX09
ATC
lamotrigine; oral
1.8
7.9
126
735
D09AB01
ATC
zinc bandage without supplements; topical
2.7
7.9
42
160
N02BF01
ATC
gabapentin; oral
1.5
7.9
218
1461
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
1.9
7.8
101
552
I48.9
ICD-10 Finland
Atrial fibrillation and atrial flutter, unspecified
1.7
7.8
131
776
N06AB05
ATC
paroxetine; oral
1.7
7.8
129
761
N39.4
ICD-10 Finland
Other specified urinary incontinence
1.7
7.8
140
845
NH1BA
NOMESCO Finland
Ankle extensive X-ray examination
2.2
7.7
66
311
127
Kela drug reimbursment
Transplant complication
2.5
7.7
46
185
SPAT1216
SPAT
Assessment of functional ability
1.5
7.7
255
1775
J01.0
ICD-10 Finland
Acute maxillary sinusitis
1.3
7.6
560
4457
SPAT1312
SPAT
General health counselling
1.3
7.6
691
5661
D82
ICPC
Teeth/gum disease
1.3
7.6
911
7730
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
1.4
7.6
393
2964
N03AG01
ATC
valproic acid; systemic, rectal
1.7
7.6
136
819
A01
ICPC
Pain general/multiple sites
1.5
7.6
211
1415
L30.0
ICD-10 Finland
Nummular dermatitis
1.9
7.6
90
479
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
1.8
7.5
113
647
QDA10
NOMESCO Finland
Incision of skin of lower limb
3.8
7.5
22
58
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
1.8
7.5
102
568
SDA03
NOMESCO Finland
Periodontal treatment
1.3
7.5
956
8176
N05AF03
ATC
chlorprothixene; systemic
2.2
7.5
63
296
H02AB07
ATC
prednisone; oral
1.5
7.5
250
1743
J01FA09
ATC
clarithromycin; systemic
1.3
7.5
688
5648
D10
ICPC
Vomiting
1.6
7.4
152
948
J01CA04
ATC
amoxicillin; systemic
1.3
7.4
2033
19012
F10.9
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Unspecified mental and behavioural disorder
3.1
7.4
29
93
ZXD35
NOMESCO Finland
Usual procedure
2.1
7.4
66
317
L02.9
ICD-10 Finland
Cutaneous abscess, furuncle and carbuncle, unspecified
2.0
7.4
78
399
R25.2
ICD-10 Finland
Cramp and spasm
2.3
7.3
55
246
I50.0
ICD-10 Finland
Congestive heart failure
1.8
7.3
107
608
X44
ICD-10 Finland
Accidental poisoning by and exposure to other and unspecified drugs, medicaments and biological substances
2.5
7.3
43
172
R11
ICD-10 Finland
Nausea and vomiting
1.6
7.3
181
1183
QDB05
NOMESCO Finland
Revision of wound of skin of lower limb
2.2
7.3
58
266
TPH04
NOMESCO Finland
Cathetrisation of vein
1.3
7.3
455
3534
1363A
ICD-9 Finland
Other and unspecified infectious and parasitic diseases, Pneumocystosis
+∞
7.3
7
*
SPAT1309
SPAT
Guidance related to psychoactive substances / risk behaviour
2.0
7.3
75
380
D73
ICPC
Gastroenteritis presumed infection
1.9
7.3
93
507
D05AX52
ATC
calcipotriol, combinations; topical
1.7
7.3
117
684
M01AH05
ATC
etoricoxib; oral
1.3
7.3
1460
13133
L01.0
ICD-10 Finland
Impetigo [any organism] [any site]
2.3
7.3
52
228
R03BB04
ATC
tiotropium bromide; inhalant
1.6
7.3
178
1160
Y83.9
ICD-10 Finland
Surgical procedure, unspecified as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
2.1
7.2
69
340
T81.0
ICD-10 Finland
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
1.7
7.2
120
708
F19.20
ICD-10 Finland
Addiction relationship caused by several drugs in combination and by other psychoactive substances currently independent
4.3
7.2
18
42
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
1.3
7.2
471
3684
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
1.4
7.2
283
2035
A56.0
ICD-10 Finland
Chlamydial infection of lower genitourinary tract
2.3
7.2
54
242
D64.9
ICD-10 Finland
Anaemia, unspecified
1.6
7.2
186
1228
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
1.8
7.2
101
568
IHZ01, ,
SPAT
2.8
7.2
34
122
J01CF05
ATC
flucloxacillin; systemic
1.6
7.1
168
1085
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
2.0
7.1
76
390
L89
ICD-10 Finland
Decubitus ulcer and pressure area
2.8
7.1
35
128
V03AE01
ATC
polystyrene sulfonate; oral
2.9
7.1
31
106
N76.0
ICD-10 Finland
Acute vaginitis
1.6
7.1
143
889
S76
ICPC
Skin infection other
1.7
7.1
118
697
T90
ICPC
Diabetes non-insulin dependent
1.3
7.1
476
3737
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
1.7
7.1
131
797
ZXE10
NOMESCO Finland
More than one and less than three hours
1.3
7.0
706
5851
E000002, ,
ATC
1.5
7.0
236
1646
F29
ICD-10 Finland
Unspecified nonorganic psychosis
1.8
7.0
96
535
E66.01
ICD-10 Finland
Obesity due to excess calories
1.5
7.0
225
1555
XQ802
NOMESCO Finland
Epicutan test
1.9
7.0
87
471
ZY010
NOMESCO Finland
Hospital outpatient
1.7
7.0
134
823
A11CC03
ATC
alfacalcidol; systemic
2.3
7.0
51
226
ZYC01
NOMESCO Finland
Remote contact by phone
1.6
7.0
148
933
S93.4
ICD-10 Finland
Sprain and strain of ankle
1.4
7.0
282
2039
A06AC51
ATC
ispaghula, combinations; oral
1.9
6.9
89
488
Z2446
NOMESCO Finland
Social worker
1.6
6.8
151
961
L08.0
ICD-10 Finland
Pyoderma
3.4
6.8
24
72
L01BA01
ATC
methotrexate; systemic
2.0
6.8
68
341
M03BC01
ATC
orphenadrine (citrate); systemic
1.3
6.8
487
3857
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
1.5
6.8
228
1590
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
1.6
6.8
139
868
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
1.5
6.8
239
1683
-1, ,
NOMESCO Finland
1.3
6.8
804
6796
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
1.6
6.7
170
1116
C09AA02
ATC
enalapril; systemic
1.4
6.7
321
2387
J44.0
ICD-10 Finland
Chronic obstructive pulmonary disease with acute lower respiratory infection
1.9
6.7
80
427
L08.8
ICD-10 Finland
Other specified local infections of skin and subcutaneous tissue
2.0
6.7
73
378
SAA03
NOMESCO Finland
Extended examination of mouth
1.2
6.7
955
8245
S16
ICPC
Bruise/contusion
2.0
6.7
67
337
F41.09
ICD-10 Finland
UNS Panic Syndrome
1.9
6.7
74
386
ZXE00
NOMESCO Finland
One hour or less
1.3
6.6
804
6809
N17
ICPC
Vertigo/dizziness
1.5
6.6
239
1691
A63.0
ICD-10 Finland
Anogenital (venereal) warts
1.8
6.6
89
494
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
1.4
6.6
268
1938
A02BC05
ATC
esomeprazole; systemic
1.3
6.6
837
7126
XQ858
NOMESCO Finland
Oxygen partial pressure measurement
3.2
6.6
25
79
N06AA09
ATC
amitriptyline; systemic
1.6
6.6
165
1083
D09
ICPC
Nausea
1.7
6.5
121
737
SPAT1262
SPAT
Handing over of treatment supplies
1.4
6.5
326
2444
TLC00
NOMESCO Finland
Insertion of intrauterine device
1.7
6.5
123
753
R96
ICPC
Asthma
1.5
6.5
191
1297
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
2.3
6.5
48
214
A10BH05
ATC
linagliptin; oral
1.8
6.5
84
461
NF1AA
NOMESCO Finland
Hip X-ray examination
1.6
6.5
148
950
K62.5
ICD-10 Finland
Haemorrhage of anus and rectum
1.7
6.5
115
693
X14
ICPC
Vaginal discharge
2.2
6.5
53
247
IFA99, ,
SPAT
3.9
6.4
18
46
SPAT1247
SPAT
Outpatient detoxication and monitoring
3.9
6.4
18
46
TLC02
NOMESCO Finland
Simple extraction of IUD
1.9
6.4
76
405
K21.0
ICD-10 Finland
Gastro-oesophageal reflux disease with oesophagitis
1.5
6.4
192
1309
XCH00
NOMESCO Finland
Eye pressure measurement
1.8
6.4
87
485
D06
ICPC
Abdominal pain localized other
1.5
6.4
187
1269
K57.3
ICD-10 Finland
Diverticular disease of large intestine without perforation or abscess
1.4
6.4
309
2304
G44.2
ICD-10 Finland
Tension-type headache
1.4
6.4
286
2105
J09
ICD-10 Finland
Influenza due to identified zoonotic or pandemic influenza virus
2.0
6.3
63
316
SPAT1234
SPAT
Support of social functional capacity
1.8
6.3
88
494
Z03
ICPC
Housing/neighbourhood problem
3.6
6.3
20
56
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
1.3
6.3
447
3533
TK800
NOMESCO Finland
Hemodialysis
2.2
6.3
50
230
F32.3
ICD-10 Finland
Severe depressive episode with psychotic symptoms
2.2
6.3
50
230
R52.2
ICD-10 Finland
Other chronic pain
1.8
6.3
82
452
K08.80
ICD-10 Finland
Toothache NOS
1.5
6.3
205
1424
13399
ICD-8 Finland
Acariasis, Other
+∞
6.3
6
*
B89
ICD-10 Finland
Unspecified parasitic disease
+∞
6.3
6
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
1.7
6.2
117
715
G47.3
ICD-10 Finland
Sleep apnoea
1.3
6.2
541
4395
L01
ICD-10 Finland
Impetigo
2.5
6.2
38
156
L40.8
ICD-10 Finland
Other psoriasis
3.4
6.1
21
62
V03AA01, ,
ATC
2.4
6.1
39
163
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
1.8
6.1
84
470
M54.3
ICD-10 Finland
Sciatica
1.7
6.1
117
719
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
1.3
6.1
441
3495
M05BA04
ATC
alendronic acid; oral
1.7
6.1
112
682
M10.0
ICD-10 Finland
Idiopathic gout
1.9
6.0
70
371
T00.9
ICD-10 Finland
Multiple superficial injuries, unspecified
3.6
6.0
19
53
Z01.6
ICD-10 Finland
Radiological examination, not elsewhere classified
1.4
6.0
223
1586
NH3BA
NOMESCO Finland
Foot and toes extensive X-ray examination
1.9
6.0
75
407
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
1.6
6.0
148
967
F32
ICD-10 Finland
Depressive episode
1.6
6.0
122
761
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
1.3
6.0
651
5432

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
7.2e-01
1.7e+00
2.7e+00
9.0e+00
3.7e+00
2.8e+00
1.1e+00
cases:13.55%
controls:7.11%
cases:13.71%
controls:2.90%
cases:7.18%
controls:0.49%
cases:69.28%
controls:0.03%
cases:17.69%
controls:0.51%
cases:32.74%
controls:2.93%
cases:18.62%
controls:6.90%
230
1195
1468
15601
233
487
1466
16319
122
83
1577
16723
1177
5
522
16801
300
85
1396
16679
531
474
1091
15683
235
863
1027
11641
ivermectin; oral
P02CF01 [21604957]
2.9e+00
4.2e+00
—
1.0e+50
5.9e+00
4.0e+00
1.3e+00
cases:1.24%
controls:0.07%
cases:6.89%
controls:0.11%
—
—
cases:14.01%
controls:0.00%
cases:9.55%
controls:0.03%
cases:7.21%
controls:0.15%
cases:1.98%
controls:0.54%
21
11
1677
16785
117
19
1582
16787
—
238
0
1461
16806
162
5
1534
16759
117
24
1505
16133
25
67
1237
12437
hydrocortisone; local oral
A01AC03 [21600036]
7.4e-01
2.5e+00
3.9e+00
1.0e+50
5.2e+00
3.0e+00
1.3e+00
cases:2.47%
controls:1.20%
cases:4.41%
controls:0.37%
cases:2.47%
controls:0.05%
cases:5.41%
controls:0.00%
cases:6.25%
controls:0.04%
cases:5.55%
controls:0.30%
cases:4.28%
controls:1.21%
42
201
1656
16595
75
62
1624
16744
42
9
1657
16797
92
0
1607
16806
106
6
1590
16758
90
49
1532
16108
54
151
1208
12353
chlorhexidine, combinations
D08AC52 [21602208]
7.4e-01
2.4e+00
3.9e+00
1.0e+50
5.0e+00
2.7e+00
1.3e+00
cases:4.30%
controls:2.09%
cases:6.59%
controls:0.65%
cases:4.24%
controls:0.09%
cases:7.30%
controls:0.00%
cases:9.02%
controls:0.07%
cases:7.58%
controls:0.56%
cases:6.50%
controls:1.90%
73
351
1625
16445
112
109
1587
16697
72
15
1627
16791
124
0
1575
16806
153
11
1543
16753
123
91
1499
16066
82
237
1180
12267
chlorhexidine
S02AA09 [21605155]
7.4e-01
2.4e+00
3.9e+00
1.0e+50
5.0e+00
2.7e+00
1.3e+00
cases:4.30%
controls:2.09%
cases:6.59%
controls:0.65%
cases:4.24%
controls:0.09%
cases:7.30%
controls:0.00%
cases:9.02%
controls:0.07%
cases:7.58%
controls:0.56%
cases:6.50%
controls:1.90%
73
351
1625
16445
112
109
1587
16697
72
15
1627
16791
124
0
1575
16806
153
11
1543
16753
123
91
1499
16066
82
237
1180
12267
chlorhexidine
D09AA12 [21602275]
7.4e-01
2.4e+00
3.9e+00
1.0e+50
5.0e+00
2.7e+00
1.3e+00
cases:4.30%
controls:2.09%
cases:6.59%
controls:0.65%
cases:4.24%
controls:0.09%
cases:7.30%
controls:0.00%
cases:9.02%
controls:0.07%
cases:7.58%
controls:0.56%
cases:6.50%
controls:1.90%
73
351
1625
16445
112
109
1587
16697
72
15
1627
16791
124
0
1575
16806
153
11
1543
16753
123
91
1499
16066
82
237
1180
12267
chlorhexidine
S03AA04 [21605193]
7.4e-01
2.4e+00
3.9e+00
1.0e+50
5.0e+00
2.7e+00
1.3e+00
cases:4.30%
controls:2.09%
cases:6.59%
controls:0.65%
cases:4.24%
controls:0.09%
cases:7.30%
controls:0.00%
cases:9.02%
controls:0.07%
cases:7.58%
controls:0.56%
cases:6.50%
controls:1.90%
73
351
1625
16445
112
109
1587
16697
72
15
1627
16791
124
0
1575
16806
153
11
1543
16753
123
91
1499
16066
82
237
1180
12267
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
7.4e-01
2.4e+00
3.9e+00
1.0e+50
5.0e+00
2.7e+00
1.3e+00
cases:4.30%
controls:2.09%
cases:6.59%
controls:0.65%
cases:4.24%
controls:0.09%
cases:7.30%
controls:0.00%
cases:9.02%
controls:0.07%
cases:7.58%
controls:0.56%
cases:6.50%
controls:1.90%
73
351
1625
16445
112
109
1587
16697
72
15
1627
16791
124
0
1575
16806
153
11
1543
16753
123
91
1499
16066
82
237
1180
12267
hydrocortisone and antiseptics
D07BA04 [21602146]
7.4e-01
2.4e+00
3.9e+00
1.0e+50
5.0e+00
2.7e+00
1.3e+00
cases:4.30%
controls:2.10%
cases:6.59%
controls:0.65%
cases:4.24%
controls:0.09%
cases:7.30%
controls:0.00%
cases:9.02%
controls:0.07%
cases:7.58%
controls:0.56%
cases:6.50%
controls:1.90%
73
352
1625
16444
112
109
1587
16697
72
15
1627
16791
124
0
1575
16806
153
11
1543
16753
123
91
1499
16066
82
237
1180
12267
hydrocortisone
D07XA01 [21602180]
7.4e-01
2.4e+00
3.9e+00
1.0e+50
5.0e+00
2.7e+00
1.3e+00
cases:4.30%
controls:2.10%
cases:6.59%
controls:0.65%
cases:4.24%
controls:0.09%
cases:7.30%
controls:0.00%
cases:9.02%
controls:0.07%
cases:7.58%
controls:0.56%
cases:6.50%
controls:1.90%
73
352
1625
16444
112
109
1587
16697
72
15
1627
16791
124
0
1575
16806
153
11
1543
16753
123
91
1499
16066
82
237
1180
12267
triamcinolone and antiseptics
D07BB03 [21602150]
7.4e-01
2.4e+00
3.9e+00
1.0e+50
5.0e+00
2.7e+00
1.3e+00
cases:4.36%
controls:2.13%
cases:6.71%
controls:0.65%
cases:4.24%
controls:0.09%
cases:7.30%
controls:0.00%
cases:9.02%
controls:0.07%
cases:7.58%
controls:0.57%
cases:6.50%
controls:1.92%
74
358
1624
16438
114
109
1585
16697
72
15
1627
16791
124
0
1575
16806
153
11
1543
16753
123
92
1499
16065
82
240
1180
12264
hydroxyzine; oral, parenteral
N05BB01 [21604590]
8.5e-01
2.9e+00
3.9e+00
—
3.1e+00
2.2e+00
1.4e+00
cases:5.06%
controls:2.22%
cases:13.36%
controls:0.82%
cases:9.24%
controls:0.20%
—
—
cases:4.25%
controls:0.20%
cases:6.41%
controls:0.76%
cases:6.81%
controls:1.74%
86
373
1612
16423
227
138
1472
16668
157
34
1542
16772
—
72
34
1624
16730
104
122
1518
16035
86
218
1176
12286
Dermatitis, unspecified
L30.9 [45572271]
8.1e-01
2.5e+00
4.2e+00
1.0e+50
3.6e+00
2.2e+00
8.2e-01
cases:5.12%
controls:2.35%
cases:9.89%
controls:0.93%
cases:8.12%
controls:0.13%
cases:2.24%
controls:0.00%
cases:3.07%
controls:0.09%
cases:8.14%
controls:0.94%
cases:6.81%
controls:3.13%
87
394
1611
16402
168
157
1531
16649
138
22
1561
16784
38
0
1661
16806
52
15
1644
16749
132
152
1490
16005
86
391
1176
12113
hydrocortisone; oral, parenteral
H02AB09 [21602737]
7.4e-01
2.1e+00
3.1e+00
—
4.2e+00
2.5e+00
1.2e+00
cases:3.18%
controls:1.54%
cases:4.83%
controls:0.59%
cases:2.59%
controls:0.12%
—
—
cases:6.37%
controls:0.10%
cases:5.98%
controls:0.52%
cases:4.68%
controls:1.46%
54
259
1644
16537
82
99
1617
16707
44
20
1655
16786
—
108
17
1588
16747
97
84
1525
16073
59
182
1203
12322
hydrocortisone and antiinfectives
S01CA03 [21603654]
6.1e-01
2.0e+00
3.7e+00
1.0e+50
4.5e+00
1.9e+00
1.1e+00
cases:2.18%
controls:1.20%
cases:2.47%
controls:0.35%
cases:1.82%
controls:0.05%
cases:1.88%
controls:0.00%
cases:3.01%
controls:0.04%
cases:2.28%
controls:0.33%
cases:2.77%
controls:0.91%
37
201
1661
16595
42
58
1657
16748
31
8
1668
16798
32
0
1667
16806
51
6
1645
16758
37
54
1585
16103
35
114
1227
12390
hydrocortisone
S02BA01 [21605166]
6.4e-01
2.3e+00
3.8e+00
1.0e+50
4.1e+00
2.0e+00
9.2e-01
cases:10.78%
controls:5.98%
cases:17.01%
controls:1.97%
cases:8.30%
controls:0.20%
cases:8.95%
controls:0.00%
cases:11.73%
controls:0.22%
cases:11.78%
controls:1.83%
cases:13.47%
controls:5.82%
183
1005
1515
15791
289
331
1410
16475
141
34
1558
16772
152
0
1547
16806
199
37
1497
16727
191
296
1431
15861
170
728
1092
11776
Scabies
B86 [45561769]
1.9e+00
4.2e+00
—
1.0e+50
—
5.6e+00
1.8e+00
cases:1.18%
controls:0.18%
cases:6.65%
controls:0.11%
—
—
cases:79.64%
controls:0.00%
—
—
cases:22.75%
controls:0.11%
cases:2.54%
controls:0.41%
20
31
1678
16765
113
18
1586
16788
—
1353
0
346
16806
—
369
17
1253
16140
32
51
1230
12453
hydrocortisone
A07EA02 [21600654]
6.1e-01
2.3e+00
3.7e+00
1.0e+50
4.1e+00
1.9e+00
9.1e-01
cases:11.90%
controls:6.81%
cases:18.19%
controls:2.26%
cases:9.01%
controls:0.24%
cases:9.36%
controls:0.00%
cases:12.44%
controls:0.24%
cases:12.70%
controls:2.12%
cases:14.74%
controls:6.53%
202
1143
1496
15653
309
379
1390
16427
153
40
1546
16766
159
0
1540
16806
211
40
1485
16724
206
342
1416
15815
186
817
1076
11687
hydrocortisone
C05AA01 [21601608]
6.1e-01
2.3e+00
3.7e+00
1.0e+50
4.1e+00
1.9e+00
9.1e-01
cases:11.90%
controls:6.81%
cases:18.19%
controls:2.26%
cases:9.01%
controls:0.24%
cases:9.36%
controls:0.00%
cases:12.44%
controls:0.24%
cases:12.70%
controls:2.12%
cases:14.74%
controls:6.53%
202
1143
1496
15653
309
379
1390
16427
153
40
1546
16766
159
0
1540
16806
211
40
1485
16724
206
342
1416
15815
186
817
1076
11687
hydrocortisone aceponate
D07AC16 [21602135]
5.9e-01
2.3e+00
3.7e+00
1.0e+50
4.1e+00
1.9e+00
9.1e-01
cases:11.60%
controls:6.76%
cases:18.07%
controls:2.24%
cases:9.01%
controls:0.24%
cases:9.36%
controls:0.00%
cases:12.44%
controls:0.24%
cases:12.70%
controls:2.10%
cases:14.66%
controls:6.49%
197
1136
1501
15660
307
377
1392
16429
153
40
1546
16766
159
0
1540
16806
211
40
1485
16724
206
340
1416
15817
185
811
1077
11693
hydrocortisone
D07AA02 [21602102]
5.9e-01
2.3e+00
3.7e+00
1.0e+50
4.1e+00
1.9e+00
9.1e-01
cases:11.60%
controls:6.76%
cases:18.07%
controls:2.24%
cases:9.01%
controls:0.24%
cases:9.36%
controls:0.00%
cases:12.44%
controls:0.24%
cases:12.70%
controls:2.10%
cases:14.66%
controls:6.49%
197
1136
1501
15660
307
377
1392
16429
153
40
1546
16766
159
0
1540
16806
211
40
1485
16724
206
340
1416
15817
185
811
1077
11693
hydrocortisone butyrate
D07AB02 [21602106]
5.9e-01
2.3e+00
3.7e+00
1.0e+50
4.1e+00
1.9e+00
9.1e-01
cases:11.60%
controls:6.76%
cases:18.07%
controls:2.24%
cases:9.01%
controls:0.24%
cases:9.36%
controls:0.00%
cases:12.44%
controls:0.24%
cases:12.70%
controls:2.10%
cases:14.66%
controls:6.49%
197
1136
1501
15660
307
377
1392
16429
153
40
1546
16766
159
0
1540
16806
211
40
1485
16724
206
340
1416
15817
185
811
1077
11693
hydrocortisone buteprate
D07AB11 [21602115]
5.9e-01
2.3e+00
3.7e+00
1.0e+50
4.1e+00
1.9e+00
9.1e-01
cases:11.60%
controls:6.76%
cases:18.07%
controls:2.24%
cases:9.01%
controls:0.24%
cases:9.36%
controls:0.00%
cases:12.44%
controls:0.24%
cases:12.70%
controls:2.10%
cases:14.66%
controls:6.49%
197
1136
1501
15660
307
377
1392
16429
153
40
1546
16766
159
0
1540
16806
211
40
1485
16724
206
340
1416
15817
185
811
1077
11693
antibiotics in combination with corticosteroids
D01AA20 [21601918]
5.6e-01
2.0e+00
4.0e+00
1.0e+50
4.3e+00
2.0e+00
1.1e+00
cases:2.36%
controls:1.36%
cases:2.59%
controls:0.36%
cases:1.82%
controls:0.04%
cases:1.88%
controls:0.00%
cases:3.13%
controls:0.04%
cases:2.47%
controls:0.35%
cases:3.01%
controls:1.06%
40
229
1658
16567
44
60
1655
16746
31
6
1668
16800
32
0
1667
16806
53
7
1643
16757
40
57
1582
16100
38
132
1224
12372
General Practice
1 [38004446]
6.1e-01
9.5e-01
1.6e+00
5.7e+00
1.8e+00
9.6e-01
6.0e-01
cases:19.61%
controls:11.66%
cases:9.95%
controls:4.09%
cases:2.88%
controls:0.62%
cases:9.65%
controls:0.04%
cases:3.83%
controls:0.67%
cases:10.85%
controls:4.45%
cases:17.67%
controls:10.52%
333
1959
1365
14837
169
688
1530
16118
49
105
1650
16701
164
6
1535
16800
65
112
1631
16652
176
719
1446
15438
223
1315
1039
11189
betamethasone
D07AC01 [21602120]
5.2e-01
2.0e+00
3.6e+00
—
3.4e+00
1.8e+00
8.7e-01
cases:9.48%
controls:5.88%
cases:14.30%
controls:2.16%
cases:7.65%
controls:0.23%
—
—
cases:7.49%
controls:0.27%
cases:12.15%
controls:2.31%
cases:13.00%
controls:5.88%
161
988
1537
15808
243
363
1456
16443
130
38
1569
16768
—
127
46
1569
16718
197
373
1425
15784
164
735
1098
11769
betamethasone
A07EA04 [21600656]
5.2e-01
2.0e+00
3.6e+00
—
3.4e+00
1.8e+00
8.7e-01
cases:9.48%
controls:5.88%
cases:14.30%
controls:2.16%
cases:7.65%
controls:0.23%
—
—
cases:7.49%
controls:0.27%
cases:12.15%
controls:2.31%
cases:13.00%
controls:5.88%
161
988
1537
15808
243
363
1456
16443
130
38
1569
16768
—
127
46
1569
16718
197
373
1425
15784
164
735
1098
11769
betamethasone
C05AA05 [21601610]
5.2e-01
2.0e+00
3.6e+00
—
3.4e+00
1.8e+00
8.7e-01
cases:9.48%
controls:5.88%
cases:14.30%
controls:2.16%
cases:7.65%
controls:0.23%
—
—
cases:7.49%
controls:0.27%
cases:12.15%
controls:2.31%
cases:13.00%
controls:5.88%
161
988
1537
15808
243
363
1456
16443
130
38
1569
16768
—
127
46
1569
16718
197
373
1425
15784
164
735
1098
11769
betamethasone
S02BA07 [21605169]
5.2e-01
2.0e+00
3.6e+00
—
3.4e+00
1.8e+00
8.7e-01
cases:9.48%
controls:5.88%
cases:14.30%
controls:2.16%
cases:7.65%
controls:0.23%
—
—
cases:7.49%
controls:0.27%
cases:12.15%
controls:2.31%
cases:13.00%
controls:5.88%
161
988
1537
15808
243
363
1456
16443
130
38
1569
16768
—
127
46
1569
16718
197
373
1425
15784
164
735
1098
11769
desonide
D07AB08 [21602112]
6.8e-01
2.2e+00
3.5e+00
—
3.4e+00
1.9e+00
2.5e-01
cases:3.24%
controls:1.67%
cases:5.12%
controls:0.58%
cases:1.88%
controls:0.06%
—
—
cases:1.77%
controls:0.06%
cases:3.02%
controls:0.48%
cases:1.98%
controls:1.54%
55
280
1643
16516
87
97
1612
16709
32
10
1667
16796
—
30
10
1666
16754
49
77
1573
16080
25
193
1237
12311
clobetasol
D07AD01 [21602141]
6.3e-01
1.9e+00
3.4e+00
—
3.0e+00
1.7e+00
8.2e-01
cases:3.53%
controls:1.91%
cases:4.94%
controls:0.80%
cases:1.88%
controls:0.07%
—
—
cases:2.00%
controls:0.10%
cases:4.19%
controls:0.80%
cases:4.68%
controls:2.12%
60
321
1638
16475
84
135
1615
16671
32
11
1667
16795
—
34
17
1662
16747
68
130
1554
16027
59
265
1203
12239
other preparations, combinations; ointment
C05AX03 [21601631]
5.2e-01
1.6e+00
3.1e+00
—
3.9e+00
1.3e+00
9.0e-01
cases:4.00%
controls:2.43%
cases:3.88%
controls:0.83%
cases:2.00%
controls:0.10%
—
—
cases:3.30%
controls:0.07%
cases:3.08%
controls:0.85%
cases:4.91%
controls:2.06%
68
408
1630
16388
66
139
1633
16667
34
16
1665
16790
—
56
12
1640
16752
50
138
1572
16019
62
258
1200
12246
hydrocortisone and antiinfectives
S03CA04 [21605208]
6.0e-01
1.4e+00
3.2e+00
—
3.9e+00
1.4e+00
7.9e-01
cases:3.71%
controls:2.07%
cases:2.65%
controls:0.68%
cases:1.82%
controls:0.08%
—
—
cases:3.07%
controls:0.07%
cases:2.53%
controls:0.66%
cases:3.96%
controls:1.84%
63
348
1635
16448
45
114
1654
16692
31
13
1668
16793
—
52
11
1644
16753
41
107
1581
16050
50
230
1212
12274
hydrocortisone and antiinfectives
S02CA03 [21605175]
6.0e-01
1.4e+00
3.2e+00
—
3.9e+00
1.4e+00
7.9e-01
cases:3.71%
controls:2.07%
cases:2.65%
controls:0.68%
cases:1.82%
controls:0.08%
—
—
cases:3.07%
controls:0.07%
cases:2.53%
controls:0.66%
cases:3.96%
controls:1.84%
63
348
1635
16448
45
114
1654
16692
31
13
1668
16793
—
52
11
1644
16753
41
107
1581
16050
50
230
1212
12274
Pruritus, unspecified
L29.9 [45548195]
1.4e+00
4.3e+00
—
1.0e+50
—
4.1e+00
1.3e+00
cases:0.82%
controls:0.20%
cases:4.41%
controls:0.07%
—
—
cases:1.24%
controls:0.00%
—
—
cases:3.58%
controls:0.06%
cases:0.95%
controls:0.26%
14
34
1684
16762
75
11
1624
16795
—
21
0
1678
16806
—
58
10
1564
16147
12
33
1250
12471
combinations of corticosteroids
D07AB30 [21602118]
5.9e-01
1.7e+00
2.9e+00
—
3.5e+00
1.5e+00
8.1e-01
cases:16.20%
controls:9.71%
cases:16.24%
controls:3.54%
cases:7.36%
controls:0.45%
—
—
cases:11.38%
controls:0.38%
cases:14.06%
controls:3.46%
cases:18.86%
controls:9.37%
275
1631
1423
15165
276
595
1423
16211
125
76
1574
16730
—
193
64
1503
16700
228
559
1394
15598
238
1172
1024
11332
combinations of corticosteroids
D07XB30 [21602188]
5.9e-01
1.7e+00
2.9e+00
—
3.5e+00
1.5e+00
8.1e-01
cases:16.20%
controls:9.71%
cases:16.24%
controls:3.54%
cases:7.36%
controls:0.45%
—
—
cases:11.38%
controls:0.38%
cases:14.06%
controls:3.46%
cases:18.86%
controls:9.37%
275
1631
1423
15165
276
595
1423
16211
125
76
1574
16730
—
193
64
1503
16700
228
559
1394
15598
238
1172
1024
11332
mometasone
D07AC13 [21602132]
3.4e-01
2.1e+00
3.5e+00
—
2.9e+00
1.5e+00
7.6e-01
cases:5.42%
controls:3.90%
cases:9.24%
controls:1.27%
cases:3.71%
controls:0.12%
—
—
cases:2.48%
controls:0.14%
cases:5.36%
controls:1.26%
cases:6.81%
controls:3.32%
92
655
1606
16141
157
214
1542
16592
63
20
1636
16786
—
42
23
1654
16741
87
203
1535
15954
86
415
1176
12089
Inpatient Visit
IP [9201]
3.1e-01
6.1e-01
8.7e-01
5.7e+00
1.9e+00
7.0e-01
5.5e-01
cases:12.90%
controls:9.82%
cases:6.30%
controls:3.51%
cases:1.29%
controls:0.55%
cases:7.89%
controls:0.03%
cases:2.65%
controls:0.39%
cases:6.29%
controls:3.21%
cases:12.68%
controls:7.73%
219
1650
1479
15146
107
590
1592
16216
22
92
1677
16714
134
5
1565
16801
45
65
1651
16699
102
519
1520
15638
160
967
1102
11537
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
5.8e-01
1.6e+00
2.8e+00
—
3.4e+00
1.3e+00
7.4e-01
cases:6.54%
controls:3.76%
cases:6.06%
controls:1.33%
cases:2.47%
controls:0.15%
—
—
cases:3.77%
controls:0.13%
cases:4.87%
controls:1.36%
cases:7.13%
controls:3.53%
111
631
1587
16165
103
223
1596
16583
42
25
1657
16781
—
64
22
1632
16742
79
220
1543
15937
90
441
1172
12063
Kidney transplant status
Z94.0 [45566477]
1.6e+00
1.5e+00
1.7e+00
—
2.1e+00
1.7e+00
1.9e+00
cases:0.65%
controls:0.13%
cases:0.71%
controls:0.15%
cases:0.47%
controls:0.09%
—
—
cases:0.53%
controls:0.07%
cases:0.74%
controls:0.14%
cases:0.87%
controls:0.14%
11
22
1687
16774
12
26
1687
16780
8
15
1691
16791
—
9
11
1687
16753
12
23
1610
16134
11
17
1251
12487
Emergency Medicine
93 [38004510]
4.5e-01
6.5e-01
1.4e+00
4.9e+00
1.0e+00
6.9e-01
5.8e-01
cases:24.97%
controls:17.53%
cases:15.01%
controls:8.48%
cases:4.18%
controls:1.05%
cases:6.06%
controls:0.05%
cases:3.24%
controls:1.22%
cases:15.60%
controls:8.52%
cases:27.81%
controls:17.81%
424
2944
1274
13852
255
1425
1444
15381
71
176
1628
16630
103
8
1596
16798
55
204
1641
16560
253
1376
1369
14781
351
2227
911
10277
cefalexin; oral
J01DB01 [21602870]
4.5e-01
9.1e-01
1.9e+00
3.2e+00
1.5e+00
7.3e-01
4.3e-01
cases:34.81%
controls:25.47%
cases:17.25%
controls:7.75%
cases:5.30%
controls:0.86%
cases:0.88%
controls:0.04%
cases:4.13%
controls:0.94%
cases:14.43%
controls:7.53%
cases:32.33%
controls:23.77%
591
4278
1107
12518
293
1302
1406
15504
90
144
1609
16662
15
6
1684
16800
70
157
1626
16607
234
1216
1388
14941
408
2972
854
9532
permethrin
P03AC04 [21604984]
2.4e+00
4.2e+00
1.0e+50
1.0e+50
—
—
2.2e+00
cases:0.82%
controls:0.08%
cases:2.24%
controls:0.04%
cases:1.35%
controls:0.00%
cases:5.41%
controls:0.00%
—
—
—
—
cases:1.03%
controls:0.12%
14
13
1684
16783
38
6
1661
16800
23
0
1676
16806
92
0
1607
16806
—
—
13
15
1249
12489
Bipolar affective disorder, unspecified
F31.9 [45571758]
1.2e+00
1.7e+00
2.4e+00
—
—
1.7e+00
1.6e+00
cases:1.00%
controls:0.29%
cases:0.77%
controls:0.14%
cases:0.53%
controls:0.05%
—
—
—
—
cases:0.68%
controls:0.13%
cases:1.66%
controls:0.34%
17
49
1681
16747
13
24
1686
16782
9
8
1690
16798
—
—
11
21
1611
16136
21
42
1241
12462
Monocytes [#/volume] in Blood
26484-6 [3001604]
3.6e-01
8.8e-01
1.6e+00
3.2e+00
1.1e+00
7.5e-01
6.4e-01
cases:18.08%
controls:13.39%
cases:15.83%
controls:7.22%
cases:6.59%
controls:1.46%
cases:0.71%
controls:0.03%
cases:4.01%
controls:1.37%
cases:13.81%
controls:7.02%
cases:20.92%
controls:12.28%
307
2249
1391
14547
269
1214
1430
15592
112
246
1587
16560
12
5
1687
16801
68
230
1628
16534
224
1134
1398
15023
264
1536
998
10968
Basophils [#/volume] in Blood
26444-0 [3006315]
3.6e-01
8.8e-01
1.5e+00
3.2e+00
1.1e+00
7.5e-01
6.4e-01
cases:18.20%
controls:13.41%
cases:15.83%
controls:7.24%
cases:6.59%
controls:1.48%
cases:0.71%
controls:0.03%
cases:4.01%
controls:1.38%
cases:13.87%
controls:7.07%
cases:21.00%
controls:12.32%
309
2252
1389
14544
269
1217
1430
15589
112
249
1587
16557
12
5
1687
16801
68
231
1628
16533
225
1142
1397
15015
265
1541
997
10963
Skin symptom/complaint other
S29 [2002000993]
1.1e-01
1.8e+00
3.0e+00
—
2.0e+00
9.8e-01
6.8e-01
cases:3.00%
controls:2.70%
cases:4.94%
controls:0.87%
cases:2.35%
controls:0.12%
—
—
cases:0.71%
controls:0.10%
cases:2.34%
controls:0.89%
cases:5.07%
controls:2.63%
51
453
1647
16343
84
146
1615
16660
40
21
1659
16785
—
12
16
1684
16748
38
144
1584
16013
64
329
1198
12175
ANTIHYPERTENSIVE_DRUG - yes
ANTIHYPERTENSIVE_DRUG-1 [2002330215]
1.7e+00
2.2e+00
—
—
—
1.9e+00
2.5e+00
cases:0.94%
controls:0.17%
cases:0.71%
controls:0.08%
—
—
—
—
—
—
cases:0.68%
controls:0.10%
cases:1.03%
controls:0.09%
16
28
1682
16768
12
13
1687
16793
—
—
—
11
16
1611
16141
13
11
1249
12493
ciclosporin; oral, parenteral
L04AD01 [21603924]
1.4e+00
1.5e+00
1.8e+00
—
2.0e+00
1.9e+00
1.8e+00
cases:1.06%
controls:0.27%
cases:0.77%
controls:0.17%
cases:0.47%
controls:0.08%
—
—
cases:0.29%
controls:0.04%
cases:0.99%
controls:0.15%
cases:1.27%
controls:0.22%
18
46
1680
16750
13
29
1686
16777
8
13
1691
16793
—
5
7
1691
16757
16
24
1606
16133
16
27
1246
12477
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
3.4e-01
8.6e-01
1.6e+00
3.2e+00
1.1e+00
7.5e-01
6.0e-01
cases:18.55%
controls:13.96%
cases:15.83%
controls:7.37%
cases:6.65%
controls:1.48%
cases:0.71%
controls:0.03%
cases:3.95%
controls:1.40%
cases:14.00%
controls:7.12%
cases:21.00%
controls:12.69%
315
2344
1383
14452
269
1238
1430
15568
113
249
1586
16557
12
5
1687
16801
67
235
1629
16529
227
1151
1395
15006
265
1587
997
10917
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
4.1e-01
1.7e+00
2.5e+00
1.0e+50
2.3e+00
1.9e+00
5.5e-01
cases:2.65%
controls:1.77%
cases:2.65%
controls:0.51%
cases:0.82%
controls:0.07%
cases:0.35%
controls:0.00%
cases:0.53%
controls:0.05%
cases:2.53%
controls:0.38%
cases:2.22%
controls:1.29%
45
298
1653
16498
45
86
1654
16720
14
12
1685
16794
6
0
1693
16806
9
9
1687
16755
41
62
1581
16095
28
161
1234
12343
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
5.0e-01
1.0e+00
1.4e+00
3.1e+00
1.0e+00
5.9e-01
6.1e-01
cases:18.20%
controls:11.87%
cases:13.89%
controls:5.41%
cases:5.00%
controls:1.26%
cases:0.88%
controls:0.04%
cases:2.89%
controls:1.07%
cases:9.49%
controls:5.49%
cases:17.99%
controls:10.64%
309
1993
1389
14803
236
910
1463
15896
85
211
1614
16595
15
7
1684
16799
49
180
1647
16584
154
887
1468
15270
227
1330
1035
11174
Scabies/other acariasis
S72 [2002001036]
—
3.5e+00
1.0e+50
1.0e+50
—
3.1e+00
1.7e+00
—
—
cases:2.24%
controls:0.07%
cases:1.00%
controls:0.00%
cases:0.53%
controls:0.00%
—
—
cases:1.60%
controls:0.07%
cases:0.63%
controls:0.12%
—
38
12
1661
16794
17
0
1682
16806
9
0
1690
16806
—
26
12
1596
16145
8
15
1254
12489
Eosinophils [#/volume] in Blood
26449-9 [3013115]
3.6e-01
8.7e-01
1.5e+00
3.1e+00
1.0e+00
7.5e-01
6.3e-01
cases:18.85%
controls:13.95%
cases:16.24%
controls:7.53%
cases:6.65%
controls:1.61%
cases:0.77%
controls:0.04%
cases:4.01%
controls:1.48%
cases:14.24%
controls:7.27%
cases:21.55%
controls:12.77%
320
2343
1378
14453
276
1265
1423
15541
113
271
1586
16535
13
6
1686
16800
68
248
1628
16516
231
1175
1391
14982
272
1597
990
10907
betamethasone
S03BA03 [21605203]
5.6e-01
1.5e+00
2.1e+00
—
2.3e+00
9.4e-01
6.6e-01
cases:3.06%
controls:1.78%
cases:2.77%
controls:0.65%
cases:0.59%
controls:0.07%
—
—
cases:0.71%
controls:0.07%
cases:1.73%
controls:0.68%
cases:3.57%
controls:1.88%
52
299
1646
16497
47
110
1652
16696
10
12
1689
16794
—
12
12
1684
16752
28
110
1594
16047
45
235
1217
12269
Pruritus
S02 [2002000967]
1.2e+00
3.7e+00
—
—
—
2.7e+00
9.7e-01
cases:1.12%
controls:0.33%
cases:3.83%
controls:0.10%
—
—
—
—
—
—
cases:1.36%
controls:0.09%
cases:1.03%
controls:0.39%
19
55
1679
16741
65
17
1634
16789
—
—
—
22
15
1600
16142
13
49
1249
12455
Infectious Disease
44 [38004484]
7.4e-01
1.0e+00
1.5e+00
1.0e+50
2.0e+00
1.2e+00
1.1e+00
cases:4.18%
controls:2.05%
cases:2.12%
controls:0.78%
cases:0.65%
controls:0.15%
cases:1.18%
controls:0.00%
cases:0.83%
controls:0.11%
cases:2.34%
controls:0.74%
cases:4.36%
controls:1.50%
71
344
1627
16452
36
131
1663
16675
11
25
1688
16781
20
0
1679
16806
14
18
1682
16746
38
120
1584
16037
55
187
1207
12317
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
3.8e-01
8.1e-01
1.3e+00
2.9e+00
1.0e+00
5.8e-01
5.6e-01
cases:28.33%
controls:21.28%
cases:22.60%
controls:11.50%
cases:8.06%
controls:2.40%
cases:1.00%
controls:0.05%
cases:5.48%
controls:2.10%
cases:18.68%
controls:11.43%
cases:29.56%
controls:19.38%
481
3575
1217
13221
384
1932
1315
14874
137
404
1562
16402
17
9
1682
16797
93
352
1603
16412
303
1846
1319
14311
373
2423
889
10081
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.8e-01
5.8e-01
1.2e+00
3.4e+00
1.0e+00
5.6e-01
3.6e-01
cases:40.58%
controls:34.13%
cases:30.25%
controls:19.47%
cases:12.01%
controls:3.77%
cases:4.47%
controls:0.16%
cases:9.38%
controls:3.56%
cases:29.22%
controls:19.10%
cases:41.44%
controls:33.05%
689
5732
1009
11064
514
3272
1185
13534
204
634
1495
16172
76
27
1623
16779
159
596
1537
16168
474
3086
1148
13071
523
4132
739
8372
Outpatient Visit
OP [9202]
2.6e-01
3.3e-01
5.7e-01
4.5e+00
1.1e+00
4.1e-01
2.6e-01
cases:73.44%
controls:68.14%
cases:56.39%
controls:48.15%
cases:15.30%
controls:9.26%
cases:27.84%
controls:0.45%
cases:21.76%
controls:8.57%
cases:54.50%
controls:44.27%
cases:72.82%
controls:67.39%
1247
11444
451
5352
958
8092
741
8714
260
1557
1439
15249
473
75
1226
16731
369
1437
1327
15327
884
7153
738
9004
919
8427
343
4077
Local dermatologic skincare
TQW80 [2001310149]
7.1e-01
2.0e+00
—
1.0e+50
—
3.5e+00
1.8e+00
cases:0.59%
controls:0.29%
cases:0.53%
controls:0.07%
—
—
cases:0.77%
controls:0.00%
—
—
cases:1.60%
controls:0.05%
cases:0.95%
controls:0.15%
10
49
1688
16747
9
12
1690
16794
—
13
0
1686
16806
—
26
8
1596
16149
12
19
1250
12485
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
3.1e-01
7.2e-01
1.5e+00
2.8e+00
8.0e-01
6.0e-01
4.2e-01
cases:26.15%
controls:20.59%
cases:17.60%
controls:9.43%
cases:6.18%
controls:1.39%
cases:0.71%
controls:0.04%
cases:2.65%
controls:1.21%
cases:15.23%
controls:8.94%
cases:24.96%
controls:17.98%
444
3458
1254
13338
299
1585
1400
15221
105
234
1594
16572
12
7
1687
16799
45
203
1651
16561
247
1444
1375
14713
315
2248
947
10256
azathioprine; oral, parenteral
L04AX01 [21603927]
8.3e-01
1.3e+00
1.0e+00
—
1.9e+00
1.5e+00
1.5e+00
cases:1.53%
controls:0.67%
cases:1.65%
controls:0.43%
cases:0.35%
controls:0.12%
—
—
cases:0.94%
controls:0.14%
cases:1.66%
controls:0.36%
cases:2.14%
controls:0.47%
26
113
1672
16683
28
73
1671
16733
6
21
1693
16785
—
16
23
1680
16741
27
58
1595
16099
27
59
1235
12445
Psoriasis vulgaris
L40.0 [45543370]
1.1e+00
1.2e+00
1.6e+00
1.0e+50
2.0e+00
1.5e+00
1.4e+00
cases:1.47%
controls:0.48%
cases:0.94%
controls:0.30%
cases:0.35%
controls:0.07%
cases:0.88%
controls:0.00%
cases:0.47%
controls:0.07%
cases:1.54%
controls:0.34%
cases:1.90%
controls:0.48%
25
81
1673
16715
16
50
1683
16756
6
12
1693
16794
15
0
1684
16806
8
11
1688
16753
25
55
1597
16102
24
60
1238
12444
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
3.4e-01
7.5e-01
1.1e+00
2.7e+00
8.4e-01
6.7e-01
6.2e-01
cases:20.55%
controls:15.60%
cases:16.42%
controls:8.46%
cases:6.53%
controls:2.17%
cases:0.77%
controls:0.05%
cases:4.54%
controls:2.02%
cases:14.61%
controls:8.08%
cases:22.58%
controls:13.52%
349
2621
1349
14175
279
1421
1420
15385
111
365
1588
16441
13
9
1686
16797
77
338
1619
16426
237
1306
1385
14851
285
1690
977
10814
Infective dermatitis
L30.3 [45577034]
9.3e-01
2.6e+00
—
1.0e+50
—
2.9e+00
1.5e+00
cases:0.59%
controls:0.23%
cases:1.00%
controls:0.08%
—
—
cases:0.71%
controls:0.00%
—
—
cases:1.48%
controls:0.08%
cases:1.43%
controls:0.31%
10
39
1688
16757
17
13
1682
16793
—
12
0
1687
16806
—
24
13
1598
16144
18
39
1244
12465
cetirizine; oral
R06AE07 [21603497]
5.3e-01
1.4e+00
2.1e+00
1.0e+50
1.6e+00
9.1e-01
4.8e-01
cases:13.43%
controls:8.35%
cases:14.07%
controls:4.05%
cases:5.18%
controls:0.65%
cases:1.35%
controls:0.00%
cases:2.71%
controls:0.54%
cases:8.82%
controls:3.75%
cases:11.65%
controls:7.53%
228
1402
1470
15394
239
681
1460
16125
88
110
1611
16696
23
0
1676
16806
46
91
1650
16673
143
606
1479
15551
147
942
1115
11562
Alcohol depence active use
F10.24 [2000501681]
2.4e+00
—
—
—
—
2.3e+00
2.2e+00
cases:0.41%
controls:0.04%
—
—
—
—
—
—
—
—
cases:0.37%
controls:0.04%
cases:0.63%
controls:0.07%
7
6
1691
16790
—
—
—
—
6
6
1616
16151
8
9
1254
12495
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
8.9e-01
2.4e+00
1.0e+50
1.0e+50
—
2.6e+00
9.6e-01
cases:1.88%
controls:0.79%
cases:1.88%
controls:0.17%
cases:0.94%
controls:0.00%
cases:1.12%
controls:0.00%
—
—
cases:2.40%
controls:0.18%
cases:1.51%
controls:0.58%
32
132
1666
16664
32
28
1667
16778
16
0
1683
16806
19
0
1680
16806
—
39
29
1583
16128
19
73
1243
12431
prednisolone
A07EA01 [21600653]
5.8e-01
1.3e+00
2.1e+00
—
1.4e+00
8.6e-01
7.0e-01
cases:14.61%
controls:8.77%
cases:12.12%
controls:3.77%
cases:4.65%
controls:0.59%
—
—
cases:2.65%
controls:0.70%
cases:8.20%
controls:3.64%
cases:14.34%
controls:7.70%
248
1473
1450
15323
206
633
1493
16173
79
99
1620
16707
—
45
117
1651
16647
133
588
1489
15569
181
963
1081
11541
prednisolone; oral, parenteral
H02AB06 [21602734]
5.8e-01
1.3e+00
2.1e+00
—
1.4e+00
8.5e-01
6.9e-01
cases:14.55%
controls:8.72%
cases:12.07%
controls:3.75%
cases:4.53%
controls:0.59%
—
—
cases:2.65%
controls:0.70%
cases:8.08%
controls:3.63%
cases:14.18%
controls:7.68%
247
1464
1451
15332
205
631
1494
16175
77
99
1622
16707
—
45
117
1651
16647
131
587
1491
15570
179
960
1083
11544
Medical doctor
Z2221 [2001311556]
2.2e-02
9.4e-01
1.8e+00
—
2.1e+00
1.2e+00
7.6e-01
cases:3.36%
controls:3.29%
cases:1.88%
controls:0.74%
cases:0.47%
controls:0.08%
—
—
cases:0.53%
controls:0.07%
cases:1.73%
controls:0.54%
cases:3.65%
controls:1.74%
57
552
1641
16244
32
125
1667
16681
8
13
1691
16793
—
9
11
1687
16753
28
88
1594
16069
46
217
1216
12287
Erysipelas
A46 [45561706]
4.2e-01
1.0e+00
2.2e+00
—
2.4e+00
1.2e+00
6.2e-01
cases:2.24%
controls:1.48%
cases:1.59%
controls:0.58%
cases:0.47%
controls:0.05%
—
—
cases:0.71%
controls:0.07%
cases:1.54%
controls:0.48%
cases:2.77%
controls:1.51%
38
249
1660
16547
27
98
1672
16708
8
9
1691
16797
—
12
11
1684
16753
25
78
1597
16079
35
189
1227
12315
antibiotics in combination with other drugs
S01AA20 [21603571]
2.9e-01
7.8e-01
2.2e+00
—
2.6e+00
6.9e-01
4.6e-01
cases:8.07%
controls:6.16%
cases:4.12%
controls:1.94%
cases:1.88%
controls:0.21%
—
—
cases:3.18%
controls:0.25%
cases:3.70%
controls:1.89%
cases:8.56%
controls:5.56%
137
1034
1561
15762
70
326
1629
16480
32
35
1667
16771
—
54
42
1642
16722
60
305
1562
15852
108
695
1154
11809
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
5.9e-01
8.4e-01
1.8e+00
—
1.6e+00
1.1e+00
7.1e-01
cases:2.36%
controls:1.32%
cases:2.18%
controls:0.95%
cases:0.88%
controls:0.14%
—
—
cases:0.83%
controls:0.17%
cases:2.84%
controls:0.96%
cases:3.72%
controls:1.86%
40
222
1658
16574
37
160
1662
16646
15
24
1684
16782
—
14
29
1682
16735
46
155
1576
16002
47
233
1215
12271
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
6.0e-01
8.4e-01
1.8e+00
—
1.6e+00
1.1e+00
6.7e-01
cases:2.53%
controls:1.41%
cases:2.24%
controls:0.98%
cases:0.94%
controls:0.16%
—
—
cases:0.88%
controls:0.18%
cases:3.02%
controls:0.99%
cases:3.57%
controls:1.86%
43
237
1655
16559
38
165
1661
16641
16
27
1683
16779
—
15
30
1681
16734
49
160
1573
15997
45
232
1217
12272
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
5.8e-01
8.6e-01
1.8e+00
—
1.6e+00
1.1e+00
6.6e-01
cases:2.59%
controls:1.46%
cases:2.35%
controls:1.01%
cases:0.94%
controls:0.16%
—
—
cases:0.88%
controls:0.18%
cases:3.02%
controls:1.02%
cases:3.65%
controls:1.92%
44
246
1654
16550
40
170
1659
16636
16
27
1683
16779
—
15
31
1681
16733
49
165
1573
15992
46
240
1216
12264
Supplier / Service Provider
OMOP5117446 [33004]
-6.1e-01
-7.6e-01
-7.0e-02
—
2.3e+00
2.6e+00
3.0e+00
cases:18.67%
controls:29.64%
cases:4.36%
controls:8.89%
cases:0.88%
controls:0.95%
—
—
cases:0.53%
controls:0.05%
cases:5.98%
controls:0.48%
cases:14.82%
controls:0.85%
317
4978
1381
11818
74
1494
1625
15312
15
159
1684
16647
—
9
9
1687
16755
97
78
1525
16079
187
106
1075
12398
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
3.5e-01
4.7e-01
1.1e+00
2.6e+00
8.5e-01
4.6e-01
5.5e-01
cases:15.37%
controls:11.38%
cases:8.42%
controls:5.46%
cases:2.71%
controls:0.88%
cases:0.41%
controls:0.03%
cases:1.95%
controls:0.84%
cases:8.14%
controls:5.31%
cases:16.56%
controls:10.24%
261
1911
1437
14885
143
917
1556
15889
46
148
1653
16658
7
5
1692
16801
33
141
1663
16623
132
858
1490
15299
209
1281
1053
11223
Nephrology
39 [38004479]
8.2e-01
9.1e-01
1.3e+00
—
1.5e+00
9.9e-01
8.6e-01
cases:1.88%
controls:0.84%
cases:1.59%
controls:0.65%
cases:1.00%
controls:0.27%
—
—
cases:1.06%
controls:0.23%
cases:1.54%
controls:0.58%
cases:2.06%
controls:0.88%
32
141
1666
16655
27
109
1672
16697
17
45
1682
16761
—
18
39
1678
16725
25
93
1597
16064
26
110
1236
12394
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
3.6e-01
5.0e-01
1.1e+00
2.7e+00
7.0e-01
5.9e-01
4.3e-01
cases:19.08%
controls:14.13%
cases:9.54%
controls:5.99%
cases:2.53%
controls:0.83%
cases:0.71%
controls:0.05%
cases:1.83%
controls:0.92%
cases:9.62%
controls:5.56%
cases:18.94%
controls:13.19%
324
2373
1374
14423
162
1006
1537
15800
43
140
1656
16666
12
8
1687
16798
31
154
1665
16610
156
898
1466
15259
239
1649
1023
10855
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
7.5e-01
9.4e-01
1.3e+00
—
1.3e+00
1.0e+00
1.0e+00
cases:4.30%
controls:2.07%
cases:2.41%
controls:0.95%
cases:0.88%
controls:0.23%
—
—
cases:0.94%
controls:0.27%
cases:2.84%
controls:1.02%
cases:4.52%
controls:1.65%
73
348
1625
16448
41
160
1658
16646
15
39
1684
16767
—
16
45
1680
16719
46
164
1576
15993
57
206
1205
12298
Venereal disease screening
171128005 [4064905]
8.4e-01
2.0e+00
2.1e+00
—
—
1.9e+00
1.6e+00
cases:1.71%
controls:0.74%
cases:1.12%
controls:0.15%
cases:0.29%
controls:0.04%
—
—
—
—
cases:1.17%
controls:0.17%
cases:2.93%
controls:0.62%
29
125
1669
16671
19
25
1680
16781
5
6
1694
16800
—
—
19
28
1603
16129
37
77
1225
12427
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
5.0e-01
1.1e+00
1.8e+00
—
1.5e+00
9.9e-01
5.1e-01
cases:8.83%
controls:5.57%
cases:7.24%
controls:2.58%
cases:2.65%
controls:0.47%
—
—
cases:2.00%
controls:0.47%
cases:6.78%
controls:2.64%
cases:9.03%
controls:5.64%
150
935
1548
15861
123
433
1576
16373
45
79
1654
16727
—
34
79
1662
16685
110
427
1512
15730
114
705
1148
11799
glycerol
A06AX01 [21600597]
4.7e-01
1.9e+00
—
1.0e+50
—
2.8e+00
1.6e+00
cases:0.59%
controls:0.37%
cases:0.59%
controls:0.09%
—
—
cases:0.29%
controls:0.00%
—
—
cases:0.99%
controls:0.06%
cases:0.79%
controls:0.16%
10
62
1688
16734
10
15
1689
16791
—
5
0
1694
16806
—
16
10
1606
16147
10
20
1252
12484
glycerol; rectal
A06AG04 [21600587]
4.7e-01
1.9e+00
—
1.0e+50
—
2.8e+00
1.6e+00
cases:0.59%
controls:0.37%
cases:0.59%
controls:0.09%
—
—
cases:0.29%
controls:0.00%
—
—
cases:0.99%
controls:0.06%
cases:0.79%
controls:0.16%
10
62
1688
16734
10
15
1689
16791
—
5
0
1694
16806
—
16
10
1606
16147
10
20
1252
12484
Psychiatry
26 [38004469]
6.6e-01
7.9e-01
8.2e-01
1.4e+00
8.4e-01
9.3e-01
8.2e-01
cases:12.07%
controls:6.64%
cases:7.47%
controls:3.55%
cases:3.30%
controls:1.48%
cases:0.59%
controls:0.14%
cases:3.60%
controls:1.58%
cases:8.63%
controls:3.60%
cases:13.63%
controls:6.52%
205
1116
1493
15680
127
597
1572
16209
56
248
1643
16558
10
24
1689
16782
61
265
1635
16499
140
582
1482
15575
172
815
1090
11689
Bacteria identified in Blood by Culture
600-7 [3023368]
4.1e-01
7.9e-01
1.5e+00
—
1.8e+00
1.0e+00
7.4e-01
cases:7.30%
controls:4.98%
cases:4.18%
controls:1.93%
cases:1.06%
controls:0.23%
—
—
cases:1.47%
controls:0.26%
cases:4.87%
controls:1.81%
cases:9.11%
controls:4.56%
124
836
1574
15960
71
325
1628
16481
18
39
1681
16767
—
25
43
1671
16721
79
293
1543
15864
115
570
1147
11934
Hemodialysis
TK800 [2001305768]
1.9e+00
1.8e+00
2.5e+00
—
—
1.6e+00
1.1e+00
cases:0.77%
controls:0.12%
cases:0.41%
controls:0.07%
cases:0.35%
controls:0.03%
—
—
—
—
cases:0.31%
controls:0.06%
cases:0.48%
controls:0.15%
13
20
1685
16776
7
11
1692
16795
6
5
1693
16801
—
—
5
10
1617
16147
6
19
1256
12485
zopiclone; oral
N05CF01 [21604654]
4.6e-01
4.3e-01
8.7e-01
2.3e+00
1.0e+00
5.1e-01
5.8e-01
cases:8.36%
controls:5.47%
cases:4.65%
controls:3.08%
cases:2.00%
controls:0.85%
cases:0.35%
controls:0.04%
cases:2.06%
controls:0.77%
cases:4.75%
controls:2.91%
cases:8.40%
controls:4.88%
142
918
1556
15878
79
517
1620
16289
34
143
1665
16663
6
6
1693
16800
35
129
1661
16635
77
470
1545
15687
106
610
1156
11894
fusidic acid
D09AA02 [21602265]
3.7e-01
9.2e-01
2.7e+00
—
1.6e+00
9.2e-01
3.9e-01
cases:5.48%
controls:3.85%
cases:2.71%
controls:1.10%
cases:0.94%
controls:0.07%
—
—
cases:0.47%
controls:0.10%
cases:2.65%
controls:1.07%
cases:5.55%
controls:3.81%
93
646
1605
16150
46
185
1653
16621
16
11
1683
16795
—
8
16
1688
16748
43
173
1579
15984
70
477
1192
12027
fusidic acid; ointment
D06AX01 [21602062]
3.7e-01
9.2e-01
2.7e+00
—
1.6e+00
9.2e-01
3.9e-01
cases:5.48%
controls:3.85%
cases:2.71%
controls:1.10%
cases:0.94%
controls:0.07%
—
—
cases:0.47%
controls:0.10%
cases:2.65%
controls:1.07%
cases:5.55%
controls:3.81%
93
646
1605
16150
46
185
1653
16621
16
11
1683
16795
—
8
16
1688
16748
43
173
1579
15984
70
477
1192
12027
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
6.5e-01
7.2e-01
1.5e+00
—
1.7e+00
6.9e-01
8.2e-01
cases:3.47%
controls:1.84%
cases:1.94%
controls:0.96%
cases:0.82%
controls:0.18%
—
—
cases:0.83%
controls:0.15%
cases:1.97%
controls:1.00%
cases:3.41%
controls:1.54%
59
309
1639
16487
33
161
1666
16645
14
31
1685
16775
—
14
25
1682
16739
32
161
1590
15996
43
192
1219
12312
Emergency Room Visit
ER [9203]
6.3e-01
9.1e-01
1.5e+00
—
1.5e+00
9.0e-01
6.4e-01
cases:42.64%
controls:28.44%
cases:19.13%
controls:8.71%
cases:4.65%
controls:1.09%
—
—
cases:4.66%
controls:1.09%
cases:17.45%
controls:7.93%
cases:36.53%
controls:23.30%
724
4777
974
12019
325
1463
1374
15343
79
184
1620
16622
—
79
182
1617
16582
283
1282
1339
14875
461
2913
801
9591
Pharmacy visit
OMOP4822462 [581458]
1.2e-01
5.4e-01
9.1e-01
3.3e+00
9.1e-01
4.0e-01
2.3e-01
cases:87.87%
controls:86.57%
cases:84.40%
controls:75.99%
cases:61.39%
controls:38.95%
cases:38.02%
controls:2.27%
cases:61.97%
controls:39.66%
cases:82.98%
controls:76.62%
cases:91.28%
controls:89.32%
1492
14540
206
2256
1434
12771
265
4035
1043
6546
656
10260
646
382
1053
16424
1051
6649
645
10115
1346
12380
276
3777
1152
11168
110
1336
Chronic alcohol abuse
P15 [2002000811]
1.4e+00
1.5e+00
—
—
—
1.9e+00
1.2e+00
cases:1.24%
controls:0.32%
cases:0.65%
controls:0.14%
—
—
—
—
—
—
cases:0.74%
controls:0.11%
cases:1.11%
controls:0.34%
21
53
1677
16743
11
24
1688
16782
—
—
—
12
18
1610
16139
14
43
1248
12461
Thorax X-ray examination
GD1AA [2001303617]
5.3e-01
7.3e-01
1.5e+00
—
1.5e+00
9.1e-01
7.3e-01
cases:11.43%
controls:7.06%
cases:5.06%
controls:2.50%
cases:1.18%
controls:0.26%
—
—
cases:1.18%
controls:0.27%
cases:6.10%
controls:2.56%
cases:12.04%
controls:6.17%
194
1186
1504
15610
86
420
1613
16386
20
43
1679
16763
—
20
45
1676
16719
99
413
1523
15744
152
771
1110
11733
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.4e-01
3.6e-01
8.8e-01
3.0e+00
8.7e-01
3.3e-01
2.6e-01
cases:40.16%
controls:34.60%
cases:30.96%
controls:23.80%
cases:10.54%
controls:4.64%
cases:3.94%
controls:0.21%
cases:9.55%
controls:4.22%
cases:30.33%
controls:23.82%
cases:41.52%
controls:35.47%
682
5812
1016
10984
526
3999
1173
12807
179
779
1520
16027
67
35
1632
16771
162
708
1534
16056
492
3848
1130
12309
524
4435
738
8069
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.4e-01
3.7e-01
8.9e-01
2.9e+00
8.8e-01
3.3e-01
2.5e-01
cases:40.16%
controls:34.48%
cases:30.78%
controls:23.51%
cases:10.42%
controls:4.56%
cases:3.88%
controls:0.21%
cases:9.49%
controls:4.18%
cases:30.09%
controls:23.59%
cases:41.20%
controls:35.28%
682
5791
1016
11005
523
3951
1176
12855
177
767
1522
16039
66
36
1633
16770
161
701
1535
16063
488
3812
1134
12345
520
4411
742
8093
Pruritus
L29 [45596372]
—
3.8e+00
—
—
—
2.1e+00
1.5e+00
—
—
cases:2.06%
controls:0.05%
—
—
—
—
—
—
cases:0.55%
controls:0.07%
cases:0.40%
controls:0.09%
—
35
8
1664
16798
—
—
—
9
11
1613
16146
5
11
1257
12493
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.0e-01
4.1e-01
9.4e-01
3.0e+00
7.9e-01
3.5e-01
2.0e-01
cases:43.35%
controls:38.40%
cases:36.96%
controls:28.07%
cases:13.71%
controls:5.84%
cases:4.30%
controls:0.23%
cases:11.32%
controls:5.46%
cases:35.76%
controls:28.13%
cases:44.77%
controls:39.87%
736
6449
962
10347
628
4717
1071
12089
233
982
1466
15824
73
39
1626
16767
192
915
1504
15849
580
4545
1042
11612
565
4985
697
7519
desloratadine; oral
R06AX27 [21603526]
6.0e-02
1.3e+00
2.3e+00
—
1.3e+00
9.3e-01
3.3e-01
cases:5.89%
controls:5.57%
cases:10.18%
controls:2.93%
cases:4.47%
controls:0.48%
—
—
cases:1.95%
controls:0.54%
cases:7.46%
controls:3.09%
cases:7.84%
controls:5.74%
100
935
1598
15861
173
493
1526
16313
76
80
1623
16726
—
33
90
1663
16674
121
499
1501
15658
99
718
1163
11786
Office Visit
OMOP4822458 [581477]
6.1e-01
9.0e-01
1.3e+00
—
1.7e+00
8.5e-01
5.1e-01
cases:13.07%
controls:7.53%
cases:4.41%
controls:1.84%
cases:1.12%
controls:0.32%
—
—
cases:1.65%
controls:0.31%
cases:3.58%
controls:1.57%
cases:7.92%
controls:4.93%
222
1264
1476
15532
75
309
1624
16497
19
53
1680
16753
—
28
52
1668
16712
58
253
1564
15904
100
617
1162
11887
Recurrent depressive disorder, unspecified
F33.9 [45581458]
1.1e+00
1.4e+00
1.7e+00
—
2.0e+00
1.3e+00
4.9e-01
cases:1.35%
controls:0.48%
cases:0.59%
controls:0.15%
cases:0.29%
controls:0.05%
—
—
cases:0.41%
controls:0.05%
cases:0.80%
controls:0.22%
cases:0.87%
controls:0.54%
23
80
1675
16716
10
25
1689
16781
5
9
1694
16797
—
7
9
1689
16755
13
35
1609
16122
11
67
1251
12437
Normoblasts [#/volume] in Blood
715-3 [3021589]
1.3e-01
4.1e-01
1.1e+00
2.5e+00
9.1e-01
4.7e-01
3.5e-01
cases:13.78%
controls:12.29%
cases:12.18%
controls:8.45%
cases:5.41%
controls:1.86%
cases:0.88%
controls:0.07%
cases:4.25%
controls:1.75%
cases:12.58%
controls:8.21%
cases:17.04%
controls:12.60%
234
2064
1464
14732
207
1420
1492
15386
92
312
1607
16494
15
12
1684
16794
72
293
1624
16471
204
1327
1418
14830
215
1576
1047
10928
Besnier prurigo
L20.0 [45562534]
5.3e-01
1.4e+00
2.0e+00
—
1.7e+00
1.5e+00
7.5e-01
cases:2.00%
controls:1.18%
cases:2.12%
controls:0.52%
cases:0.59%
controls:0.08%
—
—
cases:0.41%
controls:0.08%
cases:2.10%
controls:0.46%
cases:2.61%
controls:1.25%
34
199
1664
16597
36
87
1663
16719
10
13
1689
16793
—
7
13
1689
16751
34
74
1588
16083
33
156
1229
12348
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
2.9e-01
3.8e-01
8.6e-01
2.5e+00
6.3e-01
5.3e-01
5.3e-01
cases:24.32%
controls:19.32%
cases:12.54%
controls:8.97%
cases:2.88%
controls:1.24%
cases:0.65%
controls:0.05%
cases:2.42%
controls:1.30%
cases:13.13%
controls:8.15%
cases:25.44%
controls:16.72%
413
3245
1285
13551
213
1507
1486
15299
49
209
1650
16597
11
9
1688
16797
41
218
1655
16546
213
1316
1409
14841
321
2091
941
10413
methylprednisolone; oral, parenteral
H02AB04 [21602732]
6.4e-01
1.3e+00
1.9e+00
—
6.8e-01
1.0e+00
7.7e-01
cases:2.36%
controls:1.25%
cases:1.77%
controls:0.47%
cases:0.65%
controls:0.10%
—
—
cases:0.29%
controls:0.15%
cases:1.42%
controls:0.51%
cases:2.61%
controls:1.22%
40
210
1658
16586
30
79
1669
16727
11
16
1688
16790
—
5
25
1691
16739
23
82
1599
16075
33
153
1229
12351
Skin texture symptom/complaint
S21 [2002000986]
4.4e-01
1.5e+00
3.2e+00
—
—
1.0e+00
4.6e-01
cases:2.65%
controls:1.71%
cases:2.71%
controls:0.61%
cases:1.59%
controls:0.07%
—
—
—
—
cases:1.79%
controls:0.67%
cases:3.25%
controls:2.07%
45
288
1653
16508
46
103
1653
16703
27
11
1672
16795
—
—
29
108
1593
16049
41
259
1221
12245
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1.8e-01
4.5e-01
1.0e+00
2.7e+00
7.2e-01
3.5e-01
2.1e-01
cases:41.22%
controls:36.87%
cases:34.26%
controls:25.01%
cases:12.36%
controls:4.88%
cases:1.65%
controls:0.11%
cases:8.37%
controls:4.27%
cases:32.61%
controls:25.34%
cases:43.66%
controls:38.52%
700
6192
998
10604
582
4203
1117
12603
210
820
1489
15986
28
18
1671
16788
142
715
1554
16049
529
4094
1093
12063
551
4816
711
7688
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
3.1e-01
4.1e-01
8.7e-01
2.3e+00
8.0e-01
5.2e-01
4.6e-01
cases:23.03%
controls:17.99%
cases:11.77%
controls:8.12%
cases:2.71%
controls:1.15%
cases:0.53%
controls:0.05%
cases:2.54%
controls:1.15%
cases:11.59%
controls:7.26%
cases:22.66%
controls:15.67%
391
3022
1307
13774
200
1365
1499
15441
46
193
1653
16613
9
9
1690
16797
43
193
1653
16571
188
1173
1434
14984
286
1960
976
10544
Poisoning by systemic antibiotics
T36 [45756588]
1.3e+00
1.5e+00
—
—
—
1.6e+00
1.3e+00
cases:1.71%
controls:0.49%
cases:0.59%
controls:0.14%
—
—
—
—
—
—
cases:0.49%
controls:0.10%
cases:1.58%
controls:0.43%
29
82
1669
16714
10
23
1689
16783
—
—
—
8
16
1614
16141
20
54
1242
12450
Other pruritus
L29.8 [45601220]
1.6e+00
4.0e+00
—
—
1.0e+50
—
1.6e+00
cases:0.35%
controls:0.07%
cases:1.65%
controls:0.03%
—
—
—
—
cases:0.29%
controls:0.00%
—
—
cases:0.63%
controls:0.13%
6
12
1692
16784
28
5
1671
16801
—
—
5
0
1691
16764
—
8
16
1254
12488
Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]
7.6e-01
2.0e+00
—
1.0e+50
1.9e+00
1.5e+00
1.3e+00
cases:1.71%
controls:0.81%
cases:1.29%
controls:0.17%
—
—
cases:0.29%
controls:0.00%
cases:0.35%
controls:0.05%
cases:1.36%
controls:0.30%
cases:2.77%
controls:0.79%
29
136
1669
16660
22
29
1677
16777
—
5
0
1694
16806
6
9
1690
16755
22
49
1600
16108
35
99
1227
12405
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
6.5e-01
9.7e-01
1.1e+00
1.0e+50
2.3e+00
8.3e-01
8.2e-01
cases:3.89%
controls:2.07%
cases:1.77%
controls:0.68%
cases:0.29%
controls:0.10%
cases:0.35%
controls:0.00%
cases:0.65%
controls:0.07%
cases:1.42%
controls:0.63%
cases:3.17%
controls:1.42%
66
348
1632
16448
30
114
1669
16692
5
17
1694
16789
6
0
1693
16806
11
11
1685
16753
23
101
1599
16056
40
177
1222
12327
Basement membrane zone BP180 Ab [Units/volume] in Serum by Immunoassay
57738-7 [40760848]
1.9e+00
—
—
—
—
3.6e+00
1.4e+00
cases:0.53%
controls:0.08%
—
—
—
—
—
—
—
—
cases:1.36%
controls:0.04%
cases:0.48%
controls:0.12%
9
13
1689
16783
—
—
—
—
22
6
1600
16151
6
15
1256
12489
Case Management Agency
251B00000X [38004193]
1.3e-01
2.3e-01
7.8e-01
3.8e+00
5.3e-01
2.3e-01
9.5e-02
cases:66.96%
controls:64.13%
cases:63.21%
controls:57.84%
cases:42.91%
controls:25.62%
cases:43.79%
controls:1.78%
cases:36.56%
controls:25.42%
cases:63.13%
controls:57.66%
cases:66.64%
controls:64.49%
1137
10772
561
6024
1074
9720
625
7086
729
4305
970
12501
744
299
955
16507
620
4261
1076
12503
1024
9316
598
6841
841
8064
421
4440
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
2.9e-01
7.7e-01
1.7e+00
—
1.5e+00
8.7e-01
6.2e-01
cases:8.83%
controls:6.77%
cases:5.59%
controls:2.67%
cases:1.12%
controls:0.20%
—
—
cases:1.06%
controls:0.24%
cases:5.12%
controls:2.21%
cases:10.78%
controls:6.12%
150
1137
1548
15659
95
449
1604
16357
19
33
1680
16773
—
18
41
1678
16723
83
357
1539
15800
136
765
1126
11739
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
6.1e-01
8.3e-01
1.5e+00
—
1.2e+00
6.3e-01
6.8e-01
cases:6.65%
controls:3.74%
cases:2.83%
controls:1.25%
cases:0.82%
controls:0.18%
—
—
cases:0.71%
controls:0.21%
cases:2.34%
controls:1.26%
cases:7.05%
controls:3.72%
113
629
1585
16167
48
210
1651
16596
14
31
1685
16775
—
12
35
1684
16729
38
204
1584
15953
89
465
1173
12039
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
4.6e-01
1.0e+00
1.4e+00
—
1.2e+00
6.1e-01
7.4e-01
cases:10.13%
controls:6.63%
cases:5.89%
controls:2.17%
cases:1.24%
controls:0.32%
—
—
cases:1.12%
controls:0.33%
cases:4.13%
controls:2.30%
cases:11.57%
controls:5.88%
172
1114
1526
15682
100
364
1599
16442
21
53
1678
16753
—
19
55
1677
16709
67
371
1555
15786
146
735
1116
11769
Blasts/Leukocytes in Blood
26446-5 [3025159]
5.7e-01
8.0e-01
1.5e+00
—
1.5e+00
9.8e-01
6.0e-01
cases:2.36%
controls:1.35%
cases:2.24%
controls:1.02%
cases:0.88%
controls:0.20%
—
—
cases:0.83%
controls:0.18%
cases:2.84%
controls:1.08%
cases:3.57%
controls:1.99%
40
226
1658
16570
38
171
1661
16635
15
33
1684
16773
—
14
31
1682
16733
46
175
1576
15982
45
249
1217
12255
levocetirizine; oral
R06AE09 [21603498]
3.9e-01
1.4e+00
2.1e+00
1.0e+50
9.4e-01
1.1e+00
7.3e-01
cases:2.41%
controls:1.64%
cases:3.18%
controls:0.77%
cases:1.18%
controls:0.14%
cases:0.65%
controls:0.00%
cases:0.41%
controls:0.16%
cases:2.16%
controls:0.75%
cases:3.17%
controls:1.55%
41
276
1657
16520
54
130
1645
16676
20
24
1679
16782
11
0
1688
16806
7
27
1689
16737
35
121
1587
16036
40
194
1222
12310
INR in Blood by Coagulation assay
34714-6 [3032080]
4.5e-01
5.3e-01
7.7e-01
2.5e+00
5.4e-01
5.1e-01
5.9e-01
cases:14.78%
controls:9.94%
cases:7.65%
controls:4.67%
cases:2.88%
controls:1.36%
cases:1.06%
controls:0.09%
cases:2.30%
controls:1.35%
cases:7.27%
controls:4.49%
cases:14.82%
controls:8.76%
251
1670
1447
15126
130
784
1569
16022
49
229
1650
16577
18
15
1681
16791
39
226
1657
16538
118
725
1504
15432
187
1095
1075
11409
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
7.7e-01
9.2e-01
1.4e+00
—
1.7e+00
1.1e+00
7.8e-01
cases:4.89%
controls:2.33%
cases:1.82%
controls:0.73%
cases:0.35%
controls:0.09%
—
—
cases:0.53%
controls:0.10%
cases:2.10%
controls:0.72%
cases:4.44%
controls:2.09%
83
392
1615
16404
31
123
1668
16683
6
15
1693
16791
—
9
16
1687
16748
34
117
1588
16040
56
261
1206
12243
Other specified dermatitis
L30.8 [45581941]
—
2.5e+00
—
—
—
2.8e+00
9.9e-01
—
—
cases:0.82%
controls:0.07%
—
—
—
—
—
—
cases:1.11%
controls:0.07%
cases:0.79%
controls:0.30%
—
14
12
1685
16794
—
—
—
18
11
1604
16146
10
37
1252
12467
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
1.4e-01
3.3e-01
7.8e-01
2.8e+00
7.2e-01
3.2e-01
2.5e-01
cases:30.98%
controls:28.08%
cases:26.84%
controls:20.93%
cases:9.06%
controls:4.37%
cases:2.94%
controls:0.18%
cases:8.14%
controls:4.12%
cases:27.13%
controls:21.22%
cases:35.90%
controls:30.35%
526
4716
1172
12080
456
3517
1243
13289
154
734
1545
16072
50
30
1649
16776
138
690
1558
16074
440
3428
1182
12729
453
3795
809
8709
Monocytes/Leukocytes in Blood
26485-3 [3019069]
3.2e-01
7.9e-01
1.6e+00
—
1.2e+00
7.0e-01
6.1e-01
cases:16.84%
controls:12.81%
cases:13.83%
controls:6.78%
cases:6.06%
controls:1.25%
—
—
cases:4.01%
controls:1.26%
cases:12.15%
controls:6.44%
cases:18.78%
controls:11.20%
286
2151
1412
14645
235
1139
1464
15667
103
210
1596
16596
—
68
211
1628
16553
197
1040
1425
15117
237
1401
1025
11103
Basophils/Leukocytes in Blood
30180-4 [3022096]
3.0e-01
8.1e-01
1.6e+00
—
1.2e+00
7.3e-01
6.0e-01
cases:16.37%
controls:12.71%
cases:14.01%
controls:6.73%
cases:6.06%
controls:1.26%
—
—
cases:3.95%
controls:1.25%
cases:12.45%
controls:6.43%
cases:18.70%
controls:11.22%
278
2134
1420
14662
238
1131
1461
15675
103
212
1596
16594
—
67
210
1629
16554
202
1039
1420
15118
236
1403
1026
11101
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
3.8e-01
1.0e+00
2.2e+00
—
1.4e+00
1.1e+00
9.2e-01
cases:4.59%
controls:3.19%
cases:3.00%
controls:1.10%
cases:0.71%
controls:0.08%
—
—
cases:0.35%
controls:0.08%
cases:2.96%
controls:1.05%
cases:6.02%
controls:2.50%
78
535
1620
16261
51
185
1648
16621
12
13
1687
16793
—
6
14
1690
16750
48
169
1574
15988
76
312
1186
12192
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
3.1e-01
8.0e-01
1.6e+00
—
1.2e+00
7.1e-01
5.9e-01
cases:16.55%
controls:12.74%
cases:13.89%
controls:6.77%
cases:6.06%
controls:1.25%
—
—
cases:3.89%
controls:1.26%
cases:12.27%
controls:6.42%
cases:18.54%
controls:11.18%
281
2140
1417
14656
236
1138
1463
15668
103
210
1596
16596
—
66
211
1630
16553
199
1038
1423
15119
234
1398
1028
11106
Nummular dermatitis
L30.0 [45562535]
1.1e+00
1.9e+00
—
—
—
2.2e+00
1.0e+00
cases:0.82%
controls:0.27%
cases:0.88%
controls:0.14%
—
—
—
—
—
—
cases:0.92%
controls:0.11%
cases:0.95%
controls:0.34%
14
45
1684
16751
15
23
1684
16783
—
—
—
15
17
1607
16140
12
43
1250
12461
Therapeutic discussion
SPAT1240 [2001700341]
8.8e-01
9.7e-01
1.2e+00
—
1.4e+00
1.0e+00
8.8e-01
cases:5.12%
controls:2.19%
cases:1.88%
controls:0.72%
cases:0.47%
controls:0.15%
—
—
cases:0.65%
controls:0.16%
cases:1.60%
controls:0.58%
cases:3.57%
controls:1.51%
87
368
1611
16428
32
121
1667
16685
8
25
1691
16781
—
11
27
1685
16737
26
93
1596
16064
45
189
1217
12315
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
3.1e-01
7.9e-01
1.6e+00
—
1.2e+00
7.0e-01
5.6e-01
cases:17.31%
controls:13.28%
cases:14.01%
controls:6.86%
cases:6.12%
controls:1.28%
—
—
cases:4.01%
controls:1.28%
cases:12.39%
controls:6.57%
cases:18.94%
controls:11.72%
294
2231
1404
14565
238
1153
1461
15653
104
215
1595
16591
—
68
214
1628
16550
201
1061
1421
15096
239
1466
1023
11038
CBC panel - Blood by Automated count
58410-2 [40761511]
1.9e-01
3.1e-01
6.9e-01
2.5e+00
8.0e-01
3.4e-01
2.0e-01
cases:41.05%
controls:36.53%
cases:27.31%
controls:21.62%
cases:7.71%
controls:4.02%
cases:2.65%
controls:0.21%
cases:7.61%
controls:3.56%
cases:26.57%
controls:20.52%
cases:39.86%
controls:35.13%
697
6135
1001
10661
464
3633
1235
13173
131
676
1568
16130
45
36
1654
16770
129
597
1567
16167
431
3316
1191
12841
503
4393
759
8111
Inpatient Hospital
21 [8717]
4.3e-01
7.2e-01
1.3e+00
—
1.3e+00
8.3e-01
4.9e-01
cases:33.27%
controls:24.55%
cases:14.30%
controls:7.49%
cases:3.59%
controls:1.04%
—
—
cases:4.25%
controls:1.16%
cases:14.61%
controls:6.95%
cases:28.13%
controls:19.39%
565
4123
1133
12673
243
1258
1456
15548
61
174
1638
16632
—
72
195
1624
16569
237
1123
1385
15034
355
2424
907
10080
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
3.0e-01
7.6e-01
1.6e+00
—
1.1e+00
6.9e-01
5.5e-01
cases:16.78%
controls:13.02%
cases:13.42%
controls:6.76%
cases:5.94%
controls:1.29%
—
—
cases:3.77%
controls:1.26%
cases:12.15%
controls:6.46%
cases:18.46%
controls:11.52%
285
2186
1413
14610
228
1136
1471
15670
101
217
1598
16589
—
64
212
1632
16552
197
1043
1425
15114
233
1440
1029
11064
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.2e-01
3.3e-01
9.0e-01
2.7e+00
7.4e-01
2.9e-01
1.3e-01
cases:46.82%
controls:43.76%
cases:41.02%
controls:33.26%
cases:16.48%
controls:7.41%
cases:4.89%
controls:0.33%
cases:13.44%
controls:6.91%
cases:39.64%
controls:33.04%
cases:48.81%
controls:45.46%
795
7350
903
9446
697
5589
1002
11217
280
1246
1419
15560
83
56
1616
16750
228
1158
1468
15606
643
5339
979
10818
616
5684
646
6820
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.2e-01
3.3e-01
9.1e-01
2.7e+00
7.4e-01
2.8e-01
1.3e-01
cases:46.76%
controls:43.72%
cases:40.91%
controls:33.16%
cases:16.48%
controls:7.38%
cases:4.89%
controls:0.33%
cases:13.38%
controls:6.90%
cases:39.46%
controls:33.00%
cases:48.73%
controls:45.39%
794
7343
904
9453
695
5573
1004
11233
280
1240
1419
15566
83
56
1616
16750
227
1156
1469
15608
640
5332
982
10825
615
5676
647
6828
Platelets [#/volume] in Blood
26515-7 [3007461]
1.3e-01
3.3e-01
9.1e-01
2.7e+00
7.3e-01
2.9e-01
1.4e-01
cases:46.76%
controls:43.61%
cases:40.91%
controls:33.13%
cases:16.42%
controls:7.36%
cases:4.89%
controls:0.33%
cases:13.27%
controls:6.88%
cases:39.52%
controls:32.93%
cases:48.73%
controls:45.31%
794
7325
904
9471
695
5568
1004
11238
279
1237
1420
15569
83
56
1616
16750
225
1153
1471
15611
641
5320
981
10837
615
5666
647
6838
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.2e-01
3.3e-01
9.0e-01
2.7e+00
7.3e-01
2.8e-01
1.3e-01
cases:46.76%
controls:43.72%
cases:40.91%
controls:33.17%
cases:16.42%
controls:7.38%
cases:4.89%
controls:0.33%
cases:13.33%
controls:6.89%
cases:39.52%
controls:32.98%
cases:48.73%
controls:45.38%
794
7343
904
9453
695
5575
1004
11231
279
1240
1420
15566
83
56
1616
16750
226
1155
1470
15609
641
5329
981
10828
615
5674
647
6830
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.2e-01
3.3e-01
9.1e-01
2.7e+00
7.3e-01
2.8e-01
1.3e-01
cases:46.76%
controls:43.71%
cases:40.85%
controls:33.14%
cases:16.42%
controls:7.35%
cases:4.83%
controls:0.33%
cases:13.33%
controls:6.89%
cases:39.52%
controls:32.96%
cases:48.65%
controls:45.30%
794
7341
904
9455
694
5569
1005
11237
279
1236
1420
15570
82
56
1617
16750
226
1155
1470
15609
641
5326
981
10831
614
5664
648
6840
MCH [Entitic mass]
28539-5 [3035941]
1.2e-01
3.3e-01
9.1e-01
2.7e+00
7.3e-01
2.8e-01
1.4e-01
cases:46.76%
controls:43.70%
cases:40.91%
controls:33.16%
cases:16.42%
controls:7.36%
cases:4.83%
controls:0.33%
cases:13.27%
controls:6.88%
cases:39.46%
controls:32.96%
cases:48.73%
controls:45.36%
794
7340
904
9456
695
5573
1004
11233
279
1237
1420
15569
82
56
1617
16750
225
1154
1471
15610
640
5326
982
10831
615
5672
647
6832
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.2e-01
3.3e-01
9.0e-01
2.7e+00
7.3e-01
2.8e-01
1.4e-01
cases:46.76%
controls:43.76%
cases:40.91%
controls:33.17%
cases:16.42%
controls:7.37%
cases:4.83%
controls:0.34%
cases:13.33%
controls:6.90%
cases:39.58%
controls:33.03%
cases:48.81%
controls:45.43%
794
7350
904
9446
695
5575
1004
11231
279
1238
1420
15568
82
57
1617
16749
226
1157
1470
15607
642
5337
980
10820
616
5681
646
6823
Differential panel, method unspecified - Blood
69738-3 [42870588]
3.3e-01
7.9e-01
1.4e+00
—
9.8e-01
7.1e-01
7.4e-01
cases:12.01%
controls:8.97%
cases:9.95%
controls:4.78%
cases:3.71%
controls:0.94%
—
—
cases:2.36%
controls:0.90%
cases:8.82%
controls:4.52%
cases:14.42%
controls:7.45%
204
1506
1494
15290
169
804
1530
16002
63
158
1636
16648
—
40
151
1656
16613
143
730
1479
15427
182
931
1080
11573
Skin Pathology biopsy report
65754-4 [40768443]
5.9e-01
2.9e+00
—
1.0e+50
—
2.0e+00
8.5e-01
cases:1.53%
controls:0.85%
cases:2.65%
controls:0.14%
—
—
cases:0.82%
controls:0.00%
—
—
cases:1.66%
controls:0.23%
cases:1.43%
controls:0.62%
26
143
1672
16653
45
24
1654
16782
—
14
0
1685
16806
—
27
37
1595
16120
18
77
1244
12427
Rheumatology
66 [38004491]
5.6e-01
6.8e-01
1.0e+00
—
1.0e+00
7.9e-01
8.2e-01
cases:5.12%
controls:2.99%
cases:3.47%
controls:1.79%
cases:1.18%
controls:0.42%
—
—
cases:0.83%
controls:0.29%
cases:3.70%
controls:1.71%
cases:5.78%
controls:2.62%
87
502
1611
16294
59
300
1640
16506
20
71
1679
16735
—
14
49
1682
16715
60
276
1562
15881
73
328
1189
12176
Urticaria, unspecified
L50.9 [45562541]
5.5e-01
2.9e+00
—
—
—
2.0e+00
5.8e-01
cases:0.59%
controls:0.34%
cases:1.41%
controls:0.08%
—
—
—
—
—
—
cases:0.92%
controls:0.12%
cases:0.87%
controls:0.49%
10
57
1688
16739
24
13
1675
16793
—
—
—
15
20
1607
16137
11
61
1251
12443
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
3.4e-01
4.6e-01
7.5e-01
3.3e+00
9.8e-01
5.7e-01
3.9e-01
cases:5.12%
controls:3.70%
cases:3.18%
controls:2.03%
cases:0.82%
controls:0.39%
cases:0.82%
controls:0.03%
cases:1.06%
controls:0.40%
cases:3.64%
controls:2.09%
cases:5.94%
controls:4.09%
87
622
1611
16174
54
341
1645
16465
14
66
1685
16740
14
5
1685
16801
18
67
1678
16697
59
337
1563
15820
75
511
1187
11993
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
5.3e-01
7.5e-01
1.4e+00
—
1.3e+00
4.6e-01
8.9e-01
cases:5.06%
controls:3.05%
cases:3.12%
controls:1.49%
cases:1.18%
controls:0.29%
—
—
cases:0.88%
controls:0.25%
cases:2.16%
controls:1.37%
cases:5.39%
controls:2.29%
86
512
1612
16284
53
251
1646
16555
20
48
1679
16758
—
15
42
1681
16722
35
221
1587
15936
68
286
1194
12218
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
3.5e-01
7.8e-01
1.5e+00
—
1.6e+00
1.0e+00
4.3e-01
cases:2.94%
controls:2.08%
cases:2.06%
controls:0.95%
cases:0.88%
controls:0.21%
—
—
cases:0.94%
controls:0.19%
cases:2.71%
controls:1.00%
cases:3.09%
controls:2.03%
50
350
1648
16446
35
160
1664
16646
15
35
1684
16771
—
16
32
1680
16732
44
161
1578
15996
39
254
1223
12250
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
3.9e-01
6.1e-01
1.3e+00
—
1.3e+00
6.8e-01
5.0e-01
cases:10.90%
controls:7.67%
cases:6.06%
controls:3.40%
cases:1.47%
controls:0.40%
—
—
cases:1.65%
controls:0.44%
cases:5.92%
controls:3.09%
cases:11.57%
controls:7.36%
185
1288
1513
15508
103
571
1596
16235
25
68
1674
16738
—
28
74
1668
16690
96
500
1526
15657
146
920
1116
11584
carbamide
D02AE01 [21601975]
4.5e-01
1.6e+00
—
—
—
2.0e+00
1.2e+00
cases:1.06%
controls:0.68%
cases:1.00%
controls:0.20%
—
—
—
—
—
—
cases:0.86%
controls:0.12%
cases:1.11%
controls:0.35%
18
114
1680
16682
17
33
1682
16773
—
—
—
14
19
1608
16138
14
44
1248
12460
Severe psychotic and other severe mental disorders
112 [2001600112]
5.8e-01
1.5e+00
—
—
—
2.1e+00
1.1e+00
cases:0.94%
controls:0.53%
cases:0.77%
controls:0.17%
—
—
—
—
—
—
cases:0.68%
controls:0.08%
cases:1.35%
controls:0.45%
16
89
1682
16707
13
28
1686
16778
—
—
—
11
13
1611
16144
17
56
1245
12448
Dermatographic urticaria
L50.3 [45596376]
1.1e+00
3.1e+00
—
1.0e+50
—
—
1.6e+00
cases:0.47%
controls:0.16%
cases:1.06%
controls:0.05%
—
—
cases:0.53%
controls:0.00%
—
—
—
—
cases:0.87%
controls:0.18%
8
27
1690
16769
18
8
1681
16798
—
9
0
1690
16806
—
—
11
22
1251
12482
Emergency Room and Inpatient Visit
ERIP [262]
4.6e-01
6.3e-01
1.3e+00
—
1.2e+00
6.6e-01
4.7e-01
cases:9.78%
controls:6.38%
cases:5.89%
controls:3.23%
cases:1.59%
controls:0.43%
—
—
cases:1.42%
controls:0.45%
cases:6.23%
controls:3.32%
cases:11.65%
controls:7.64%
166
1071
1532
15725
100
542
1599
16264
27
72
1672
16734
—
24
75
1672
16689
101
536
1521
15621
147
955
1115
11549
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
5.9e-02
2.9e-01
8.5e-01
2.8e+00
7.1e-01
1.9e-01
3.1e-02
cases:34.22%
controls:32.91%
cases:27.43%
controls:22.06%
cases:10.36%
controls:4.72%
cases:3.47%
controls:0.21%
cases:8.55%
controls:4.40%
cases:25.09%
controls:21.77%
cases:33.68%
controls:32.98%
581
5527
1117
11269
466
3707
1233
13099
176
793
1523
16013
59
35
1640
16771
145
738
1551
16026
407
3518
1215
12639
425
4124
837
8380
pH of Venous blood
2746-6 [3012544]
4.7e-01
6.5e-01
1.9e+00
—
1.9e+00
8.9e-01
2.4e-01
cases:3.18%
controls:2.01%
cases:1.65%
controls:0.87%
cases:0.53%
controls:0.08%
—
—
cases:0.53%
controls:0.08%
cases:1.97%
controls:0.82%
cases:2.77%
controls:2.19%
54
338
1644
16458
28
146
1671
16660
9
14
1690
16792
—
9
14
1687
16750
32
133
1590
16024
35
274
1227
12230
Base excess in Venous blood by calculation
1927-3 [3002032]
5.0e-01
6.8e-01
1.7e+00
—
1.9e+00
9.0e-01
1.2e-01
cases:3.18%
controls:1.96%
cases:1.65%
controls:0.84%
cases:0.47%
controls:0.08%
—
—
cases:0.53%
controls:0.08%
cases:1.97%
controls:0.81%
cases:2.46%
controls:2.18%
54
329
1644
16467
28
142
1671
16664
8
14
1691
16792
—
9
13
1687
16751
32
131
1590
16026
31
272
1231
12232
clindamycin; oral, parenteral
J01FF01 [21602985]
6.8e-01
7.1e-01
—
—
2.1e+00
9.6e-01
7.8e-01
cases:5.01%
controls:2.60%
cases:1.47%
controls:0.73%
—
—
—
—
cases:0.71%
controls:0.08%
cases:2.03%
controls:0.79%
cases:5.86%
controls:2.78%
85
437
1613
16359
25
123
1674
16683
—
—
12
14
1684
16750
33
127
1589
16030
74
348
1188
12156
Bacteria identified in Isolate by Culture
43409-2 [3042936]
7.2e-01
9.3e-01
—
—
2.0e+00
5.5e-01
8.8e-01
cases:4.95%
controls:2.48%
cases:1.77%
controls:0.70%
—
—
—
—
cases:0.53%
controls:0.07%
cases:1.36%
controls:0.79%
cases:4.99%
controls:2.14%
84
417
1614
16379
30
118
1669
16688
—
—
9
12
1687
16752
22
127
1600
16030
63
268
1199
12236
Other urticaria
L50.8 [45562540]
8.3e-01
1.9e+00
—
—
—
2.6e+00
1.2e+00
cases:0.35%
controls:0.15%
cases:0.47%
controls:0.07%
—
—
—
—
—
—
cases:0.43%
controls:0.03%
cases:0.40%
controls:0.12%
6
26
1692
16770
8
12
1691
16794
—
—
—
7
5
1615
16152
5
15
1257
12489
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
X69 [45585661]
7.7e-01
1.4e+00
—
—
—
2.8e+00
1.7e+00
cases:0.77%
controls:0.36%
cases:0.41%
controls:0.10%
—
—
—
—
—
—
cases:0.49%
controls:0.03%
cases:1.51%
controls:0.27%
13
60
1685
16736
7
17
1692
16789
—
—
—
8
5
1614
16152
19
34
1243
12470
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
4.5e-01
6.6e-01
1.7e+00
—
1.9e+00
8.2e-01
1.4e-01
cases:3.00%
controls:1.94%
cases:1.65%
controls:0.86%
cases:0.47%
controls:0.08%
—
—
cases:0.53%
controls:0.08%
cases:1.91%
controls:0.85%
cases:2.54%
controls:2.21%
51
326
1647
16470
28
144
1671
16662
8
14
1691
16792
—
9
13
1687
16751
31
137
1591
16020
32
276
1230
12228
quetiapine; oral
N05AH04 [21604544]
6.8e-01
8.7e-01
5.4e-01
—
1.1e+00
8.1e-01
9.7e-01
cases:7.07%
controls:3.70%
cases:5.59%
controls:2.42%
cases:1.29%
controls:0.76%
—
—
cases:2.18%
controls:0.76%
cases:5.80%
controls:2.66%
cases:9.35%
controls:3.77%
120
622
1578
16174
95
406
1604
16400
22
127
1677
16679
—
37
127
1659
16637
94
429
1528
15728
118
471
1144
12033
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
8.6e-03
1.9e-01
7.2e-01
2.7e+00
7.0e-01
2.5e-01
8.6e-02
cases:29.74%
controls:29.56%
cases:24.66%
controls:21.35%
cases:9.36%
controls:4.78%
cases:3.00%
controls:0.20%
cases:8.73%
controls:4.55%
cases:25.40%
controls:20.89%
cases:32.81%
controls:30.93%
505
4965
1193
11831
419
3588
1280
13218
159
803
1540
16003
51
34
1648
16772
148
763
1548
16001
412
3375
1210
12782
414
3868
848
8636
Laboratory Visit
OMOP4822461 [32036]
7.1e-02
2.3e-01
7.6e-01
2.6e+00
6.0e-01
2.1e-01
5.9e-02
cases:50.77%
controls:48.99%
cases:49.21%
controls:43.57%
cases:24.25%
controls:13.05%
cases:9.12%
controls:0.76%
cases:20.81%
controls:12.64%
cases:48.40%
controls:43.20%
cases:52.38%
controls:50.90%
862
8228
836
8568
836
7322
863
9484
412
2194
1287
14612
155
127
1544
16679
353
2119
1343
14645
785
6980
837
9177
661
6364
601
6140
Outpatient Hospital
22 [8756]
5.2e-01
6.3e-01
1.0e+00
—
9.5e-01
7.0e-01
5.0e-01
cases:26.38%
controls:17.56%
cases:7.83%
controls:4.31%
cases:1.53%
controls:0.57%
—
—
cases:1.59%
controls:0.62%
cases:7.64%
controls:3.95%
cases:19.33%
controls:12.71%
448
2950
1250
13846
133
724
1566
16082
26
95
1673
16711
—
27
104
1669
16660
124
638
1498
15519
244
1589
1018
10915
Atopic dermatitis, unspecified
L20.9 [45548191]
6.1e-01
2.2e+00
—
1.0e+50
—
2.1e+00
5.0e-01
cases:0.77%
controls:0.42%
cases:1.24%
controls:0.14%
—
—
cases:0.47%
controls:0.00%
—
—
cases:0.99%
controls:0.12%
cases:0.71%
controls:0.43%
13
70
1685
16726
21
24
1678
16782
—
8
0
1691
16806
—
16
19
1606
16138
9
54
1253
12450
methotrexate
L01BA01 [21601423]
6.9e-01
8.4e-01
5.0e-01
—
1.0e+00
8.6e-01
9.0e-01
cases:3.47%
controls:1.77%
cases:2.83%
controls:1.24%
cases:0.82%
controls:0.50%
—
—
cases:1.30%
controls:0.48%
cases:2.84%
controls:1.23%
cases:3.65%
controls:1.51%
59
298
1639
16498
48
208
1651
16598
14
84
1685
16722
—
22
80
1674
16684
46
198
1576
15959
46
189
1216
12315
methotrexate; oral, parenteral
L04AX03 [21603929]
6.9e-01
8.4e-01
5.0e-01
—
1.0e+00
8.6e-01
9.0e-01
cases:3.47%
controls:1.77%
cases:2.83%
controls:1.24%
cases:0.82%
controls:0.50%
—
—
cases:1.30%
controls:0.48%
cases:2.84%
controls:1.23%
cases:3.65%
controls:1.51%
59
298
1639
16498
48
208
1651
16598
14
84
1685
16722
—
22
80
1674
16684
46
198
1576
15959
46
189
1216
12315
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
3.4e-01
6.5e-01
1.1e+00
—
1.0e+00
6.0e-01
5.1e-01
cases:13.13%
controls:9.73%
cases:8.71%
controls:4.72%
cases:2.71%
controls:0.90%
—
—
cases:2.00%
controls:0.74%
cases:8.69%
controls:4.95%
cases:14.50%
controls:9.28%
223
1634
1475
15162
148
794
1551
16012
46
152
1653
16654
—
34
124
1662
16640
141
800
1481
15357
183
1160
1079
11344
Teaching
WZC30 [2001310891]
6.5e-01
8.5e-01
1.5e+00
—
1.6e+00
1.1e+00
4.8e-01
cases:3.71%
controls:1.98%
cases:1.82%
controls:0.79%
cases:0.41%
controls:0.10%
—
—
cases:0.53%
controls:0.11%
cases:2.28%
controls:0.77%
cases:3.33%
controls:2.08%
63
332
1635
16464
31
133
1668
16673
7
16
1692
16790
—
9
18
1687
16746
37
124
1585
16033
42
260
1220
12244
mirtazapine; oral
N06AX11 [21604740]
5.5e-01
7.1e-01
7.3e-01
—
8.7e-01
7.7e-01
5.2e-01
cases:9.54%
controls:5.73%
cases:6.06%
controls:3.06%
cases:1.71%
controls:0.83%
—
—
cases:1.77%
controls:0.75%
cases:6.35%
controls:3.05%
cases:9.51%
controls:5.90%
162
962
1536
15834
103
515
1596
16291
29
139
1670
16667
—
30
125
1666
16639
103
493
1519
15664
120
738
1142
11766
temazepam; oral
N05CD07 [21604642]
6.7e-01
5.6e-01
1.5e+00
—
6.8e-01
9.6e-01
9.7e-01
cases:4.59%
controls:2.40%
cases:2.12%
controls:1.23%
cases:1.35%
controls:0.29%
—
—
cases:0.59%
controls:0.30%
cases:3.08%
controls:1.21%
cases:4.83%
controls:1.90%
78
403
1620
16393
36
206
1663
16600
23
49
1676
16757
—
10
50
1686
16714
50
195
1572
15962
61
237
1201
12267
Bipolar affective disorder, current episode severe depression without psychotic symptoms
F31.4 [45581456]
1.7e+00
2.1e+00
—
—
—
1.8e+00
2.5e+00
cases:0.47%
controls:0.09%
cases:0.29%
controls:0.04%
—
—
—
—
—
—
cases:0.31%
controls:0.05%
cases:0.55%
controls:0.05%
8
15
1690
16781
5
6
1694
16800
—
—
—
5
8
1617
16149
7
6
1255
12498
furosemide; oral, parenteral
C03CA01 [21601518]
5.7e-01
5.5e-01
9.3e-01
-1.0e+50
7.6e-01
6.8e-01
6.4e-01
cases:6.77%
controls:3.97%
cases:5.36%
controls:3.17%
cases:2.59%
controls:1.04%
cases:0.00%
controls:0.04%
cases:2.30%
controls:1.09%
cases:6.47%
controls:3.38%
cases:7.92%
controls:4.35%
115
666
1583
16130
91
532
1608
16274
44
175
1655
16631
0
6
1699
16800
39
183
1657
16581
105
546
1517
15611
100
544
1162
11960
Allergic urticaria
L50.0 [45581945]
5.9e-01
1.8e+00
—
—
—
2.3e+00
—
cases:0.35%
controls:0.20%
cases:0.47%
controls:0.08%
—
—
—
—
—
—
cases:0.43%
controls:0.04%
—
—
6
33
1692
16763
8
13
1691
16793
—
—
—
7
7
1615
16150
—
Essential (primary) hypertension
I10 [45591453]
1.7e-01
2.1e-01
5.8e-01
3.5e+00
6.3e-01
2.9e-01
1.9e-01
cases:14.08%
controls:12.16%
cases:8.12%
controls:6.70%
cases:2.06%
controls:1.16%
cases:2.06%
controls:0.07%
cases:2.18%
controls:1.17%
cases:9.06%
controls:6.93%
cases:15.69%
controls:13.31%
239
2043
1459
14753
138
1126
1561
15680
35
195
1664
16611
35
11
1664
16795
37
196
1659
16568
147
1119
1475
15038
198
1664
1064
10840
Supine thorax X-ray examination
GD1QA [2001303648]
4.6e-01
1.0e+00
2.0e+00
—
1.3e+00
6.7e-01
1.0e+00
cases:2.36%
controls:1.51%
cases:1.65%
controls:0.60%
cases:0.35%
controls:0.05%
—
—
cases:0.35%
controls:0.10%
cases:1.29%
controls:0.67%
cases:3.80%
controls:1.44%
40
253
1658
16543
28
101
1671
16705
6
8
1693
16798
—
6
17
1690
16747
21
108
1601
16049
48
180
1214
12324
Asthma, unspecified
J45.9 [45562456]
5.9e-01
6.1e-01
1.0e+00
—
1.2e+00
4.8e-01
6.4e-01
cases:4.95%
controls:2.80%
cases:2.77%
controls:1.52%
cases:0.88%
controls:0.33%
—
—
cases:0.94%
controls:0.30%
cases:2.22%
controls:1.39%
cases:5.39%
controls:2.91%
84
471
1614
16325
47
256
1652
16550
15
55
1684
16751
—
16
50
1680
16714
36
224
1586
15933
68
364
1194
12140
Hospital outpatient
ZY010 [2001311599]
4.2e-01
8.8e-01
1.3e+00
1.0e+50
1.7e+00
1.1e+00
1.2e+00
cases:1.47%
controls:0.97%
cases:0.94%
controls:0.39%
cases:0.35%
controls:0.10%
cases:0.65%
controls:0.00%
cases:0.59%
controls:0.11%
cases:0.92%
controls:0.30%
cases:1.82%
controls:0.58%
25
163
1673
16633
16
66
1683
16740
6
16
1693
16790
11
0
1688
16806
10
18
1686
16746
15
49
1607
16108
23
73
1239
12431
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
3.6e-01
5.6e-01
1.2e+00
—
1.2e+00
4.4e-01
6.1e-01
cases:6.83%
controls:4.86%
cases:4.30%
controls:2.51%
cases:1.18%
controls:0.36%
—
—
cases:1.24%
controls:0.36%
cases:3.95%
controls:2.57%
cases:9.27%
controls:5.25%
116
816
1582
15980
73
422
1626
16384
20
61
1679
16745
—
21
61
1675
16703
64
416
1558
15741
117
657
1145
11847
Herpesviral infection of genitalia and urogenital tract
A60.0 [45581128]
1.3e+00
—
—
—
—
2.1e+00
1.8e+00
cases:0.53%
controls:0.14%
—
—
—
—
—
—
—
—
cases:0.37%
controls:0.04%
cases:1.11%
controls:0.19%
9
24
1689
16772
—
—
—
—
6
7
1616
16150
14
24
1248
12480
Cutaneous abscess, furuncle and carbuncle of limb
L02.4 [45552967]
9.5e-01
1.7e+00
—
—
—
2.1e+00
9.4e-01
cases:0.82%
controls:0.32%
cases:0.53%
controls:0.10%
—
—
—
—
—
—
cases:0.62%
controls:0.07%
cases:0.87%
controls:0.34%
14
54
1684
16742
9
16
1690
16790
—
—
—
10
12
1612
16145
11
43
1251
12461
Guidance concerning treatment of rash and skin
SPAT1156 [2001700257]
3.1e-01
1.3e+00
1.3e+00
—
9.8e-01
1.2e+00
5.8e-01
cases:1.94%
controls:1.43%
cases:1.82%
controls:0.49%
cases:0.77%
controls:0.20%
—
—
cases:0.41%
controls:0.16%
cases:1.54%
controls:0.48%
cases:2.22%
controls:1.26%
33
241
1665
16555
31
83
1668
16723
13
34
1686
16772
—
7
26
1689
16738
25
78
1597
16079
28
157
1234
12347
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
5.3e-01
1.4e+00
1.9e+00
—
1.4e+00
3.9e-01
5.4e-01
cases:3.53%
controls:2.12%
cases:3.00%
controls:0.77%
cases:1.12%
controls:0.17%
—
—
cases:0.47%
controls:0.11%
cases:1.23%
controls:0.84%
cases:3.25%
controls:1.93%
60
356
1638
16440
51
129
1648
16677
19
28
1680
16778
—
8
19
1688
16745
20
135
1602
16022
41
241
1221
12263
Rash and other nonspecific skin eruption
R21 [45553721]
6.9e-01
2.1e+00
—
—
—
1.7e+00
7.0e-01
cases:0.65%
controls:0.33%
cases:1.06%
controls:0.14%
—
—
—
—
—
—
cases:0.55%
controls:0.10%
cases:1.03%
controls:0.51%
11
55
1687
16741
18
23
1681
16783
—
—
—
9
16
1613
16141
13
64
1249
12440
olanzapine; oral, parenteral
N05AH03 [21604543]
7.6e-01
7.9e-01
3.5e-01
—
7.8e-01
1.2e+00
1.1e+00
cases:2.24%
controls:1.06%
cases:1.71%
controls:0.78%
cases:0.41%
controls:0.29%
—
—
cases:0.53%
controls:0.24%
cases:2.34%
controls:0.74%
cases:3.25%
controls:1.14%
38
178
1660
16618
29
131
1670
16675
7
49
1692
16757
—
9
41
1687
16723
38
120
1584
16037
41
143
1221
12361
Other specified counselling
Z71.8 [45581061]
2.4e-01
1.5e-01
6.5e-01
3.3e+00
3.2e-01
4.1e-01
4.2e-01
cases:6.65%
controls:5.32%
cases:3.12%
controls:2.70%
cases:0.65%
controls:0.34%
cases:0.82%
controls:0.03%
cases:0.65%
controls:0.47%
cases:4.56%
controls:3.07%
cases:10.94%
controls:7.46%
113
893
1585
15903
53
454
1646
16352
11
57
1688
16749
14
5
1685
16801
11
79
1685
16685
74
496
1548
15661
138
933
1124
11571
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
6.0e-01
5.4e-01
1.6e+00
—
—
9.6e-01
5.9e-01
cases:4.53%
controls:2.54%
cases:1.65%
controls:0.96%
cases:0.65%
controls:0.14%
—
—
—
—
cases:2.03%
controls:0.79%
cases:3.88%
controls:2.19%
77
427
1621
16369
28
162
1671
16644
11
23
1688
16783
—
—
33
128
1589
16029
49
274
1213
12230
FEV1/FVC
19926-5 [3011505]
3.9e-01
1.1e+00
—
—
—
1.1e+00
1.5e+00
cases:2.77%
controls:1.90%
cases:1.65%
controls:0.58%
—
—
—
—
—
—
cases:1.48%
controls:0.48%
cases:3.72%
controls:0.85%
47
319
1651
16477
28
97
1671
16709
—
—
—
24
78
1598
16079
47
106
1215
12398
FEV1
20150-9 [3024653]
3.9e-01
1.1e+00
—
—
—
1.1e+00
1.5e+00
cases:2.77%
controls:1.90%
cases:1.65%
controls:0.58%
—
—
—
—
—
—
cases:1.48%
controls:0.48%
cases:3.72%
controls:0.85%
47
319
1651
16477
28
97
1671
16709
—
—
—
24
78
1598
16079
47
106
1215
12398
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
3.9e-01
1.1e+00
—
—
—
1.1e+00
1.5e+00
cases:2.77%
controls:1.90%
cases:1.65%
controls:0.58%
—
—
—
—
—
—
cases:1.48%
controls:0.48%
cases:3.72%
controls:0.85%
47
319
1651
16477
28
97
1671
16709
—
—
—
24
78
1598
16079
47
106
1215
12398
Desmosome IgG Ab [Titer] in Serum by Immunofluorescence
71368-5 [42870308]
1.6e+00
—
—
1.0e+50
—
3.7e+00
—
cases:0.41%
controls:0.08%
—
—
—
—
cases:0.29%
controls:0.00%
—
—
cases:1.23%
controls:0.03%
—
—
7
14
1691
16782
—
—
5
0
1694
16806
—
20
5
1602
16152
—
Basement membrane Ab [Titer] in Serum by Immunofluorescence
57737-9 [40760847]
1.5e+00
—
—
1.0e+50
—
3.7e+00
—
cases:0.41%
controls:0.09%
—
—
—
—
cases:0.29%
controls:0.00%
—
—
cases:1.23%
controls:0.03%
—
—
7
15
1691
16781
—
—
5
0
1694
16806
—
20
5
1602
16152
—
No procedures
SPAT1301 [2001700402]
3.3e-01
7.7e-01
1.2e+00
—
9.4e-01
8.0e-01
6.1e-01
cases:8.07%
controls:5.95%
cases:3.59%
controls:1.69%
cases:1.18%
controls:0.37%
—
—
cases:0.88%
controls:0.35%
cases:3.58%
controls:1.64%
cases:6.97%
controls:3.93%
137
999
1561
15797
61
284
1638
16522
20
63
1679
16743
—
15
58
1681
16706
58
265
1564
15892
88
491
1174
12013
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
4.7e-01
6.1e-01
1.2e+00
—
7.5e-01
7.1e-01
6.3e-01
cases:9.25%
controls:5.96%
cases:3.94%
controls:2.17%
cases:0.94%
controls:0.29%
—
—
cases:0.53%
controls:0.25%
cases:3.82%
controls:1.91%
cases:8.95%
controls:4.97%
157
1001
1541
15795
67
365
1632
16441
16
48
1683
16758
—
9
42
1687
16722
62
309
1560
15848
113
622
1149
11882
Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]
6.5e-02
6.5e-01
1.5e+00
1.0e+50
1.2e+00
9.2e-01
5.9e-01
cases:4.18%
controls:3.93%
cases:2.83%
controls:1.49%
cases:0.59%
controls:0.14%
cases:0.77%
controls:0.00%
cases:0.41%
controls:0.13%
cases:3.08%
controls:1.25%
cases:6.81%
controls:3.89%
71
660
1627
16136
48
251
1651
16555
10
23
1689
16783
13
0
1686
16806
7
21
1689
16743
50
202
1572
15955
86
487
1176
12017
ebastine; oral
R06AX22 [21603521]
3.0e-01
1.1e+00
1.9e+00
—
9.1e-01
6.4e-01
3.1e-01
cases:2.83%
controls:2.11%
cases:3.47%
controls:1.22%
cases:1.35%
controls:0.20%
—
—
cases:0.47%
controls:0.19%
cases:2.47%
controls:1.31%
cases:3.33%
controls:2.47%
48
354
1650
16442
59
205
1640
16601
23
34
1676
16772
—
8
32
1688
16732
40
212
1582
15945
42
309
1220
12195
Guidance related to psychoactive substances / risk behaviour
SPAT1309 [2001700410]
1.3e+00
2.3e+00
—
—
—
—
1.1e+00
cases:1.24%
controls:0.33%
cases:0.53%
controls:0.05%
—
—
—
—
—
—
—
—
cases:0.79%
controls:0.26%
21
56
1677
16740
9
9
1690
16797
—
—
—
—
10
33
1252
12471
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
3.0e-01
4.4e-01
1.1e+00
—
7.3e-01
4.4e-01
6.0e-01
cases:13.49%
controls:10.38%
cases:7.36%
controls:4.86%
cases:2.35%
controls:0.80%
—
—
cases:1.65%
controls:0.81%
cases:6.91%
controls:4.56%
cases:14.66%
controls:8.61%
229
1744
1469
15052
125
816
1574
15990
40
134
1659
16672
—
28
135
1668
16629
112
736
1510
15421
185
1076
1077
11428
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
7.2e-01
9.6e-01
1.2e+00
—
1.4e+00
1.1e+00
7.7e-01
cases:3.36%
controls:1.67%
cases:1.47%
controls:0.57%
cases:0.35%
controls:0.11%
—
—
cases:0.47%
controls:0.11%
cases:1.54%
controls:0.50%
cases:3.33%
controls:1.57%
57
280
1641
16516
25
96
1674
16710
6
18
1693
16788
—
8
19
1688
16745
25
80
1597
16077
42
196
1220
12308
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
6.3e-01
1.1e+00
1.9e+00
—
1.4e+00
5.8e-01
5.0e-01
cases:3.18%
controls:1.71%
cases:2.12%
controls:0.74%
cases:0.47%
controls:0.07%
—
—
cases:0.47%
controls:0.12%
cases:1.36%
controls:0.76%
cases:2.38%
controls:1.46%
54
288
1644
16508
36
125
1663
16681
8
12
1691
16794
—
8
20
1688
16744
22
123
1600
16034
30
182
1232
12322
carbamazepine; oral, rectal
N03AF01 [21604417]
1.2e+00
1.3e+00
—
—
1.1e+00
1.0e+00
2.7e-01
cases:1.53%
controls:0.45%
cases:1.06%
controls:0.29%
—
—
—
—
cases:0.35%
controls:0.11%
cases:0.99%
controls:0.35%
cases:0.79%
controls:0.61%
26
75
1672
16721
18
49
1681
16757
—
—
6
19
1690
16745
16
57
1606
16100
10
76
1252
12428
Oxygen [Partial pressure] in Capillary blood
2704-5 [3028626]
6.5e-01
1.3e+00
—
—
1.2e+00
1.2e+00
1.0e+00
cases:1.24%
controls:0.65%
cases:1.12%
controls:0.32%
—
—
—
—
cases:0.29%
controls:0.09%
cases:0.86%
controls:0.25%
cases:1.27%
controls:0.46%
21
109
1677
16687
19
53
1680
16753
—
—
5
15
1691
16749
14
41
1608
16116
16
57
1246
12447
Alcohol dependence continuous use
F10.25 [2000501682]
1.5e+00
1.8e+00
—
—
—
2.0e+00
—
cases:0.65%
controls:0.14%
cases:0.29%
controls:0.05%
—
—
—
—
—
—
cases:0.37%
controls:0.05%
—
—
11
24
1687
16772
5
8
1694
16798
—
—
—
6
8
1616
16149
—
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2.8e-01
5.5e-01
9.9e-01
—
9.9e-01
3.9e-01
3.0e-01
cases:22.32%
controls:17.79%
cases:12.36%
controls:7.52%
cases:2.77%
controls:1.05%
—
—
cases:2.30%
controls:0.86%
cases:10.85%
controls:7.63%
cases:22.82%
controls:17.91%
379
2988
1319
13808
210
1263
1489
15543
47
176
1652
16630
—
39
145
1657
16619
176
1232
1446
14925
288
2240
974
10264
Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection
40988-8 [3044254]
7.8e-01
8.4e-01
—
—
—
1.4e+00
1.3e+00
cases:1.47%
controls:0.68%
cases:0.77%
controls:0.33%
—
—
—
—
—
—
cases:1.29%
controls:0.32%
cases:1.98%
controls:0.54%
25
114
1673
16682
13
56
1686
16750
—
—
—
21
52
1601
16105
25
68
1237
12436
Dermatological photography
XQ848 [2001310110]
9.7e-01
1.4e+00
—
1.0e+50
—
2.1e+00
1.3e+00
cases:0.71%
controls:0.27%
cases:0.41%
controls:0.10%
—
—
cases:0.47%
controls:0.00%
—
—
cases:0.80%
controls:0.10%
cases:1.03%
controls:0.27%
12
45
1686
16751
7
17
1692
16789
—
8
0
1691
16806
—
13
16
1609
16141
13
34
1249
12470
venlafaxine; oral
N06AX16 [21604745]
8.0e-01
8.6e-01
6.3e-01
—
6.0e-01
8.8e-01
8.9e-01
cases:4.59%
controls:2.11%
cases:3.30%
controls:1.42%
cases:0.82%
controls:0.44%
—
—
cases:0.77%
controls:0.42%
cases:3.33%
controls:1.41%
cases:5.15%
controls:2.18%
78
355
1620
16441
56
238
1643
16568
14
74
1685
16732
—
13
71
1683
16693
54
228
1568
15929
65
272
1197
12232
Remote contact by phone
ZYC01 [2001311579]
2.3e-01
1.1e+00
—
1.0e+50
1.8e+00
1.3e+00
1.0e+00
cases:0.94%
controls:0.75%
cases:0.88%
controls:0.29%
—
—
cases:0.29%
controls:0.00%
cases:0.29%
controls:0.05%
cases:1.54%
controls:0.41%
cases:2.14%
controls:0.80%
16
126
1682
16670
15
49
1684
16757
—
5
0
1694
16806
5
8
1691
16756
25
67
1597
16090
27
100
1235
12404
Internal Medicine
11 [38004456]
3.9e-01
5.7e-01
8.3e-01
—
6.6e-01
5.4e-01
4.4e-01
cases:23.32%
controls:17.08%
cases:12.07%
controls:7.22%
cases:2.77%
controls:1.22%
—
—
cases:2.59%
controls:1.36%
cases:10.85%
controls:6.64%
cases:23.06%
controls:16.23%
396
2868
1302
13928
205
1214
1494
15592
47
205
1652
16601
—
44
228
1652
16536
176
1073
1446
15084
291
2029
971
10475
olanzapine and samidorphan
N05AH53 [955100]
9.1e-01
—
—
—
—
1.8e+00
1.7e+00
cases:0.41%
controls:0.17%
—
—
—
—
—
—
—
—
cases:0.43%
controls:0.07%
cases:0.95%
controls:0.18%
7
28
1691
16768
—
—
—
—
7
12
1615
16145
12
23
1250
12481
Laceration/cut
S18 [2002000983]
4.1e-01
7.5e-01
5.8e-01
—
1.0e+00
7.8e-01
4.2e-01
cases:10.84%
controls:7.43%
cases:5.00%
controls:2.42%
cases:0.71%
controls:0.40%
—
—
cases:1.12%
controls:0.40%
cases:4.99%
controls:2.36%
cases:10.22%
controls:6.93%
184
1248
1514
15548
85
406
1614
16400
12
67
1687
16739
—
19
67
1677
16697
81
381
1541
15776
129
867
1133
11637
Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
76080-1 [46235759]
8.1e-01
8.9e-01
2.3e+00
—
—
1.4e+00
1.2e+00
cases:1.71%
controls:0.77%
cases:0.82%
controls:0.34%
cases:0.29%
controls:0.03%
—
—
—
—
cases:1.36%
controls:0.35%
cases:2.06%
controls:0.62%
29
129
1669
16667
14
57
1685
16749
5
5
1694
16801
—
—
22
56
1600
16101
26
77
1236
12427
FEV1/FVC --post bronchodilation
69970-2 [42868459]
3.3e-01
9.5e-01
—
—
—
1.0e+00
1.4e+00
cases:2.30%
controls:1.66%
cases:1.24%
controls:0.48%
—
—
—
—
—
—
cases:1.17%
controls:0.43%
cases:3.09%
controls:0.76%
39
279
1659
16517
21
81
1678
16725
—
—
—
19
69
1603
16088
39
95
1223
12409
FEV1 --post bronchodilation
20155-8 [3023550]
3.3e-01
9.5e-01
—
—
—
1.0e+00
1.4e+00
cases:2.30%
controls:1.66%
cases:1.24%
controls:0.48%
—
—
—
—
—
—
cases:1.17%
controls:0.43%
cases:3.09%
controls:0.76%
39
279
1659
16517
21
81
1678
16725
—
—
—
19
69
1603
16088
39
95
1223
12409
FVC percent change Respiratory system
69982-7 [42868471]
3.3e-01
9.5e-01
—
—
—
1.0e+00
1.4e+00
cases:2.30%
controls:1.66%
cases:1.24%
controls:0.48%
—
—
—
—
—
—
cases:1.17%
controls:0.43%
cases:3.09%
controls:0.76%
39
279
1659
16517
21
81
1678
16725
—
—
—
19
69
1603
16088
39
95
1223
12409
FEV1 percent change
69983-5 [42868472]
3.3e-01
9.5e-01
—
—
—
1.0e+00
1.4e+00
cases:2.30%
controls:1.66%
cases:1.24%
controls:0.48%
—
—
—
—
—
—
cases:1.17%
controls:0.43%
cases:3.09%
controls:0.76%
39
279
1659
16517
21
81
1678
16725
—
—
—
19
69
1603
16088
39
95
1223
12409
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
3.3e-01
9.5e-01
—
—
—
1.0e+00
1.4e+00
cases:2.30%
controls:1.66%
cases:1.24%
controls:0.48%
—
—
—
—
—
—
cases:1.17%
controls:0.43%
cases:3.09%
controls:0.76%
39
279
1659
16517
21
81
1678
16725
—
—
—
19
69
1603
16088
39
95
1223
12409
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
1.3e-01
7.0e-01
1.5e+00
—
1.1e+00
5.8e-01
6.1e-01
cases:5.59%
controls:4.97%
cases:3.53%
controls:1.78%
cases:0.59%
controls:0.14%
—
—
cases:0.41%
controls:0.13%
cases:2.77%
controls:1.57%
cases:7.69%
controls:4.34%
95
834
1603
15962
60
299
1639
16507
10
23
1689
16783
—
7
22
1689
16742
45
254
1577
15903
97
543
1165
11961
Restricted health certificate
SPAT1283 [2001700384]
4.0e-01
9.4e-01
1.3e+00
—
1.3e+00
1.1e+00
8.6e-01
cases:5.71%
controls:3.92%
cases:1.94%
controls:0.77%
cases:0.29%
controls:0.08%
—
—
cases:0.35%
controls:0.10%
cases:2.28%
controls:0.74%
cases:4.91%
controls:2.14%
97
658
1601
16138
33
129
1666
16677
5
13
1694
16793
—
6
16
1690
16748
37
119
1585
16038
62
268
1200
12236
Pneumonia, unspecified
J18.9 [45601123]
5.5e-01
6.6e-01
1.4e+00
—
8.1e-01
6.5e-01
7.0e-01
cases:4.12%
controls:2.41%
cases:1.71%
controls:0.89%
cases:0.65%
controls:0.15%
—
—
cases:0.29%
controls:0.13%
cases:2.10%
controls:1.11%
cases:5.71%
controls:2.92%
70
405
1628
16391
29
149
1670
16657
11
26
1688
16780
—
5
22
1691
16742
34
179
1588
15978
72
365
1190
12139
Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
21416-3 [3003510]
4.8e-01
9.8e-01
1.1e+00
—
1.1e+00
1.1e+00
7.5e-01
cases:7.54%
controls:4.80%
cases:4.47%
controls:1.73%
cases:0.65%
controls:0.21%
—
—
cases:0.53%
controls:0.17%
cases:4.50%
controls:1.53%
cases:8.87%
controls:4.41%
128
806
1570
15990
76
291
1623
16515
11
36
1688
16770
—
9
29
1687
16735
73
248
1549
15909
112
551
1150
11953
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
5.6e-01
9.9e-01
—
—
—
1.0e+00
1.3e+00
cases:2.30%
controls:1.32%
cases:1.41%
controls:0.53%
—
—
—
—
—
—
cases:1.36%
controls:0.50%
cases:3.01%
controls:0.83%
39
222
1659
16574
24
89
1675
16717
—
—
—
22
81
1600
16076
38
104
1224
12400
Obstetrics / Gynecology
16 [38004461]
1.6e-01
3.3e-01
2.3e-01
2.3e+00
5.7e-01
3.8e-01
2.8e-01
cases:16.61%
controls:14.53%
cases:8.06%
controls:5.94%
cases:1.24%
controls:0.99%
cases:0.35%
controls:0.04%
cases:1.71%
controls:0.97%
cases:7.89%
controls:5.56%
cases:16.64%
controls:13.08%
282
2441
1416
14355
137
998
1562
15808
21
166
1678
16640
6
6
1693
16800
29
163
1667
16601
128
898
1494
15259
210
1636
1052
10868
Depressive episode, unspecified
F32.9 [45571760]
7.1e-01
9.4e-01
7.4e-01
—
9.1e-01
8.0e-01
7.6e-01
cases:4.06%
controls:2.03%
cases:1.82%
controls:0.72%
cases:0.41%
controls:0.20%
—
—
cases:0.41%
controls:0.17%
cases:1.85%
controls:0.84%
cases:4.20%
controls:2.00%
69
341
1629
16455
31
121
1668
16685
7
33
1692
16773
—
7
28
1689
16736
30
135
1592
16022
53
250
1209
12254
flucloxacillin; oral, parenteral
J01CF05 [21602857]
8.5e-01
1.3e+00
—
—
—
1.1e+00
5.7e-01
cases:1.35%
controls:0.58%
cases:0.94%
controls:0.26%
—
—
—
—
—
—
cases:0.86%
controls:0.30%
cases:1.66%
controls:0.95%
23
98
1675
16698
16
44
1683
16762
—
—
—
14
49
1608
16108
21
119
1241
12385
Valproate [Moles/volume] in Serum or Plasma
14946-8 [3009466]
9.0e-01
1.2e+00
—
—
—
5.7e-01
1.1e+00
cases:1.06%
controls:0.43%
cases:0.88%
controls:0.26%
—
—
—
—
—
—
cases:0.55%
controls:0.32%
cases:1.43%
controls:0.50%
18
73
1680
16723
15
44
1684
16762
—
—
—
9
51
1613
16106
18
62
1244
12442
Vancomycin [Mass/volume] in Serum or Plasma
20578-1 [3005715]
1.4e+00
—
—
—
—
—
1.7e+00
cases:0.65%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
cases:0.71%
controls:0.13%
11
26
1687
16770
—
—
—
—
—
9
16
1253
12488
Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]
4.5e-01
9.3e-01
1.0e+00
—
1.1e+00
1.1e+00
6.5e-01
cases:8.07%
controls:5.32%
cases:4.77%
controls:1.93%
cases:0.65%
controls:0.24%
—
—
cases:0.59%
controls:0.19%
cases:4.87%
controls:1.64%
cases:8.80%
controls:4.77%
137
894
1561
15902
81
324
1618
16482
11
40
1688
16766
—
10
32
1686
16732
79
265
1543
15892
111
597
1151
11907
Ankle extensive X-ray examination
NH1BA [2001308239]
1.1e+00
—
—
—
—
1.8e+00
1.4e+00
cases:0.71%
controls:0.24%
—
—
—
—
—
—
—
—
cases:0.43%
controls:0.07%
cases:0.79%
controls:0.20%
12
41
1686
16755
—
—
—
—
7
12
1615
16145
10
25
1252
12479
Intravenous
ZX120 [2001311495]
7.4e-01
5.0e-01
1.3e+00
—
—
1.2e+00
1.2e+00
cases:2.06%
controls:0.99%
cases:0.65%
controls:0.39%
cases:0.35%
controls:0.10%
—
—
—
—
cases:0.92%
controls:0.29%
cases:1.90%
controls:0.56%
35
167
1663
16629
11
66
1688
16740
6
17
1693
16789
—
—
15
47
1607
16110
24
70
1238
12434
Administration of medicine
SPAT1254 [2001700355]
5.1e-01
8.7e-01
8.3e-01
—
7.5e-01
1.0e+00
7.4e-01
cases:4.12%
controls:2.52%
cases:1.88%
controls:0.80%
cases:0.71%
controls:0.31%
—
—
cases:0.71%
controls:0.33%
cases:2.10%
controls:0.77%
cases:3.17%
controls:1.54%
70
423
1628
16373
32
134
1667
16672
12
52
1687
16754
—
12
56
1684
16708
34
125
1588
16032
40
192
1222
12312
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
4.4e-01
1.1e+00
1.5e+00
—
1.5e+00
9.1e-01
6.7e-01
cases:4.71%
controls:3.08%
cases:3.00%
controls:1.01%
cases:0.41%
controls:0.09%
—
—
cases:0.29%
controls:0.07%
cases:1.97%
controls:0.80%
cases:4.52%
controls:2.36%
80
517
1618
16279
51
170
1648
16636
7
15
1692
16791
—
5
11
1691
16753
32
130
1590
16027
57
295
1205
12209
Consultation of another employee
SPAT1260 [2001700361]
5.3e-01
9.3e-01
1.7e+00
—
—
5.1e-01
5.1e-01
cases:4.71%
controls:2.83%
cases:1.94%
controls:0.77%
cases:0.47%
controls:0.09%
—
—
—
—
cases:1.48%
controls:0.90%
cases:3.09%
controls:1.87%
80
476
1618
16320
33
130
1666
16676
8
15
1691
16791
—
—
24
145
1598
16012
39
234
1223
12270
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
2.8e-01
9.1e-01
2.2e+00
—
—
5.2e-01
7.8e-01
cases:1.53%
controls:1.16%
cases:1.12%
controls:0.45%
cases:0.65%
controls:0.07%
—
—
—
—
cases:0.68%
controls:0.40%
cases:1.66%
controls:0.77%
26
195
1672
16601
19
76
1680
16730
11
12
1688
16794
—
—
11
65
1611
16092
21
96
1241
12408
Fever, unspecified
R50.9 [45582716]
5.8e-01
9.4e-01
1.9e+00
—
—
9.6e-01
6.4e-01
cases:2.89%
controls:1.63%
cases:1.24%
controls:0.49%
cases:0.35%
controls:0.05%
—
—
—
—
cases:1.23%
controls:0.48%
cases:3.01%
controls:1.62%
49
274
1649
16522
21
82
1678
16724
6
9
1693
16797
—
—
20
77
1602
16080
38
202
1224
12302
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
2.3e-01
7.4e-01
2.3e+00
1.0e+50
1.2e+00
5.2e-01
3.4e-01
cases:7.71%
controls:6.20%
cases:3.88%
controls:1.90%
cases:1.35%
controls:0.13%
cases:0.41%
controls:0.00%
cases:0.53%
controls:0.16%
cases:2.90%
controls:1.75%
cases:7.13%
controls:5.18%
131
1042
1567
15754
66
319
1633
16487
23
22
1676
16784
7
0
1692
16806
9
27
1687
16737
47
283
1575
15874
90
648
1172
11856
Suture or treatment of traumatic wound
SPAT1149 [2001700250]
6.7e-01
1.4e+00
—
—
—
8.0e-01
1.0e+00
cases:2.41%
controls:1.24%
cases:1.24%
controls:0.32%
—
—
—
—
—
—
cases:0.62%
controls:0.28%
cases:2.38%
controls:0.86%
41
209
1657
16587
21
53
1678
16753
—
—
—
10
45
1612
16112
30
108
1232
12396
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
2.4e-01
9.2e-01
2.2e+00
—
1.6e+00
6.2e-01
3.4e-01
cases:2.41%
controls:1.91%
cases:1.65%
controls:0.67%
cases:0.41%
controls:0.05%
—
—
cases:0.29%
controls:0.06%
cases:1.29%
controls:0.70%
cases:2.30%
controls:1.65%
41
321
1657
16475
28
112
1671
16694
7
8
1692
16798
—
5
10
1691
16754
21
113
1601
16044
29
206
1233
12298
aripiprazole; oral, parenteral
N05AX12 [21604562]
6.1e-01
8.0e-01
6.8e-01
—
3.2e-01
1.2e+00
1.1e+00
cases:1.71%
controls:0.93%
cases:1.59%
controls:0.72%
cases:0.47%
controls:0.24%
—
—
cases:0.35%
controls:0.26%
cases:1.91%
controls:0.60%
cases:2.54%
controls:0.86%
29
157
1669
16639
27
121
1672
16685
8
40
1691
16766
—
6
43
1690
16721
31
97
1591
16060
32
107
1230
12397
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
5.1e-01
5.6e-01
9.0e-01
—
4.1e-01
5.3e-01
5.3e-01
cases:11.25%
controls:7.08%
cases:5.71%
controls:3.34%
cases:1.06%
controls:0.43%
—
—
cases:0.71%
controls:0.47%
cases:5.61%
controls:3.37%
cases:11.33%
controls:7.02%
191
1189
1507
15607
97
562
1602
16244
18
73
1681
16733
—
12
79
1684
16685
91
544
1531
15613
143
878
1119
11626
Dermatoscopy
XQ845 [2001310108]
—
—
—
1.0e+50
—
3.0e+00
—
—
—
—
—
—
—
cases:2.24%
controls:0.00%
—
—
cases:1.11%
controls:0.06%
—
—
—
—
—
38
0
1661
16806
—
18
9
1604
16148
—
magnesium hydroxide; oral
G04BX01 [21602658]
5.4e-01
7.7e-01
7.7e-01
—
—
1.3e+00
1.6e+00
cases:0.77%
controls:0.45%
cases:0.59%
controls:0.27%
cases:0.29%
controls:0.14%
—
—
—
—
cases:0.92%
controls:0.24%
cases:1.74%
controls:0.34%
13
75
1685
16721
10
46
1689
16760
5
23
1694
16783
—
—
15
39
1607
16118
22
43
1240
12461
magnesium hydroxide; oral
A02AA04 [21600052]
5.4e-01
7.7e-01
7.7e-01
—
—
1.3e+00
1.6e+00
cases:0.77%
controls:0.45%
cases:0.59%
controls:0.27%
cases:0.29%
controls:0.14%
—
—
—
—
cases:0.92%
controls:0.24%
cases:1.74%
controls:0.34%
13
75
1685
16721
10
46
1689
16760
5
23
1694
16783
—
—
15
39
1607
16118
22
43
1240
12461
General health counselling
SPAT1312 [2001700413]
2.8e-01
4.9e-01
7.1e-01
—
1.3e+00
6.6e-01
5.7e-01
cases:10.19%
controls:7.89%
cases:3.30%
controls:2.04%
cases:0.41%
controls:0.20%
—
—
cases:0.71%
controls:0.20%
cases:3.21%
controls:1.68%
cases:7.61%
controls:4.44%
173
1325
1525
15471
56
343
1643
16463
7
34
1692
16772
—
12
34
1684
16730
52
272
1570
15885
96
555
1166
11949
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
2.7e-01
9.1e-01
2.0e+00
—
—
4.9e-01
6.4e-01
cases:1.83%
controls:1.40%
cases:1.47%
controls:0.60%
cases:0.82%
controls:0.11%
—
—
—
—
cases:0.86%
controls:0.53%
cases:1.90%
controls:1.01%
31
235
1667
16561
25
100
1674
16706
14
18
1685
16788
—
—
14
86
1608
16071
24
126
1238
12378
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
5.6e-01
8.6e-01
1.2e+00
—
1.0e+00
9.5e-01
1.1e+00
cases:2.41%
controls:1.39%
cases:1.53%
controls:0.65%
cases:0.29%
controls:0.09%
—
—
cases:0.35%
controls:0.13%
cases:1.54%
controls:0.60%
cases:3.09%
controls:1.01%
41
233
1657
16563
26
110
1673
16696
5
15
1694
16791
—
6
21
1690
16743
25
97
1597
16060
39
126
1223
12378
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
3.0e-01
6.3e-01
1.2e+00
—
7.7e-01
5.4e-01
5.6e-01
cases:6.12%
controls:4.61%
cases:3.35%
controls:1.81%
cases:0.94%
controls:0.28%
—
—
cases:0.59%
controls:0.27%
cases:2.96%
controls:1.75%
cases:6.10%
controls:3.58%
104
774
1594
16022
57
305
1642
16501
16
47
1683
16759
—
10
46
1686
16718
48
282
1574
15875
77
448
1185
12056
Bicarbonate [Moles/volume] in Venous blood
14627-4 [3027273]
7.8e-01
1.0e+00
—
—
—
1.1e+00
2.7e-02
cases:1.65%
controls:0.76%
cases:0.82%
controls:0.30%
—
—
—
—
—
—
cases:1.05%
controls:0.35%
cases:1.11%
controls:1.08%
28
128
1670
16668
14
50
1685
16756
—
—
—
17
56
1605
16101
14
135
1248
12369
Coloscopy
UJF32 [2001305029]
5.0e-01
1.0e+00
—
—
-1.0e+50
8.2e-01
6.0e-01
cases:5.06%
controls:3.15%
cases:2.41%
controls:0.90%
—
—
—
—
cases:0.00%
controls:0.11%
cases:1.60%
controls:0.71%
cases:4.28%
controls:2.38%
86
529
1612
16267
41
152
1658
16654
—
—
0
19
1696
16745
26
115
1596
16042
54
298
1208
12206
pH of Capillary blood
2745-8 [3009343]
5.7e-01
8.8e-01
—
—
1.1e+00
9.1e-01
1.1e+00
cases:2.41%
controls:1.38%
cases:1.47%
controls:0.61%
—
—
—
—
cases:0.35%
controls:0.11%
cases:1.42%
controls:0.58%
cases:3.01%
controls:1.01%
41
232
1657
16564
25
103
1674
16703
—
—
6
19
1690
16745
23
93
1599
16064
38
126
1224
12378
Gas panel - Arterial blood
24336-0 [3019060]
7.8e-01
8.6e-01
—
—
2.1e+00
1.1e+00
1.0e+00
cases:2.30%
controls:1.07%
cases:0.65%
controls:0.27%
—
—
—
—
cases:0.29%
controls:0.04%
cases:0.86%
controls:0.29%
cases:2.06%
controls:0.75%
39
179
1659
16617
11
46
1688
16760
—
—
5
6
1691
16758
14
47
1608
16110
26
94
1236
12410
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
1.7e-01
3.3e-01
7.6e-01
1.8e+00
4.1e-01
1.8e-01
1.7e-01
cases:33.39%
controls:29.75%
cases:21.48%
controls:16.42%
cases:4.53%
controls:2.18%
cases:0.65%
controls:0.11%
cases:3.07%
controls:2.06%
cases:18.87%
controls:16.31%
cases:33.84%
controls:30.06%
567
4997
1131
11799
365
2759
1334
14047
77
366
1622
16440
11
18
1688
16788
52
345
1644
16419
306
2636
1316
13521
427
3759
835
8745
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
3.1e-01
9.3e-01
1.9e+00
1.0e+50
1.2e+00
4.6e-01
2.5e-01
cases:6.95%
controls:5.19%
cases:3.88%
controls:1.56%
cases:1.00%
controls:0.15%
cases:0.41%
controls:0.00%
cases:0.53%
controls:0.16%
cases:2.47%
controls:1.58%
cases:5.39%
controls:4.23%
118
871
1580
15925
66
263
1633
16543
17
25
1682
16781
7
0
1692
16806
9
26
1687
16738
40
255
1582
15902
68
529
1194
11975
lamotrigine; oral
N03AX09 [21604431]
7.7e-01
7.3e-01
—
—
—
9.6e-01
1.1e+00
cases:1.41%
controls:0.66%
cases:0.88%
controls:0.43%
—
—
—
—
—
—
cases:1.17%
controls:0.45%
cases:2.38%
controls:0.81%
24
111
1674
16685
15
72
1684
16734
—
—
—
19
73
1603
16084
30
101
1232
12403
Emotionally unstable personality disorder, borderline condition
F60.31 [2000502023]
1.3e+00
1.5e+00
—
—
1.8e+00
1.3e+00
1.3e+00
cases:0.65%
controls:0.18%
cases:0.59%
controls:0.13%
—
—
—
—
cases:0.29%
controls:0.05%
cases:0.62%
controls:0.17%
cases:0.87%
controls:0.24%
11
31
1687
16765
10
22
1689
16784
—
—
5
8
1691
16756
10
28
1612
16129
11
30
1251
12474
Emotionally unstable personality disorder, impulsive
F60.30 [2000502022]
1.5e+00
6.6e-01
1.3e+00
—
—
1.1e+00
1.3e+00
cases:1.12%
controls:0.26%
cases:0.41%
controls:0.21%
cases:0.29%
controls:0.08%
—
—
—
—
cases:0.68%
controls:0.22%
cases:1.27%
controls:0.34%
19
44
1679
16752
7
36
1692
16770
5
13
1694
16793
—
—
11
35
1611
16122
16
42
1246
12462
oxycodone; oral, parenteral
N02AA05 [21604260]
6.1e-01
7.8e-01
3.7e-01
—
7.3e-01
7.7e-01
6.2e-01
cases:2.24%
controls:1.23%
cases:1.65%
controls:0.76%
cases:0.41%
controls:0.29%
—
—
cases:0.53%
controls:0.26%
cases:1.73%
controls:0.80%
cases:3.25%
controls:1.77%
38
206
1660
16590
28
128
1671
16678
7
48
1692
16758
—
9
43
1687
16721
28
130
1594
16027
41
221
1221
12283
Complicated extraction of tooth
EBA05 [2001301924]
1.8e-01
3.7e-01
2.1e+00
—
2.2e+00
3.9e-01
5.7e-01
cases:3.36%
controls:2.82%
cases:1.06%
controls:0.74%
cases:0.29%
controls:0.04%
—
—
cases:0.65%
controls:0.07%
cases:1.23%
controls:0.84%
cases:4.83%
controls:2.78%
57
474
1641
16322
18
124
1681
16682
5
6
1694
16800
—
11
12
1685
16752
20
135
1602
16022
61
348
1201
12156
Oxygen saturation in Capillary blood
2709-4 [3021901]
8.0e-01
1.6e+00
—
—
—
1.2e+00
1.2e+00
cases:0.65%
controls:0.29%
cases:0.77%
controls:0.15%
—
—
—
—
—
—
cases:0.49%
controls:0.15%
cases:1.03%
controls:0.32%
11
49
1687
16747
13
26
1686
16780
—
—
—
8
25
1614
16132
13
40
1249
12464
Pulmonary Disease
29 [38004472]
4.0e-01
4.1e-01
9.0e-01
—
5.8e-01
5.9e-01
4.7e-01
cases:10.19%
controls:7.05%
cases:5.65%
controls:3.82%
cases:1.65%
controls:0.68%
—
—
cases:1.24%
controls:0.70%
cases:6.29%
controls:3.58%
cases:10.46%
controls:6.83%
173
1184
1525
15612
96
642
1603
16164
28
114
1671
16692
—
21
117
1675
16647
102
579
1520
15578
132
854
1130
11650
General Surgery
2 [38004447]
4.4e-01
4.9e-01
8.0e-01
—
8.5e-01
6.2e-01
3.6e-01
cases:18.85%
controls:12.99%
cases:6.30%
controls:3.97%
cases:1.12%
controls:0.51%
—
—
cases:1.18%
controls:0.51%
cases:6.91%
controls:3.85%
cases:16.72%
controls:12.26%
320
2181
1378
14615
107
667
1592
16139
19
85
1680
16721
—
20
85
1676
16679
112
622
1510
15535
211
1533
1051
10971
Physical Medicine And Rehabilitation
25 [38004468]
6.0e-01
6.7e-01
3.3e-01
—
9.3e-01
7.6e-01
7.2e-01
cases:9.42%
controls:5.39%
cases:4.00%
controls:2.08%
cases:0.47%
controls:0.34%
—
—
cases:0.77%
controls:0.30%
cases:3.82%
controls:1.83%
cases:9.59%
controls:4.91%
160
905
1538
15891
68
350
1631
16456
8
57
1691
16749
—
13
51
1683
16713
62
296
1560
15861
121
614
1141
11890
pregabalin; oral
N02BF02 [955152]
7.2e-01
6.5e-01
7.4e-01
—
5.7e-01
6.0e-01
7.6e-01
cases:6.07%
controls:3.04%
cases:2.88%
controls:1.53%
cases:1.18%
controls:0.57%
—
—
cases:1.00%
controls:0.57%
cases:2.90%
controls:1.61%
cases:5.94%
controls:2.87%
103
510
1595
16286
49
257
1650
16549
20
95
1679
16711
—
17
95
1679
16669
47
260
1575
15897
75
359
1187
12145
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
5.6e-01
8.6e-01
1.3e+00
—
—
6.1e-01
6.8e-01
cases:4.48%
controls:2.61%
cases:2.65%
controls:1.14%
cases:0.53%
controls:0.14%
—
—
—
—
cases:2.59%
controls:1.42%
cases:5.47%
controls:2.86%
76
438
1622
16358
45
192
1654
16614
9
24
1690
16782
—
—
42
229
1580
15928
69
357
1193
12147
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
4.5e-01
6.2e-01
6.8e-01
—
9.9e-01
7.5e-01
8.9e-01
cases:4.71%
controls:3.05%
cases:2.47%
controls:1.35%
cases:0.47%
controls:0.24%
—
—
cases:0.59%
controls:0.22%
cases:2.65%
controls:1.27%
cases:6.18%
controls:2.62%
80
513
1618
16283
42
227
1657
16579
8
40
1691
16766
—
10
37
1686
16727
43
206
1579
15951
78
328
1184
12176
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
4.9e-01
6.6e-01
—
—
—
8.9e-01
6.5e-01
cases:5.77%
controls:3.63%
cases:1.88%
controls:0.98%
—
—
—
—
—
—
cases:2.03%
controls:0.84%
cases:5.07%
controls:2.71%
98
610
1600
16186
32
165
1667
16641
—
—
—
33
136
1589
16021
64
339
1198
12165
Choriogonadotropin [Units/volume] in Serum or Plasma
19080-1 [3018171]
3.3e-01
9.1e-01
—
—
1.7e+00
8.6e-01
9.1e-01
cases:2.41%
controls:1.76%
cases:1.24%
controls:0.50%
—
—
—
—
cases:0.35%
controls:0.07%
cases:1.29%
controls:0.55%
cases:3.17%
controls:1.30%
41
295
1657
16501
21
84
1678
16722
—
—
6
11
1690
16753
21
89
1601
16068
40
163
1222
12341
One hour or less
ZXE00 [2001311394]
3.8e-01
6.0e-01
1.6e+00
—
1.5e+00
8.1e-01
8.8e-01
cases:7.60%
controls:5.33%
cases:2.41%
controls:1.34%
cases:0.35%
controls:0.07%
—
—
cases:0.47%
controls:0.10%
cases:1.97%
controls:0.89%
cases:6.34%
controls:2.72%
129
896
1569
15900
41
225
1658
16581
6
12
1693
16794
—
8
17
1688
16747
32
144
1590
16013
80
340
1182
12164
Granulocytes [#/volume] in Blood
30394-1 [3035715]
1.0e+00
1.7e+00
—
—
—
1.6e+00
7.8e-01
cases:1.24%
controls:0.46%
cases:0.59%
controls:0.11%
—
—
—
—
—
—
cases:0.37%
controls:0.07%
cases:0.55%
controls:0.26%
21
77
1677
16719
10
19
1689
16787
—
—
—
6
12
1616
16145
7
32
1255
12472
risperidone; oral, parenteral
N05AX08 [21604559]
6.0e-01
8.6e-01
5.4e-01
—
6.8e-01
1.1e+00
7.2e-01
cases:1.83%
controls:1.01%
cases:1.35%
controls:0.58%
cases:0.29%
controls:0.17%
—
—
cases:0.41%
controls:0.21%
cases:1.54%
controls:0.53%
cases:2.38%
controls:1.18%
31
170
1667
16626
23
97
1676
16709
5
29
1694
16777
—
7
35
1689
16729
25
86
1597
16071
30
147
1232
12357
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
7.1e-01
7.2e-01
6.2e-01
-1.0e+50
5.8e-01
7.1e-01
5.1e-01
cases:11.25%
controls:5.86%
cases:4.36%
controls:2.17%
cases:0.88%
controls:0.48%
cases:0.00%
controls:0.03%
cases:0.77%
controls:0.43%
cases:4.19%
controls:2.10%
cases:8.72%
controls:5.44%
191
985
1507
15811
74
365
1625
16441
15
80
1684
16726
0
5
1699
16801
13
72
1683
16692
68
339
1554
15818
110
680
1152
11824
pH of Serum or Plasma
2753-2 [3018418]
2.1e-01
3.7e-01
1.2e+00
—
8.9e-01
3.4e-01
5.5e-01
cases:7.95%
controls:6.54%
cases:4.36%
controls:3.04%
cases:1.71%
controls:0.52%
—
—
cases:1.30%
controls:0.54%
cases:4.13%
controls:2.98%
cases:9.51%
controls:5.71%
135
1099
1563
15697
74
511
1625
16295
29
87
1670
16719
—
22
90
1674
16674
67
482
1555
15675
120
714
1142
11790
Scheduled procedure
ZXD10 [2001311387]
2.7e-01
5.4e-01
—
—
1.8e+00
6.2e-01
7.9e-01
cases:5.83%
controls:4.50%
cases:1.82%
controls:1.07%
—
—
—
—
cases:0.41%
controls:0.07%
cases:1.29%
controls:0.70%
cases:4.75%
controls:2.22%
99
756
1599
16040
31
180
1668
16626
—
—
7
11
1689
16753
21
113
1601
16044
60
277
1202
12227
Atrial fibrillation and flutter
I48 [45596206]
2.8e-01
2.4e-01
2.9e-01
2.6e+00
2.1e-01
3.4e-01
3.8e-01
cases:4.77%
controls:3.66%
cases:2.35%
controls:1.86%
cases:0.47%
controls:0.35%
cases:0.41%
controls:0.03%
cases:0.47%
controls:0.38%
cases:2.28%
controls:1.63%
cases:4.60%
controls:3.17%
81
615
1617
16181
40
312
1659
16494
8
59
1691
16747
7
5
1692
16801
8
64
1688
16700
37
264
1585
15893
58
397
1204
12107
Genital candidiasis female
X72 [2002001357]
2.6e+00
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.41%
controls:0.03%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.05%
cases:0.00%
controls:0.10%
7
5
1691
16791
—
—
—
—
0
8
1622
16149
0
12
1262
12492
Bicarbonate [Moles/volume] in Capillary blood
1961-2 [3015235]
4.9e-01
1.3e+00
—
—
1.3e+00
1.1e+00
1.3e+00
cases:0.71%
controls:0.43%
cases:0.94%
controls:0.25%
—
—
—
—
cases:0.29%
controls:0.08%
cases:0.74%
controls:0.26%
cases:1.74%
controls:0.49%
12
73
1686
16723
16
42
1683
16764
—
—
5
13
1691
16751
12
42
1610
16115
22
61
1240
12443
Ammonium ion [Moles/volume] in Plasma
1845-7 [3023183]
1.1e+00
1.2e+00
—
—
—
—
1.5e+00
cases:1.00%
controls:0.33%
cases:0.29%
controls:0.09%
—
—
—
—
—
—
—
—
cases:1.19%
controls:0.27%
17
55
1681
16741
5
15
1694
16791
—
—
—
—
15
34
1247
12470
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
4.3e-01
4.7e-01
8.7e-01
—
7.1e-01
4.9e-01
3.5e-01
cases:14.49%
controls:9.92%
cases:7.00%
controls:4.50%
cases:1.29%
controls:0.55%
—
—
cases:1.24%
controls:0.61%
cases:6.84%
controls:4.31%
cases:13.71%
controls:10.05%
246
1667
1452
15129
119
757
1580
16049
22
92
1677
16714
—
21
103
1675
16661
111
696
1511
15461
173
1257
1089
11247
azithromycin; oral, parenteral
J01FA10 [21602978]
2.9e-01
4.4e-01
1.3e+00
—
—
5.6e-01
4.4e-01
cases:9.78%
controls:7.48%
cases:2.83%
controls:1.84%
cases:0.71%
controls:0.20%
—
—
—
—
cases:3.39%
controls:1.96%
cases:9.75%
controls:6.49%
166
1257
1532
15539
48
310
1651
16496
12
33
1687
16773
—
—
55
317
1567
15840
123
812
1139
11692
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
6.0e-01
7.2e-01
4.3e-01
—
8.9e-01
7.4e-01
1.1e+00
cases:1.83%
controls:1.01%
cases:1.59%
controls:0.78%
cases:0.41%
controls:0.27%
—
—
cases:0.71%
controls:0.29%
cases:1.66%
controls:0.80%
cases:2.93%
controls:1.01%
31
170
1667
16626
27
131
1672
16675
7
45
1692
16761
—
12
49
1684
16715
27
129
1595
16028
37
126
1225
12378
Bacterial infection, unspecified
A49.9 [45590816]
4.4e-01
1.3e+00
—
—
—
9.4e-01
1.2e+00
cases:1.30%
controls:0.84%
cases:1.29%
controls:0.34%
—
—
—
—
—
—
cases:0.74%
controls:0.29%
cases:2.06%
controls:0.65%
22
141
1676
16655
22
57
1677
16749
—
—
—
12
47
1610
16110
26
81
1236
12423
Gastroenterology
10 [38004455]
4.4e-01
7.2e-01
8.3e-01
—
-2.4e-02
7.5e-01
6.1e-01
cases:7.60%
controls:5.03%
cases:4.47%
controls:2.24%
cases:1.00%
controls:0.44%
—
—
cases:0.47%
controls:0.48%
cases:4.32%
controls:2.09%
cases:7.92%
controls:4.48%
129
844
1569
15952
76
376
1623
16430
17
74
1682
16732
—
8
81
1688
16683
70
338
1552
15819
100
560
1162
11944
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
9.5e-01
1.6e+00
—
—
—
9.7e-01
9.3e-01
cases:1.18%
controls:0.46%
cases:1.06%
controls:0.23%
—
—
—
—
—
—
cases:0.55%
controls:0.21%
cases:1.11%
controls:0.44%
20
77
1678
16719
18
38
1681
16768
—
—
—
9
34
1613
16123
14
55
1248
12449
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
9.5e-02
2.0e-01
3.5e-01
2.5e+00
2.6e-01
2.0e-01
1.9e-01
cases:20.20%
controls:18.72%
cases:11.77%
controls:9.82%
cases:1.88%
controls:1.34%
cases:0.65%
controls:0.05%
cases:1.83%
controls:1.42%
cases:9.25%
controls:7.70%
cases:18.86%
controls:16.07%
343
3144
1355
13652
200
1651
1499
15155
32
225
1667
16581
11
9
1688
16797
31
238
1665
16526
150
1244
1472
14913
238
2009
1024
10495
Connective tissue diseases, rheumatoid arthritis and comparable disease
202 [2001600200]
9.7e-01
1.5e+00
-1.0e+50
—
—
1.1e+00
4.2e-01
cases:1.77%
controls:0.68%
cases:0.71%
controls:0.15%
cases:0.00%
controls:0.03%
—
—
—
—
cases:0.37%
controls:0.12%
cases:0.71%
controls:0.47%
30
114
1668
16682
12
26
1687
16780
0
5
1699
16801
—
—
6
19
1616
16138
9
59
1253
12445
bupropion; oral
N06AX12 [21604741]
8.6e-01
7.5e-01
1.1e+00
—
5.3e-01
9.0e-01
7.3e-01
cases:2.47%
controls:1.06%
cases:1.29%
controls:0.61%
cases:0.53%
controls:0.17%
—
—
cases:0.35%
controls:0.21%
cases:1.54%
controls:0.63%
cases:2.85%
controls:1.40%
42
178
1656
16618
22
103
1677
16703
9
29
1690
16777
—
6
35
1690
16729
25
102
1597
16055
36
175
1226
12329
amoxicillin; oral, parenteral
J01CA04 [21602823]
3.6e-01
4.0e-01
5.3e-01
—
1.1e+00
3.2e-01
3.3e-01
cases:25.80%
controls:19.53%
cases:8.65%
controls:6.00%
cases:1.18%
controls:0.70%
—
—
cases:1.89%
controls:0.64%
cases:8.63%
controls:6.42%
cases:24.25%
controls:18.76%
438
3280
1260
13516
147
1008
1552
15798
20
117
1679
16689
—
32
108
1664
16656
140
1038
1482
15119
306
2346
956
10158
Xerosis cutis
L85.3 [45577054]
—
2.1e+00
—
—
—
2.5e+00
—
—
—
cases:0.29%
controls:0.04%
—
—
—
—
—
—
cases:0.37%
controls:0.03%
—
—
—
5
6
1694
16800
—
—
—
6
5
1616
16152
—
Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32730-4 [3043723]
4.2e-01
1.0e+00
2.5e+00
—
—
5.8e-01
6.7e-01
cases:0.94%
controls:0.62%
cases:0.77%
controls:0.28%
cases:0.35%
controls:0.03%
—
—
—
—
cases:0.43%
controls:0.24%
cases:0.95%
controls:0.49%
16
104
1682
16692
13
47
1686
16759
6
5
1693
16801
—
—
7
39
1615
16118
12
61
1250
12443
Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2868-8 [3005229]
4.2e-01
1.0e+00
2.5e+00
—
—
5.8e-01
6.6e-01
cases:0.94%
controls:0.62%
cases:0.77%
controls:0.28%
cases:0.35%
controls:0.03%
—
—
—
—
cases:0.43%
controls:0.24%
cases:0.95%
controls:0.50%
16
104
1682
16692
13
47
1686
16759
6
5
1693
16801
—
—
7
39
1615
16118
12
62
1250
12442
Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32731-2 [3043747]
4.2e-01
1.0e+00
2.5e+00
—
—
5.8e-01
6.9e-01
cases:0.94%
controls:0.62%
cases:0.77%
controls:0.28%
cases:0.35%
controls:0.03%
—
—
—
—
cases:0.43%
controls:0.24%
cases:0.95%
controls:0.48%
16
104
1682
16692
13
47
1686
16759
6
5
1693
16801
—
—
7
39
1615
16118
12
60
1250
12444
Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2865-4 [3015322]
1.9e-01
1.1e+00
2.5e+00
—
—
5.8e-01
5.6e-01
cases:0.71%
controls:0.58%
cases:0.77%
controls:0.27%
cases:0.35%
controls:0.03%
—
—
—
—
cases:0.43%
controls:0.24%
cases:0.79%
controls:0.46%
12
98
1686
16698
13
45
1686
16761
6
5
1693
16801
—
—
7
39
1615
16118
10
57
1252
12447
Osmolality of Urine
2695-5 [3026782]
2.4e-01
4.0e-01
1.3e+00
—
1.1e+00
6.1e-01
5.8e-01
cases:5.54%
controls:4.42%
cases:2.30%
controls:1.55%
cases:0.71%
controls:0.20%
—
—
cases:0.53%
controls:0.18%
cases:2.40%
controls:1.32%
cases:4.83%
controls:2.76%
94
742
1604
16054
39
260
1660
16546
12
33
1687
16773
—
9
30
1687
16734
39
214
1583
15943
61
345
1201
12159
Treatment of a patient needing special arrangements
WYA30 [2001310874]
2.3e-01
1.3e+00
—
—
—
7.6e-01
1.2e+00
cases:1.53%
controls:1.22%
cases:1.00%
controls:0.29%
—
—
—
—
—
—
cases:0.55%
controls:0.26%
cases:2.54%
controls:0.77%
26
205
1672
16591
17
48
1682
16758
—
—
—
9
42
1613
16115
32
96
1230
12408
Short blood count panel - Blood
55429-5 [40758558]
7.2e-02
4.6e-01
1.1e+00
2.3e+00
7.0e-01
4.7e-01
4.3e-01
cases:7.24%
controls:6.78%
cases:4.41%
controls:2.83%
cases:1.77%
controls:0.59%
cases:0.29%
controls:0.03%
cases:1.18%
controls:0.59%
cases:4.44%
controls:2.83%
cases:8.08%
controls:5.40%
123
1138
1575
15658
75
475
1624
16331
30
99
1669
16707
5
5
1694
16801
20
99
1676
16665
72
457
1550
15700
102
675
1160
11829
pH of Specimen
17433-4 [3019225]
5.9e-01
6.4e-01
7.2e-01
—
7.2e-01
7.8e-01
1.1e+00
cases:3.77%
controls:2.12%
cases:1.88%
controls:1.01%
cases:0.29%
controls:0.14%
—
—
cases:0.29%
controls:0.14%
cases:1.73%
controls:0.80%
cases:3.65%
controls:1.26%
64
356
1634
16440
32
169
1667
16637
5
24
1694
16782
—
5
24
1691
16740
28
129
1594
16028
46
158
1216
12346

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
73
104
7.19
48.79
1.4
1.3
92.00
74.55
titre
—
5
11
74
108
7.02
48.39
1.4
1.3
948.33
1104.29
titre
—
6
7
1496
11395
1.73
39.81
8.1
6.7
10.42
11.71
umol/l
5.46
1426
10908
1571
12148
1.73
39.40
8.9
7.0
0.20
0.19
e9/l
1.18
1388
10701
227
908
2.64
37.86
1.3
1.2
—
—
—
0
0
1524
11773
1.70
37.51
8.7
6.7
0.04
0.04
e9/l
0.62
1343
10220
1520
11759
1.70
36.97
8.7
6.7
0.59
0.58
e9/l
0.63
1338
10204
1416
10817
1.67
35.53
8.8
7.0
8.61
8.82
%
2.23
1335
10236
1543
12058
1.68
35.43
8.7
6.8
1.94
1.96
e9/l
0.13
1391
10723
1410
10796
1.66
34.74
8.8
7.0
0.68
0.68
%
0.04
1328
10206
1409
10795
1.66
34.56
8.8
6.9
2.95
2.84
%
1.07
1324
10213
1434
11138
1.63
32.46
8.8
6.9
28.14
28.47
%
0.55
1369
10650
1409
10959
1.62
31.19
8.5
6.7
56.95
56.75
%
0.26
1354
10550
1723
14085
1.65
31.12
5.3
4.2
1130.96
1249.85
e6/l
0.04
29
199
981
7000
1.64
30.75
3.5
2.7
56.16
71.49
u/l
0.75
897
6555
844
5806
1.67
30.48
6.0
4.4
—
—
—
0
0
1618
13061
1.62
30.36
11.8
9.8
4.27
4.08
e9/l
2.36
1440
11392
1251
9582
1.58
28.56
16.9
12.7
1.22
1.20
inr
0.59
1054
7981
445
2636
1.83
26.94
1.9
1.7
—
—
—
0
0
1325
10406
1.55
26.27
9.3
7.6
1.21
1.21
mmol/l
0.68
1143
9098
1957
16850
1.64
25.57
10.8
8.1
78.67
77.82
u/l
0.35
1874
16116
1208
9347
1.54
25.26
9.5
7.1
1.21
1.21
mmol/l
0.07
1138
8725
1582
13012
1.54
24.77
7.3
5.4
6.67
6.64
mmol/l
0.18
1506
12277
896
6576
1.55
23.29
2.6
2.3
236.20
244.18
u/l
0.08
858
6280
1900
16390
1.58
23.11
5.4
4.2
11.61
10.41
mm/h
3.08
1790
15467
1195
9397
1.50
22.12
6.9
5.4
35.58
36.29
g/l
3.96
1118
8896
465
2949
1.70
21.83
8.9
6.8
1.09
1.04
mmol/l
1.95
436
2769
551
3693
1.62
20.76
4.5
3.9
0.81
0.82
mmol/l
1.63
526
3529
1036
7993
1.49
20.60
4.7
3.5
93.32
59.81
ng/l
0.24
708
5222
777
5647
1.53
20.57
2.6
2.3
2.83
2.71
mg/l
0.67
658
4914
298
1692
1.86
20.35
1.6
1.3
322.91
300.26
u/ml
0.07
277
1578
483
3194
1.63
19.05
2.2
2.1
—
—
—
0
0
267
1506
1.86
18.57
4.6
3.9
5.14
5.15
kpa
0.08
260
1455
745
5466
1.51
18.49
2.6
2.1
—
—
—
0
0
260
1470
1.85
17.93
4.7
3.9
7.41
7.41
ph
1.35
221
1214
474
3188
1.59
17.28
2.1
1.7
—
—
—
0
0
1185
9604
1.43
17.17
3.7
3.2
6.16
6.18
ph
0.25
682
5563
329
2031
1.71
16.78
5.6
4.8
0.73
0.96
%
0.86
108
607
317
1943
1.72
16.58
5.3
4.6
0.53
0.68
%
0.77
106
571
135
622
2.23
16.40
4.9
2.8
—
—
—
0
0
317
1950
1.71
16.36
5.5
4.9
0.07
0.13
%
0.93
97
526
736
5500
1.47
16.30
6.9
4.8
—
—
—
0
0
455
3074
1.58
16.18
1.8
1.7
1146.26
1162.13
nmol/l
0.13
354
2383
401
2633
1.62
16.07
3.5
3.1
5.98
7.71
umol/l
2.24
335
2319
754
5676
1.46
16.03
3.8
3.2
1332.77
1089.48
ng/l
0.86
624
4775
426
2848
1.59
15.82
1.6
1.5
—
—
—
0
0
1416
11953
1.40
15.69
4.4
3.6
3.74
5.12
estimate
0.13
344
2502
915
7169
1.42
15.58
4.1
3.3
54.86
70.83
e6/l
0.33
747
5422
1420
12004
1.40
15.53
4.4
3.6
3.12
0.14
estimate
0.47
321
2334
835
6445
1.43
15.41
4.6
3.7
0.00
0.00
estimate
1.79
315
2327
802
6146
1.44
15.38
5.9
4.4
7.39
7.40
ph
0.38
595
4399
661
4889
1.47
15.27
3.7
2.7
5.85
5.65
e6/l
0.13
627
4457
1399
11826
1.39
15.13
4.4
3.6
0.00
0.00
estimate
0.50
345
2482
1033
8304
1.40
15.04
4.7
3.9
59.14
72.69
e6/l
0.42
778
5747
313
1966
1.67
14.89
5.8
5.1
0.05
0.11
%
0.77
92
483
294
1821
1.69
14.74
4.0
4.0
7.36
7.34
ph
1.08
220
1363
321
2036
1.66
14.70
11.8
8.7
9.29
9.07
mmol/l
0.22
311
1973
798
6179
1.42
14.23
3.9
3.2
0.35
0.40
e6/l
0.30
625
4469
98
419
2.39
14.19
3.6
3.7
4.17
4.14
e9/l
0.05
98
419
348
2273
1.61
14.15
2.6
2.3
344.31
377.46
nmol/l
2.59
322
2128
898
7103
1.40
14.15
2.8
2.5
—
—
—
0
0
744
5706
1.42
13.95
1.4
1.3
1.53
1.74
u/ml
0.18
193
1584
476
3348
1.52
13.94
1.5
1.4
455.53
436.70
titre
0.10
103
678
991
7994
1.39
13.80
4.1
3.4
36.00
34.36
u/l
0.18
936
7573
1102
9088
1.37
13.21
4.3
3.4
1.71
0.03
estimate
0.49
293
2077
1181
9846
1.36
13.20
2.8
2.5
73.05
74.58
nmol/l
1.15
1096
9114
741
5745
1.40
12.87
3.4
2.8
—
—
—
0
0
741
5754
1.40
12.72
1.8
1.7
18.96
19.75
nmol/l
0.84
636
5016
106
494
2.19
12.58
5.8
3.8
—
—
—
0
0
260
1633
1.66
12.31
2.9
2.7
66.62
66.82
g/l
0.14
243
1528
1110
9241
1.35
12.20
2.2
2.0
98.92
95.82
pmol/l
1.29
644
5152
2368
22318
1.63
12.18
22.8
14.5
22.75
23.54
mg/l
0.56
2031
18228
285
1839
1.62
12.12
5.1
3.7
—
—
—
0
0
556
4137
1.44
12.06
3.7
2.8
515.89
549.22
mosm/kgh2o
3.06
510
3647
61
225
2.75
12.00
1.6
1.5
1.49
1.27
promille
0.50
52
183
175
999
1.81
11.67
6.0
2.7
—
—
—
0
0
432
3089
1.48
11.50
2.3
1.9
—
—
—
0
0
563
4238
1.42
11.38
1.8
1.7
102575529.13
35628508.81
pmol/l
0.89
466
3646
653
5050
1.39
11.26
1.6
1.5
2.47
2.36
g/l
0.57
414
3273
1210
10284
1.33
11.24
15.6
11.2
0.00
0.00
e9/l
0.67
997
8438
1821
16451
1.35
10.90
4.5
3.4
52.26
47.06
u/l
1.30
1722
15715
519
3885
1.42
10.76
1.4
1.3
10.23
9.45
u/ml
0.11
206
1577
93
440
2.15
10.68
5.9
4.5
2.22
2.47
mmol/l
0.38
59
287
490
3638
1.43
10.62
3.3
2.6
13.03
13.90
umol/l
1.84
457
3428
440
3203
1.45
10.62
3.1
2.7
149.84
130.73
ug/g
0.53
336
2597
2364
22385
1.57
10.57
24.5
16.5
139.47
139.67
mmol/l
3.90
2321
21973
106
530
2.04
10.53
3.8
3.5
56.74
57.56
%
0.26
106
530
574
4393
1.39
10.43
2.0
1.7
—
—
—
0
0
103
517
2.03
10.14
3.3
2.3
132.94
132.36
g/l
0.09
90
412
742
5948
1.35
10.00
3.1
2.7
349.27
345.11
umol/l
0.48
669
5368
456
3380
1.42
9.92
2.5
2.3
30.32
29.62
s
1.72
445
3289
424
3102
1.44
9.91
3.4
2.7
22.88
24.03
%
1.02
394
2923
241
1567
1.59
9.90
6.7
4.1
1.22
1.22
mmol/l
0.57
219
1373
1886
17236
1.34
9.73
4.6
4.2
14.63
14.63
pmol/l
0.02
1742
16017
456
3391
1.42
9.73
3.4
2.6
2.34
2.34
g/l
0.04
428
3168
2363
22452
1.53
9.51
24.6
16.7
3.98
3.97
mmol/l
1.95
2313
21994
2192
20532
1.41
9.51
5.7
5.0
1.84
1.85
mu/l
0.19
2050
19265
399
2909
1.44
9.48
3.3
3.3
4.63
4.81
e9/l
0.13
340
2600
61
255
2.43
9.39
1.2
1.5
282.31
281.92
mosm/kgh2o
0.05
51
198
38
124
3.09
9.36
2.2
3.3
67.94
145.53
umol/l
2.15
17
73
1204
10391
1.29
9.36
3.3
2.8
—
—
estimate
—
0
0
308
2145
1.49
9.26
2.6
2.5
0.22
0.22
g/l
0.19
290
2014
144
833
1.77
9.22
4.0
4.3
24.43
24.74
mmol/l
0.75
137
781
923
7724
1.30
8.97
4.4
3.5
7.94
8.38
mmol/l
2.02
792
6708
119
657
1.85
8.89
1.5
1.4
274.12
285.79
ug/g
0.21
60
383
344
2470
1.45
8.84
10.8
9.0
1.04
0.85
mmol/l
0.42
294
2040
134
769
1.78
8.83
3.6
3.8
363.80
397.88
mg/l
0.11
70
372
186
1179
1.62
8.50
4.7
2.0
—
—
—
0
0
277
1921
1.49
8.49
3.1
2.8
10.51
10.54
g/l
0.04
261
1781
343
2484
1.44
8.41
10.8
9.1
7.42
7.41
ph
1.66
196
1379
2467
23758
1.65
8.36
26.0
18.1
80.15
77.08
umol/l
2.48
2437
23529
353
2573
1.43
8.35
1.5
1.4
—
—
—
0
0
542
4244
1.35
8.33
1.4
1.3
30.88
27.57
iu/ml
0.16
160
1252
78
381
2.08
8.32
5.9
6.1
382.24
367.78
umol/l
0.24
70
341
185
1183
1.61
8.16
3.0
2.4
6017.09
6233.79
u/l
0.04
54
460
322
2318
1.44
8.15
4.0
3.0
1.80
1.77
%
0.24
291
2110
45
175
2.60
8.09
1.8
1.6
18.87
30.62
%
1.83
32
113
41
152
2.72
8.09
8.1
1.9
—
—
—
0
0
210
1389
1.56
8.02
4.3
2.1
—
—
—
0
0
135
801
1.72
7.95
2.4
2.4
327.67
445.75
ug/l
0.55
122
762
338
2467
1.42
7.93
4.8
4.5
31.19
31.22
%
0.02
238
1735
340
2486
1.42
7.89
10.9
9.1
5.08
5.12
kpa
0.39
333
2408
2225
21042
1.38
7.84
5.2
4.7
5.96
5.89
mmol/l
1.33
2062
19681
223
1504
1.53
7.80
2.1
1.9
1.56
1.32
g/l
0.60
208
1404
311
2244
1.44
7.77
6.3
4.3
7.37
7.38
ph
0.49
173
1285
58
259
2.27
7.76
2.5
3.1
—
—
—
0
0
308
2219
1.44
7.75
6.3
4.3
5.90
5.85
kpa
0.44
303
2158
339
2487
1.42
7.72
10.9
9.1
11.94
12.46
kpa
0.91
333
2408
196
1291
1.56
7.64
2.3
1.8
0.38
0.31
mg/l
0.75
104
648
310
2244
1.43
7.60
11.3
9.4
95.38
95.79
%
0.52
302
2179
279
1984
1.45
7.53
14.0
10.5
—
—
—
0
0
293
2103
1.44
7.52
10.8
10.0
122.36
124.06
g/l
0.67
288
2061
1260
11121
1.26
7.52
3.6
3.1
149.34
121.46
ug/l
2.41
1179
10548
847
7133
1.28
7.52
3.7
3.4
2.35
2.35
mmol/l
0.10
775
6585
64
303
2.14
7.44
6.3
6.3
11.12
11.39
mg/l
0.22
59
278
695
5719
1.29
7.39
5.7
4.4
89.23
90.59
%
0.73
676
5616
299
2164
1.43
7.34
6.4
4.3
2.10
1.74
mmol/l
1.09
275
1861
52
228
2.31
7.27
1.6
1.7
62.81
58.49
%
0.29
32
154
401
3056
1.37
7.27
1.4
1.2
—
—
—
0
0
651
5322
1.30
7.26
4.2
3.6
1.02
1.30
kg/l
0.50
404
3529
163
1043
1.60
7.20
4.8
4.1
—
—
—
0
0
104
590
1.79
7.18
1.7
1.3
—
—
—
0
0
218
1491
1.50
7.15
4.4
2.0
—
—
—
0
0
146
913
1.63
7.08
1.8
1.9
1.44
1.49
g/l
0.36
122
804
2449
23638
1.55
7.07
15.5
11.4
29.75
27.98
u/l
0.99
2394
23113
630
5145
1.30
7.05
2.1
1.8
1.07
1.14
mg/l
0.29
492
3899
263
1874
1.45
7.02
5.3
3.7
4.70
4.66
kpa
0.11
258
1820
66
326
2.05
6.89
4.2
3.8
1.06
1.32
%
0.44
59
304
246
1737
1.46
6.89
3.8
2.9
70.64
71.42
e9/l
0.12
191
1272
218
1503
1.49
6.88
4.5
2.0
—
—
—
0
0
217
1498
1.49
6.81
3.4
2.0
—
—
—
0
0
152
971
1.60
6.77
2.1
1.8
3.97
6.85
iu/ml
1.81
37
239
68
342
2.01
6.77
1.8
1.3
65.59
65.12
mmol/l
0.03
56
282
28
93
3.03
6.77
1.7
1.6
5.78
3.91
%
—
9
22
797
6741
1.26
6.66
4.0
3.0
0.88
0.03
estimate
0.48
287
2002
142
898
1.61
6.60
1.3
1.2
0.27
0.91
u/ml
0.98
15
68
69
354
1.97
6.51
1.6
1.3
18.78
20.95
u/l
0.31
56
292
110
654
1.71
6.49
1.4
1.3
34.97
2.41
u/ml
—
10
55
129
802
1.64
6.43
6.6
4.4
1.65
1.43
mg/l
1.61
118
747
187
1269
1.51
6.39
1.4
1.2
—
—
—
0
0
119
729
1.66
6.29
2.0
1.7
0.22
0.24
g/l
1.10
113
687
57
278
2.07
6.19
1.4
1.3
—
—
—
0
0
121
751
1.64
6.09
2.0
1.6
1.17
1.20
g/l
0.61
115
708
975
8510
1.23
6.00
2.1
2.0
—
—
—
0
0
108
655
1.68
5.95
1.4
1.3
3.43
10.74
u/ml
1.46
13
99
241
1743
1.42
5.94
2.8
2.4
0.31
0.37
e6/l
0.28
230
1657
138
892
1.58
5.89
5.6
3.4
25.57
25.14
mmol/l
0.54
131
855
506
4106
1.29
5.84
4.8
3.7
235.95
491.08
ng/l
2.44
373
2990
209
1479
1.45
5.81
4.6
2.0
—
—
—
0
0
93
547
1.73
5.74
2.9
3.3
34.08
36.16
umol/l
0.29
84
503
15
27
5.58
5.68
3.8
2.4
—
—
—
0
0
190
1329
1.46
5.61
4.4
3.4
130.71
131.56
g/l
0.20
184
1297
472
3842
1.28
5.28
3.1
2.9
1.05
0.93
e6/l
0.21
268
1970
227
1663
1.40
5.22
2.4
2.3
6.95
8.73
ug/l
0.83
202
1512
282
2144
1.35
5.16
1.7
1.5
—
—
—
0
0
164
1136
1.47
5.11
4.5
3.1
0.68
0.62
%
0.95
164
1130
799
6923
1.22
5.09
4.7
4.3
12.78
8.72
mg/mmol
1.15
524
4597
55
286
1.94
5.07
3.8
3.3
0.70
0.81
nmol/l
1.58
49
229
10
12
8.36
5.06
3.6
4.2
—
—
—
0
0
49
246
2.01
4.99
7.9
5.2
6.80
7.25
mmol/l
0.57
43
210
167
1168
1.46
4.96
4.5
3.1
1.57
1.31
%
1.44
167
1160
15
41
3.67
4.92
1.4
1.2
—
—
—
0
0
155
1071
1.48
4.91
1.3
1.3
—
—
—
0
0
204
1487
1.40
4.84
4.8
4.5
101.83
86.81
ng/l
0.85
181
1335
2185
20930
1.26
4.70
4.4
4.1
1.39
1.32
mmol/l
3.44
2043
19698
94
587
1.62
4.69
1.7
1.5
—
—
—
0
0
43
211
2.06
4.68
3.7
3.7
53.85
55.37
%
0.15
37
189
64
360
1.80
4.66
2.3
2.3
6.53
6.52
umol/l
0.00
42
268
24
91
2.65
4.65
2.6
3.0
0.59
0.62
mmol/l
0.74
24
91
155
1083
1.46
4.65
2.0
2.1
0.00
0.69
estimate
0.51
50
369
183
1320
1.42
4.62
8.6
7.1
25.07
24.45
mmol/l
1.56
178
1271
39
186
2.11
4.58
1.3
1.3
122730.07
92785.27
e6/l
0.09
29
123
38
180
2.13
4.54
3.3
3.2
15.10
13.02
index
0.50
21
124
224
1679
1.37
4.51
1.3
1.2
93.17
137.85
u/ml
1.61
73
628
98
625
1.59
4.50
3.8
3.6
67.88
44.94
mg/l
0.45
72
526
98
626
1.59
4.47
3.8
3.6
56.27
56.04
mg/l
0.01
73
524
103
666
1.57
4.47
8.7
9.0
—
—
—
0
0
781
6830
1.20
4.41
4.1
3.6
72.57
50.84
mg/l
1.17
523
4629
55
302
1.84
4.35
2.9
3.1
—
—
—
0
0
7
6
11.69
4.27
5.6
2.5
—
—
—
0
0
261
2021
1.32
4.24
2.0
2.0
0.02
0.02
estimate
0.02
63
478
122
829
1.49
4.23
2.2
2.0
4.76
1.78
ug/l
0.49
109
750
217
1636
1.36
4.22
2.6
2.4
26.72
20.75
au/ml
0.27
17
199
28
121
2.33
4.17
3.4
4.5
5.81
8.69
mg/l
2.17
23
106
32
147
2.19
4.15
41.3
39.7
7.13
7.42
ug/l
0.38
27
133
130
904
1.46
4.04
2.4
1.8
—
—
—
0
0
33
156
2.13
4.00
1.1
1.0
—
—
—
0
0
281
2219
1.30
3.97
3.6
2.6
37.59
60.92
u/l
0.52
235
1894
2159
20743
1.23
3.97
6.7
5.8
39.38
38.75
mmol/mol
2.22
2031
19719
36
178
2.04
3.89
1.3
1.1
—
—
—
0
0
2515
24665
1.48
3.88
31.9
21.7
30.35
30.30
pg
0.69
2493
24459
201
1519
1.35
3.87
1.4
1.3
59.75
50.39
au/ml
0.16
13
106
2515
24667
1.48
3.86
32.9
22.4
40.75
41.59
%
2.16
2492
24451
426
3549
1.24
3.86
3.2
3.0
2.78
2.09
e6/l
0.67
219
1680
2515
24668
1.48
3.85
32.0
21.8
4.54
4.59
e12/l
5.74
2461
24190
122
848
1.46
3.81
1.2
1.3
—
—
—
0
0
463
3897
1.23
3.81
3.3
2.9
2.44
2.44
mmol/l
0.75
418
3510
15
49
3.07
3.80
1.3
1.2
—
—
—
0
0
2515
24674
1.47
3.77
32.1
21.9
6.97
6.72
e9/l
4.59
2461
24189
2515
24675
1.47
3.76
32.4
22.0
136.65
138.10
g/l
5.22
2492
24470
2514
24664
1.47
3.75
31.9
21.8
90.98
90.60
fl
3.96
2492
24459
2513
24655
1.46
3.72
32.1
21.9
254.48
250.91
e9/l
1.95
2469
24237
82
529
1.57
3.65
1.7
1.6
14396.31
13135.46
e6/l
0.11
59
370
226
1760
1.31
3.56
1.5
1.4
—
—
—
0
0
97
654
1.50
3.55
1.4
1.3
—
—
—
0
0
84
551
1.54
3.49
1.7
1.5
130.28
152.68
au/ml
0.96
26
163
12
32
3.76
3.38
1.3
1.4
—
—
—
0
0
84
556
1.53
3.37
3.7
3.5
5.43
3.12
ratio
0.38
39
301
125
901
1.41
3.26
1.6
1.7
9.24
12.89
u/ml
0.87
21
232
60
374
1.62
3.13
1.6
1.7
—
—
—
0
0
738
6589
1.17
3.11
3.0
2.7
0.00
0.02
—
8
94
91
625
1.47
3.08
1.2
1.2
—
—
—
0
0
128
936
1.39
3.08
1.1
1.1
—
—
—
0
0
84
570
1.49
3.03
3.8
3.1
3.09
1.89
index
0.98
44
304
237
1906
1.27
2.95
4.0
4.5
18.98
20.72
ug/l
0.07
199
1533
758
6807
1.16
2.93
8.2
6.3
—
—
—
0
0
12
37
3.25
2.93
5.0
6.2
78.75
45.89
ug/min
0.58
12
30
41
235
1.76
2.93
3.0
2.5
1216.56
1233.99
e6/l
0.04
34
208
23
108
2.14
2.90
1.7
1.6
1.63
3.90
u/field
0.67
16
85
7
13
5.40
2.87
1.3
1.2
—
—
—
0
0
90
629
1.45
2.82
1.3
1.3
262.32
255.80
u/ml
0.06
50
379
44
261
1.70
2.80
2.5
2.2
33.16
32.66
pg
0.32
44
261
10
28
3.58
2.78
1.0
1.0
—
—
—
0
0
41
242
1.71
2.67
3.0
2.7
1.61
1.73
g/24h
0.09
25
151
27
140
1.94
2.65
1.0
1.1
1.05
1.06
ratio
0.06
22
119
17
73
2.34
2.65
3.2
2.6
—
—
—
0
0
182
1440
1.28
2.61
3.5
2.9
152.87
167.89
ng/l
0.26
167
1301
12
42
2.87
2.54
2.3
2.4
—
—
—
0
0
27
143
1.90
2.51
1.0
1.1
1332.24
1551.34
miu/ml
0.45
27
143
17
75
2.27
2.51
3.2
2.4
0.17
0.18
e9/l
—
8
36
25
129
1.95
2.50
2.1
2.3
501.89
496.60
min
0.10
18
96
7
16
4.38
2.47
5.3
5.3
—
—
—
0
0
59
390
1.52
2.46
1.2
1.1
—
—
—
0
0
26
137
1.91
2.45
1.3
1.3
—
—
—
0
0
89
639
1.41
2.45
4.7
6.4
1.31
1.28
mmol/l
0.12
75
557
2267
22097
1.19
2.45
5.2
4.9
4.61
4.63
mmol/l
0.40
2147
21045
230
2781
0.81
2.42
1.2
1.4
—
—
—
0
0
236
1944
1.24
2.42
1.2
1.2
—
—
—
0
0
44
273
1.62
2.41
1.7
1.3
—
—
—
0
0
2285
22294
1.19
2.41
5.8
5.4
2.72
2.74
mmol/l
0.52
2152
21144
2258
22008
1.19
2.40
5.2
4.8
1.39
1.41
mmol/l
1.63
2128
20845
210
1711
1.25
2.38
2.8
2.3
6.07
6.08
ph
0.09
137
1116
17
77
2.22
2.37
2.1
2.8
26.17
31.30
umol/l
1.51
12
55
157
1237
1.29
2.35
15.4
12.3
16.17
16.24
%
0.11
152
1196
190
2337
0.80
2.35
1.5
1.7
3.62
3.47
mmol/l
1.03
137
1630
28
154
1.83
2.34
3.1
2.9
42.36
40.84
%
0.09
11
78
44
278
1.59
2.26
1.6
1.3
3.34
2.92
g/l
0.64
36
200
173
1389
1.26
2.24
3.1
3.6
4.52
4.60
pmol/l
0.44
148
1262
41
257
1.60
2.18
1.0
1.4
0.19
0.25
nmol/l
0.37
32
207
66
460
1.45
2.17
1.5
1.7
0.63
0.79
g/l
0.93
53
361
18
87
2.08
2.17
1.3
1.6
0.00
0.07
estimate
0.80
18
87
35
211
1.67
2.16
1.8
1.4
1.39
1.95
u/ml
0.23
19
120
22
115
1.92
2.15
1.7
1.6
2330.00
2920.00
titre
—
8
16
14
61
2.30
2.14
1.3
1.2
62.00
52.91
%
0.38
14
53
9
31
2.91
2.07
1.0
1.5
—
—
—
0
0
98
739
1.34
2.05
2.5
2.6
—
—
—
0
0
268
3137
0.84
2.04
1.8
1.9
3.90
3.59
ratio
2.38
215
2428
43
278
1.56
2.03
1.6
1.3
7.05
6.64
g/l
0.29
35
201
43
278
1.56
2.03
1.6
1.3
0.47
0.39
g/l
0.59
35
199
73
526
1.40
2.02
1.4
2.3
1.10
0.89
nmol/l
1.24
59
464
29
170
1.71
2.00
3.5
2.7
663.23
581.75
e6/l
0.30
22
139
120
935
1.30
2.00
4.7
5.5
1.82
1.66
%
0.46
110
884
302
2601
1.18
1.98
1.5
1.5
—
—
—
0
0
34
209
1.63
1.98
2.8
2.6
—
—
—
0
0
29
171
1.70
1.96
3.8
2.8
162.17
215.74
e6/l
1.01
23
147
7
21
3.34
1.96
1.3
1.1
—
—
—
0
0
42
273
1.55
1.95
2.8
2.1
0.97
0.91
%
0.16
32
190
52
355
1.47
1.93
2.1
1.6
337.93
345.66
mu/l
0.08
43
289
908
8442
1.12
1.92
4.5
4.8
1.64
2.10
ug/l
3.01
821
7771
22
120
1.84
1.92
2.9
2.8
1846.36
1981.13
ml
0.26
22
110
38
580
0.65
1.91
1.7
1.6
—
—
—
0
0
20
106
1.89
1.90
1.4
1.3
106.30
436.39
u/l
2.22
20
97
323
2811
1.17
1.87
1.3
1.3
—
—
—
0
0
21
114
1.85
1.87
5.0
4.4
—
—
—
0
0
21
114
1.85
1.87
1.2
1.1
168.30
194.68
iu/ml
0.26
21
114
67
484
1.39
1.85
2.4
2.4
372.65
144.05
ug/min
1.06
43
307
12
53
2.27
1.80
1.1
1.4
52.83
31.43
%
—
6
37
14
274
0.51
1.79
1.9
1.4
158.59
201.49
pmol/l
0.45
14
274
766
7080
1.12
1.79
1.5
1.5
—
—
—
0
0
46
312
1.48
1.78
1.2
1.5
34.19
93.25
mu/l
1.67
40
286
185
1541
1.22
1.76
1.3
1.2
—
—
—
0
0
1027
9650
1.11
1.75
1.9
1.9
1.50
1.41
mmol/l
2.08
847
8336
15
75
2.01
1.69
1.2
1.5
79.02
99.75
nmol/24h
0.51
15
75
30
187
1.61
1.69
2.0
2.4
—
—
—
0
0
92
711
1.30
1.67
1.4
1.3
84.00
102.54
titre
—
10
71
59
427
1.39
1.64
1.1
1.1
—
—
—
0
0
10
41
2.44
1.64
1.7
1.2
—
—
—
0
0
45
310
1.46
1.64
1.1
1.4
1.46
0.32
nmol/l
—
5
20
39
261
1.50
1.63
1.1
1.4
—
—
nmol/l
—
0
0
39
569
0.68
1.61
1.5
1.5
—
—
—
0
0
24
143
1.68
1.61
2.0
2.0
0.62
1.76
u/field
1.78
13
85
38
556
0.68
1.60
1.6
1.5
1.26
1.28
mm
0.10
29
406
10
43
2.33
1.58
1.9
1.2
—
—
—
0
0
10
43
2.33
1.58
1.9
1.2
—
—
—
0
0
10
43
2.33
1.58
1.9
1.2
—
—
—
0
0
116
932
1.26
1.57
2.9
2.4
20.74
21.07
s
0.23
93
840
31
199
1.56
1.57
1.1
1.2
—
—
—
0
0
58
424
1.38
1.54
1.2
1.1
54.87
1260.18
iu/ml
0.52
21
106
14
71
1.98
1.53
1.2
1.1
—
—
—
0
0
8
33
2.43
1.53
1.4
1.2
—
—
—
0
0
22
131
1.69
1.49
1.4
2.4
7.75
7.84
mmol/l
0.05
22
131
24
147
1.64
1.47
1.1
1.2
—
—
—
0
0
52
378
1.38
1.44
1.3
1.2
—
—
—
0
0
26
164
1.59
1.43
2.1
2.3
872.72
627.27
ml
1.03
18
110
116
944
1.24
1.43
2.4
2.3
—
—
—
0
0
37
253
1.47
1.43
1.0
1.1
—
—
—
0
0
29
188
1.55
1.42
1.2
1.1
—
—
—
0
0
45
321
1.41
1.40
1.2
1.2
—
—
—
0
0
10
46
2.18
1.40
5.7
6.1
14.80
60.67
mg/mmol
—
10
40
18
104
1.74
1.37
1.6
1.8
—
—
—
0
0
929
9818
0.92
1.36
3.1
2.9
—
—
—
0
0
13
68
1.92
1.33
3.1
2.3
10.39
15.29
umol/l
1.65
13
68
18
105
1.72
1.33
1.8
1.4
—
—
—
0
0
46
334
1.38
1.31
2.4
2.5
23.62
35.57
iu/ml
—
9
34
37
259
1.43
1.29
2.8
2.3
—
—
—
0
0
11
55
2.00
1.27
4.3
6.2
6.15
5.58
kpa
0.29
11
55
8
35
2.29
1.26
7.6
10.1
5.99
6.04
mmol/l
—
8
35
21
130
1.62
1.26
2.3
2.5
15.21
16.49
%
0.85
21
130
30
203
1.48
1.24
1.1
1.1
—
—
—
0
0
13
70
1.86
1.24
1.2
1.4
—
—
—
0
0
28
187
1.50
1.23
3.5
2.6
0.62
0.65
e9/l
0.12
28
182
72
565
1.28
1.23
1.5
1.6
737.95
1017.28
e6/l
0.20
62
433
9
45
2.00
1.23
3.4
3.1
—
—
—
0
0
58
752
0.77
1.22
1.6
1.5
77.14
59.61
ug/l
1.32
51
639
104
854
1.23
1.22
5.2
5.7
0.85
0.88
%
0.22
92
806
58
443
1.32
1.22
1.1
1.1
—
—
—
0
0
6
26
2.31
1.18
1.2
1.4
176.00
170.71
mmol/l
—
6
21
16
94
1.71
1.17
1.8
2.0
29.00
30.88
%
0.19
16
94
116
969
1.21
1.16
1.8
1.5
9.05
8.04
u/l
0.46
97
768
70
554
1.27
1.14
1.4
1.6
17.50
28.06
e6/l
0.34
58
409
54
413
1.31
1.14
8.4
3.5
14.14
8.80
pmol/l
1.34
54
413
66
520
1.28
1.12
1.3
1.6
—
—
—
0
0
26
176
1.48
1.10
1.2
1.1
—
—
—
0
0
112
941
1.20
1.07
1.2
1.3
182.56
227.72
miu/ml
0.77
39
439
24
162
1.49
1.04
1.5
1.5
77.21
79.42
umol/l
0.20
24
162
20
130
1.54
1.02
1.6
1.4
12.60
13.13
u/l
0.13
20
124
9
48
1.88
1.00
1.0
1.4
5.33
3.45
mmol/l
—
9
43
22
148
1.49
0.98
1.6
1.5
1.06
1.33
nmol/l
0.63
17
115
310
2829
1.11
0.95
2.5
2.4
13.33
13.68
nmol/l
0.34
276
2618
7
37
1.89
0.94
1.1
1.3
—
226.40
—
0
5
9
52
1.73
0.92
1.3
1.4
—
—
—
0
0
18
118
1.53
0.90
1.1
1.8
4.03
3.74
nmol/l
0.05
13
95
41
314
1.31
0.90
1.4
1.6
—
—
—
0
0
41
314
1.31
0.90
1.4
1.6
—
—
—
0
0
41
314
1.31
0.90
1.4
1.6
—
—
—
0
0
41
314
1.31
0.90
1.4
1.6
—
—
—
0
0
6
30
2.00
0.87
1.7
2.1
—
—
—
0
0
113
1307
0.86
0.85
1.5
1.7
—
—
—
0
0
118
1358
0.86
0.84
1.6
1.6
1101.03
993.56
mu/l
0.54
101
1158
8
140
0.57
0.83
1.6
1.2
6.88
8.51
mm/h
—
8
140
15
97
1.55
0.81
1.1
1.1
—
—
—
0
0
48
383
1.26
0.80
1.4
1.2
—
—
—
0
0
16
106
1.51
0.78
3.2
2.2
151.29
114.95
ng/l
0.35
16
106
81
685
1.19
0.78
1.1
1.1
—
—
—
0
0
11
67
1.64
0.75
1.2
1.1
—
—
—
0
0
11
67
1.64
0.75
1.2
1.1
—
—
—
0
0
11
67
1.64
0.75
1.2
1.1
—
—
—
0
0
5
24
2.09
0.74
1.2
1.3
5.74
6.13
mmol/l
—
5
24
93
1072
0.86
0.71
1.1
1.1
0.62
0.65
ratio
0.19
11
113
76
647
1.18
0.70
2.0
2.1
104.04
3.87
iu/l
0.49
31
286
25
186
1.35
0.70
1.2
1.1
—
—
—
0
0
12
77
1.56
0.68
1.1
1.4
—
—
—
0
0
7
42
1.67
0.68
1.3
1.2
55.57
44.33
mg/l
—
7
36
34
266
1.28
0.68
1.1
1.1
—
—
—
0
0
32
250
1.28
0.65
1.3
1.4
—
—
—
0
0
18
128
1.41
0.65
2.3
1.9
2.17
1.83
umol/l
1.12
18
117
25
189
1.33
0.64
1.4
1.4
—
—
—
0
0
99
1125
0.88
0.64
1.1
1.1
1.49
1.50
g/l
0.05
99
1125
12
79
1.52
0.62
4.8
2.8
—
—
—
0
0
23
173
1.33
0.61
1.0
1.1
0.44
0.95
u/ml
—
10
46
23
173
1.33
0.61
1.0
1.1
0.44
2.07
u/ml
0.59
11
63
13
88
1.48
0.60
1.1
2.1
—
—
—
0
0
45
372
1.21
0.59
1.6
2.1
4.77
5.12
mmol/24h
0.28
39
340
15
106
1.42
0.57
1.3
1.4
125.15
176.73
mmol/24h
1.44
15
106
49
410
1.20
0.57
1.4
1.2
5.12
4.65
u/ml
0.05
26
190
18
132
1.37
0.57
2.2
2.1
0.58
1.87
u/ml
—
7
42
148
1345
1.11
0.56
1.1
1.1
—
—
—
0
0
6
39
1.54
0.53
1.3
1.3
62.33
68.67
ug/l
—
6
39
42
501
0.84
0.52
1.2
1.2
—
—
—
0
0
51
437
1.17
0.48
6.1
7.7
11.78
11.52
mmol/l
0.20
46
394
21
163
1.29
0.48
1.0
1.0
0.99
2.47
u/ml
—
8
41
51
438
1.17
0.47
6.1
7.7
105.41
105.20
mmol/l
0.13
46
395
49
422
1.16
0.45
1.9
1.2
55.81
40.75
u/l
0.26
42
364
10
69
1.45
0.44
1.0
1.4
41.43
41.29
g/l
—
10
69
122
1117
1.10
0.43
1.9
1.7
316.54
299.12
mu/l
0.24
108
1021
23
184
1.25
0.43
1.3
1.6
—
—
—
0
0
40
468
0.85
0.42
1.3
1.1
15.11
17.07
au/ml
—
9
134
1948
19267
1.04
0.42
25.6
17.7
13.64
13.47
%
7.06
1925
19028
5
33
1.52
0.41
2.2
1.4
—
—
—
0
0
102
930
1.10
0.40
3.1
2.9
1.02
1.02
ratio
0.10
91
859
0
18
0.00
0.40
0.0
12.7
—
152.42
—
0
12
13
97
1.34
0.39
1.0
1.1
—
—
—
0
0
13
98
1.33
0.37
1.0
1.0
—
—
—
0
0
49
430
1.14
0.37
3.2
3.2
28.09
28.13
mg/l
0.00
34
279
84
764
1.10
0.36
4.1
3.7
1608.96
2312.78
u/ml
0.18
66
667
9
71
1.27
0.36
6.0
5.6
11.22
8.23
%
—
9
71
9
71
1.27
0.36
3.0
2.8
45.89
41.87
%
—
9
71
14
178
0.79
0.34
1.2
1.1
—
—
—
0
0
89
815
1.10
0.34
1.8
2.0
—
—
—
0
0
12
91
1.32
0.33
4.8
2.7
—
—
—
0
0
34
293
1.16
0.33
2.9
2.2
—
—
—
0
0
21
173
1.22
0.33
1.9
1.7
—
—
—
0
0
1952
19690
0.97
0.32
25.7
18.0
333.04
333.67
g/l
2.31
1940
19571
6
47
1.28
0.32
4.0
2.8
4.17
5.15
ug/l
—
6
47
53
475
1.12
0.31
1.1
1.1
4.33
5.69
u/ml
0.17
25
221
67
610
1.10
0.30
1.1
1.1
5.53
5.40
eliau/ml
—
7
84
141
1327
1.07
0.29
1.5
1.4
23.18
22.25
iu/l
0.14
124
1111
30
345
0.87
0.29
2.7
1.9
—
—
—
0
0
17
139
1.22
0.29
2.8
1.5
11.22
6.86
u/l
0.45
17
118
7
57
1.23
0.29
1.9
1.9
—
—
—
0
0
8
65
1.23
0.27
2.4
1.6
—
—
—
0
0
39
347
1.13
0.26
1.1
1.1
6.97
2.44
eliau/ml
—
10
169
46
414
1.11
0.26
2.6
3.9
669.59
1117.43
u/ml
0.25
39
384
64
588
1.09
0.25
1.1
1.1
0.37
1.92
u/ml
4.74
35
306
16
133
1.20
0.24
2.6
1.9
24.88
27.25
umol/l
0.67
16
124
64
591
1.08
0.23
1.1
1.1
0.53
1.15
u/ml
0.71
31
261
5
38
1.32
0.23
2.0
1.9
—
—
—
0
0
49
449
1.09
0.21
1.1
1.0
0.19
0.26
u/ml
0.20
19
155
13
107
1.22
0.21
1.4
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
391.00
—
0
10
0
10
0.00
0.21
0.0
1.0
—
4.88
—
0
10
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
29.53
—
0
10
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
5
43
1.16
0.21
1.6
2.8
11.00
2.45
%
—
5
43
65
605
1.08
0.20
1.1
1.1
2.88
5.06
u/ml
0.64
37
338
10
123
0.81
0.20
1.4
1.6
0.57
0.50
e9/l
—
10
123
24
212
1.13
0.19
1.3
1.4
7007.87
1778.39
e6/l
0.61
15
142
55
511
1.08
0.19
1.1
1.1
2.06
3.78
u/ml
0.56
29
262
15
175
0.86
0.18
1.1
1.1
101.87
110.21
pmol/l
0.27
15
175
19
167
1.14
0.16
1.2
1.2
0.61
0.56
ratio
0.31
12
95
39
421
0.93
0.15
1.3
1.2
—
—
—
0
0
9
79
1.14
0.15
1.2
1.3
27.67
28.58
s
—
9
79
44
411
1.07
0.14
1.3
1.3
—
—
—
0
0
24
218
1.10
0.13
1.2
1.2
—
—
—
0
0
61
643
0.95
0.13
1.6
1.7
—
—
—
0
0
524
5164
1.02
0.13
2.8
3.0
0.67
0.72
ug/l
0.84
321
3101
38
407
0.93
0.13
4.1
3.8
—
—
—
0
0
13
113
1.15
0.13
2.1
2.6
61.46
50.80
umol/l
0.57
13
102
43
406
1.06
0.11
1.5
1.4
54.33
164.14
pmol/l
1.94
43
396
56
535
1.05
0.10
1.2
1.1
—
—
—
0
0
19
174
1.09
0.09
1.4
1.4
—
—
—
0
0
11
97
1.13
0.09
1.0
1.1
—
—
—
0
0
6
58
1.03
0.08
1.0
1.1
43.25
41.89
iu/ml
—
6
58
20
185
1.08
0.08
1.4
1.4
36430.36
99232.53
e6/l
0.70
11
99
10
88
1.14
0.08
1.0
1.0
—
—
—
0
0
325
3292
0.99
0.08
1.6
1.5
—
—
—
0
0
6
74
0.81
0.07
1.0
2.1
—
—
—
0
0
43
449
0.96
0.07
1.6
1.5
0.31
0.36
nmol/l
0.41
32
354
21
225
0.93
0.07
1.1
1.1
31.22
19.10
u/ml
—
6
92
10
112
0.89
0.07
1.9
2.3
3.79
3.16
ug/l
—
10
101
19
177
1.07
0.06
1.1
1.3
—
—
—
0
0
70
680
1.03
0.06
1.2
1.1
2.77
2.79
u/ml
0.00
43
367
24
254
0.94
0.06
3.7
3.9
15.38
30.45
u/ml
2.02
24
248
11
100
1.10
0.05
1.3
1.2
—
922.22
—
0
18
55
536
1.03
0.04
1.2
1.1
—
—
—
0
0
12
112
1.07
0.03
1.7
2.8
22.24
91.99
ug/l
0.49
12
100
12
112
1.07
0.03
1.2
1.0
8.79
12.39
u/ml
—
6
72
11
117
0.94
0.01
1.4
1.2
—
—
—
0
0
18
173
1.04
0.01
1.2
1.2
—
—
—
0
0
20
194
1.03
0.00
1.3
1.6
12.47
12.49
umol/l
0.01
20
185
13
126
1.03
0.00
1.2
1.3
161.54
142.13
nmol/l
0.44
13
126
26
263
0.99
0.00
1.6
1.8
—
—
—
0
0
19
190
1.00
0.00
1.6
1.6
7.71
7.66
mmol/l
0.04
19
183
7
77
0.91
-0.00
2.7
2.2
32.59
64.52
ug/l
—
7
77
6
66
0.91
-0.00
1.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
332.57
—
0
7
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
37.73
—
0
6
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
1.43
—
0
5
0
6
0.00
-0.00
0.0
1.5
—
4.47
—
0
6
0
8
0.00
-0.00
0.0
1.4
—
2.18
—
0
8
0
5
0.00
-0.00
0.0
1.4
—
98.20
—
0
5
6
62
0.97
-0.00
1.2
2.4
2.09
2.87
mmol/l
—
6
55
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.3
—
1067.57
—
0
7
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
7.7
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint AB1_PEDICULOSIS_ACARIASIS_OTHERINFEST and mortality.

Females

Parameter HR [95% CI] p-value
AB1_PEDICULOSIS_ACARIASIS_OTHERINFEST 1.758 [1.47, 2.11] < 0.001
Birth year 0.994 [0.99, 1.0] 0.179

During the follow-up period (1.1.1998 — 31.12.2019), 525 out of 4530 females with AB1_PEDICULOSIS_ACARIASIS_OTHERINFEST died.

Males

Parameter HR [95% CI] p-value
AB1_PEDICULOSIS_ACARIASIS_OTHERINFEST 2.101 [1.76, 2.5] < 0.001
Birth year 0.984 [0.97, 0.99] 0.001

During the follow-up period (1.1.1998 — 31.12.2019), 744 out of 5914 males with AB1_PEDICULOSIS_ACARIASIS_OTHERINFEST died.

Mortality risk

Mortality risk for people of age

years, who have AB1_PEDICULOSIS_ACARIASIS_OTHERINFEST.

N-year risk Females Males
1 0.139% 0.388%
5 0.834% 2.288%
10 2.453% 5.89%
15 4.616% 10.678%
20 8.25% 17.124%

Relationships between endpoints

↥

Index endpoint: AB1_PEDICULOSIS_ACARIASIS_OTHERINFEST – Pediculosis, acariasis and other infestations

GWS hits: 2

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data